There	O
is	O
a	O
single	O
methionine	B
codon-initiated	O
open	O
reading	O
frame	O
of	O
1,458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	B
and	O
a	O
CAX	B
repeat	O
,	O
and	O
the	O
open	B
reading	O
frame	O
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51,659	O
daltons.	O

When	O
the	O
homeodomain	B
from	O
HB24	B
was	O
compared	O
to	O
known	O
mammalian	B
and	O
Drosophila	O
homeodomains	O
it	O
was	O
found	O
to	O
be	O
only	O
moderately	O
conserved,	O
but	O
when	O
it	O
was	O
compared	O
to	O
a	O
highly	O
diverged	O
Drosophila	B
homeodomain	O
,	O
H2.0,	B
it	O
was	O
found	O
to	O
be	O
80%	O
identical.	O

The	O
HB24	B
mRNA	O
was	O
absent	O
or	O
present	O
at	O
low	O
levels	O
in	O
normal	B
B	O
and	O
T	O
lymphocytes	O
;	O
however,	O
with	O
the	O
appropriate	O
activation	O
signal	O
HB24	B
mRNA	O
was	O
induced	O
within	O
several	O
hours	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O

Characterization	O
of	O
HB24	B
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O

Positive	O
hybridization	O
was	O
found	O
in	O
thymus	O
,	O
tonsil	O
,	O
bone	O
marrow	O
,	O
developing	O
vessels	O
,	O
and	O
in	O
fetal	O
brain	O
.	O

HB24	B
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	B
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O

Platelet-activating	B
factor	O
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	B
expression	O
in	O
a	O
human	B
B	O
cell	O
line	O
.	O

Platelet-activating	B
factor	O
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

Studies	O
of	O
the	O
actions	O
of	O
platelet-activating	B
factor	O
have	O
centered	O
mainly	O
around	O
neutrophils	B
,	O
monocytes	B
,	O
and	O
platelets	B
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	B
factor	O
on	O
B	B
lymphocytes	O
.	O

Employing	O
the	O
EBV-transformed	B
human	O
B	O
cell	O
line	O
SKW6.4	O
,	O
we	O
demonstrate	O
that	O
platelet-activating	B
factor	O
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10(-9)	O
to	O
10(-6)	O
M.	O

The	O
inactive	O
precursor,	O
lyso-platelet-activating	B
factor	O
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10(-7)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	O
.	O

We	O
also	O
show	O
that	O
platelet-activating	B
factor	O
from	O
10(-12)	O
to	O
10(-6)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-	B
platelet-activating	O
factor	O
was	O
again	O
ineffective.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet-activating	B
factor	O
binding	O
to	O
B	B
cells	O
by	O
measuring	O
platelet-activating	B
factor	O
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production.	O

Moreover,	O
platelet-activating	B
factor	O
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	B
proto-oncogenes	O
c-fos	B
and	O
c-jun	B
.	O

Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5-hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5-lipoxygenase	B
activity	O
modulates	O
platelet-activating	B
factor	O
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	B
A2	O
.	O

In	O
summary,	O
platelet-activating	B
factor	O
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	B
B	O
cell	O
line	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	B
gene	O
expression	O
by	O
a	O
novel	O
B-cell-specific	B
enhancer	O
element	O
.	O

A	O
new	O
B-cell-specific	B
enhancer	O
element	O
has	O
been	O
identified	O
3'	O
of	O
E4	B
and	O
the	O
octamerlike	B
motifs	O
in	O
the	O
human	B
immunoglobulin	O
heavy-chain	O
gene	O
enhancer	O
.	O

Tandem	O
copies	O
of	O
this	O
67-bp	B
MnlI-AluI	O
fragment	O
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	B
acetyltransferase	O
gene	O
driven	O
by	O
the	O
conalbumin	B
promoter	O
,	O
stimulated	O
transcription	O
in	O
B	B
cells	O
but	O
not	O
in	O
Jurkat	B
T	O
cells	O
or	O
HeLa	B
cells	O
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	B
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	B
cells	O
,	O
T	B
cells	O
,	O
or	O
HeLa	B
cells.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	B
motif	O
detected	O
a	O
B-cell-specific	B
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	B
cells	O
and	O
HeLa	B
cells	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	B
motif	O
stimulated	O
transcription	O
in	O
ARH77	B
and	O
Raji	B
cells	O
but	O
not	O
in	O
Jurkat	B
or	O
HeLa	B
cells	O
.	O

Furthermore,	O
a	O
mutant	B
E6	B
motif	O
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

In	O
striking	O
contrast	O
to	O
the	O
mouse	B
Ig	O
heavy-chain	O
enhancer	O
,	O
in	O
which	O
the	O
octamer	B
motif	O
acts	O
as	O
a	O
B-cell-specific	B
enhancer	O
element	O
,	O
the	O
human	B
enhancer	O
contains	O
an	O
octamerlike	B
sequence	O
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer-binding	B
proteins	O
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	O
enhancer	O
activity	O
of	O
its	O
own.	O

Interestingly,	O
the	O
MnlI-AluI	B
fragment	O
could	O
suppress	O
the	O
basal-level	O
activity	O
of	O
the	O
conalbumin	B
promoter	O
in	O
both	O
Jurkat	B
and	O
HeLa	B
cells	O
.	O

Moreover,	O
simian	B
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI-AluI	B
fragment	O
in	O
HeLa	B
cells	O
but	O
not	O
in	O
B	B
cells	O
.	O

Thus,	O
the	O
novel	O
enhancer	B
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	B
and	O
negative	O
factors	O
.	O

Charybdotoxin-sensitive,	O
Ca(2+)	O
-dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	O
or	O
B	O
cell	O
activation	O
and	O
proliferation	O
.	O

The	O
involvement	O
of	O
ion	B
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	O
binding	O
.	O

Human	B
T	O
and	O
B	O
lymphocytes	O
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca(2+)-stimulated	B
K+	O
channels.	O

We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca(2+)-dependent	B
K+	O
channels	O
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand-induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	B
and	O
T	O
cells	O
in	O
a	O
dose-dependent	O
fashion,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2+	O
.	O

However,	O
blockade	O
of	O
the	O
Ca(2+)-activated	B
K+	O
channel	O
is	O
not	O
associated	O
with	O
changes	O
in	O
cell-cycle	B
gene	O
activation	O
,	O
IL-2	B
production	O
,	O
IL-2R	B
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O

These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand-dependent	O
opening	O
of	O
Ca(2+)-activated	B
K+	O
channels	O
are	O
not	O
involved	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

Activity	O
of	O
the	O
kappa	B
B	O
enhancer	O
of	O
the	O
interleukin-2	B
receptor	O
alpha	O
chain	O
in	O
somatic	B
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF-kappa	B
B	O
.	O

The	O
two	O
nuclear	B
proteins	O
NF-kappa	B
B	O
(consisting	O
of	O
subunits	O
p50	B
an	O
dp65	B
)	O
and	O
the	O
DNA-binding	B
subunit	O
of	O
NF-kappa	B
B	O
(	O
p50	B
)	O
by	O
itself,	O
also	O
called	O
KBF1	B
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	B
T-cell	O
line	O
IARC	B
301.5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	O
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	B
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	B
cell	O
hybrids	O
between	O
IARC	B
301.5	O
and	O
a	O
murine	B
myeloma	O
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	B
and	O
NF-kappa	B
B	O
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	B
.	O

The	O
kappa	B
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	B
(	O
IL-2	B
)	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	B
alpha	O
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	B
NF-kappa	B
B	O
.	O

These	O
findings	O
show	O
that	O
nuclear	B
NF-kappa	B
B	O
is	O
necessary	O
to	O
activate	O
the	O
kappa	B
B	O
enhancer	O
,	O
while	O
KBF1	B
by	O
itself	O
is	O
not	O
sufficient.	O

We	O
propose	O
that	O
KBF1	B
is	O
a	O
competitive	O
inhibitor	O
of	O
NF-kappa	B
B	O
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	B
and	O
IL-2	B
alpha	O
genes	O
during	O
the	O
immune	O
response	O
.	O

T-helper-cell	B
determinants	O
in	O
protein	B
antigens	O
are	O
preferentially	O
located	O
in	O
cysteine-rich	B
antigen	O
segments	O
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	B
B	O
,	O
L	O
,	O
and	O
D	O
.	O

We	O
report	O
on	O
a	O
computer	O
algorithm	O
capable	O
of	O
predicting	O
the	O
location	O
of	O
T-helper-cell	B
epitopes	O
in	O
protein	B
antigen	O
(	O
Ag	B
)	O
by	O
analysing	O
the	O
Ag	B
amino	O
acid	O
sequence	O
.	O

The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	B
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	B
cathepsin	B
B	O
,	O
L	O
,	O
and	O
D	O
.	O

These	O
are	O
prominent	O
enzymes	O
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	B
protein	O
Ag	O
enter	O
APC	B
,	O
and	O
resistant	O
segments	O
in	O
Ag	B
may,	O
therefore,	O
be	O
expected	O
to	O
contain	O
more	O
T-cell	B
determinants	O
than	O
susceptible	O
segments	O
.	O

From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	O
,	O
it	O
is	O
clear	O
that	O
a	O
cysteine	O
is	O
not	O
accepted	O
in	O
any	O
of	O
the	O
S2	B
,	O
S1	O
,	O
S1'	O
,	O
and	O
S2'	O
subsites	O
of	O
cathepsin	B
B	O
and	O
L	O
,	O
and	O
not	O
in	O
the	O
S1	B
and	O
S1'	O
subsites	O
of	O
cathepsin	B
D	O
.	O

Moreover,	O
we	O
have	O
noticed	O
that	O
cysteine	B
-containing	O
T-cell	O
determinants	O
in	O
a	O
number	O
of	O
protein	B
Ag	O
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	O
,	O
glycine	O
,	O
lysine	O
,	O
leucine	O
,	O
serine	O
,	O
threonine	O
,	O
and	O
valine	O
.	O

By	O
searching	O
protein	B
Ag	O
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	O
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T-cell	B
determinants	O
in	O
the	O
Ag	B
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(positive)	O
predictions.	O

Furthermore,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	B
for	O
potential	O
amphipatic	B
alpha-helical	O
protein	O
segments	O
.	O

Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T-cell	B
determinants	O
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described.	O

Contribution	O
of	O
NF-kappa	B
B	O
and	O
Sp1	O
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T-cell	B
types	O
.	O

Starting	O
with	O
a	O
replication-incompetent	B
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF-kappa	B
B	O
and	O
Sp1	B
binding	O
sites	O
present	O
in	O
the	O
native	B
long	O
terminal	O
repeat	O
(	O
LTR	B
),	O
proviruses	O
containing	O
reconstructed	O
LTRs	B
with	O
individual	O
or	O
combinations	O
of	O
NF-kappa	B
B	O
and	O
Sp1	O
elements	O
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection-cocultivation	O
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	B
T-cell	O
types	O
depending	O
on	O
which	O
element	O
(s)	O
was	O
present	O
in	O
the	O
LTR	B
.	O

For	O
example,	O
in	O
experiments	O
involving	O
proviral	B
clones	O
with	O
LTRs	B
containing	O
one	O
or	O
two	O
NF-kappa	B
B	O
elements	O
(and	O
no	O
Sp1	B
binding	O
sites	O
),	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	B
blood	O
lymphocytes	O
=	O
MT4	B
greater	O
than	O
H9	B
greater	O
than	O
CEM	B
greater	O
than	O
Jurkat	B
)	O
was	O
observed.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	B
LTR	B
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	B
box	O
.	O

These	O
results	O
suggest	O
that	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
LTR	B
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	B
types	O
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	B
factors	O
present.	O

Stimulation	O
of	O
interferon	B
beta	O
gene	O
transcription	O
in	O
vitro	O
by	O
purified	B
NF-kappa	B
B	O
and	O
a	O
novel	O
TH	B
protein	O
.	O

The	O
human	B
interferon	O
beta	O
(	O
IFN-beta	B
)	O
regulatory	O
element	O
consists	O
of	O
multiple	O
enhanson	B
domains	O
which	O
are	O
targets	O
for	O
transcription	B
factors	O
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	B
.	O

To	O
further	O
characterize	O
the	O
protein-DNA	O
interactions	O
mediating	O
IFN-beta	B
induction	O
,	O
positive	B
regulatory	O
domain	O
(PRD)	O
II	O
binding	O
proteins	O
were	O
purified	O
from	O
phorbol	B
ester	O
induced	O
Jurkat	B
T-cells	B
and	O
from	O
IFN	O
primed,	O
cycloheximide/polyinosinic-polycytidylic	O
acid	O
treated	O
HeLa	B
S3	O
cells	O
.	O

From	O
HeLa	B
cells	O
,	O
two	O
major	O
proteins	O
of	O
52	O
and	O
45	O
kilodaltons	O
(kD)	O
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T-cells	B
,	O
four	O
proteins--a	O
major	B
protein	O
of	O
52	O
kD	O
and	O
three	O
minor	B
proteins	O
of	O
82	O
,	O
67	O
,	O
and	O
43-47	O
kD	O
--were	O
purified.	O

Also,	O
an	O
induction	O
specific	O
DNA	B
binding	O
protein	O
was	O
purified	O
from	O
HeLa	B
cells	O
that	O
interacted	O
with	O
the	O
(	B
AAGTGA	O
)4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	B
domain	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1/ISGF2	B
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	B
beta	O
promoter	O
deletions	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	B
element	O
increased	O
transcription	O
in	O
the	O
uninduced	O
extract,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	O
.	O

A	O
2-4-fold	O
increase	O
in	O
IFN-beta	B
promoter	O
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	B
and	O
PRDII	B
elements	O
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	B
and	O
tetrahexamer	B
binding	O
proteins	O
were	O
added	O
to	O
the	O
induced	O
extract,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN-beta	B
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN-beta	B
transcription	O
.	O

The	O
rhombotin	B
family	O
of	O
cysteine	B
-rich	O
LIM-domain	O
oncogenes	O
:	O
distinct	O
members	O
are	O
involved	O
in	O
T-cell	O
translocations	O
to	O
human	B
chromosomes	O
11p15	O
and	O
11p13	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	O
leukemia	O
involving	O
the	O
short	B
arm	O
of	O
human	B
chromosome	O
11	O
at	O
band	B
11p15	O
disrupts	O
the	O
rhombotin	B
gene	O
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine	B
-rich	O
regions	O
called	O
LIM	B
domains	O
,	O
which	O
show	O
homology	O
to	O
zinc-binding	B
proteins	O
and	O
to	O
iron-sulfur	B
centers	O
of	O
ferredoxins	B
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	B
gene	O
have	O
now	O
been	O
isolated.	O

One	O
of	O
these,	O
designated	O
Rhom-2	B
,	O
is	O
located	O
on	O
human	B
chromosome	O
11	O
at	O
band	B
11p13	O
,	O
where	O
a	O
cluster	O
of	O
T-cell	O
leukemia-specific	O
translocations	O
occur;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	B
are	O
upstream	O
of	O
the	O
Rhom-2	B
gene	O
.	O

Human	B
and	O
mouse	O
Rhom-2	B
are	O
highly	O
conserved	O
and,	O
like	O
rhombotin	B
,	O
encode	O
two	O
tandem	O
cysteine	B
-rich	O
LIM	O
domains	O
.	O

Rhom-2	B
mRNA	O
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

The	O
other	O
gene,	O
designated	O
Rhom-3	B
,	O
is	O
not	O
on	O
chromosome	B
11	O
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	B
domain	O
of	O
rhombotin	B
.	O

Since	O
the	O
Rhom-2	B
gene	O
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T-cell	O
tumors	O
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	B
gene	O
was	O
further	O
examined.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	B
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example.	O

Therefore,	O
chromosome	B
bands	O
11p15	B
(	O
rhombotin	B
)	O
and	O
11p13	B
(	O
Rhom-2	B
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T-cell	O
leukemia	O
,	O
with	O
the	O
11p15	B
target	O
more	O
rarely	O
involved.	O

The	O
results	O
define	O
the	O
rhombotin	B
gene	O
family	O
as	O
a	O
class	O
of	O
T-cell	B
oncogenes	O
with	O
duplicated	O
cysteine	B
-rich	O
LIM	O
domains	O
.	O

NF-kappa	B
B	O
activation	O
by	O
tumor	B
necrosis	O
factor	O
alpha	O
in	O
the	O
Jurkat	B
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	B
kinase	O
A	O
,	O
protein	B
kinase	O
C	O
,	O
and	O
Ca(2+)	B
-regulated	O
kinases	O
.	O

NF-kappa	B
B	O
is	O
a	O
DNA-binding	B
regulatory	O
factor	O
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes,	O
including	O
human	B
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
genes	O
.	O

In	O
T	B
cells	O
,	O
NF-kappa	B
B	O
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	B
necrosis	O
factor	O
alpha	O
(	O
TNF	B
alpha	O
).	O

In	O
the	O
present	O
work,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF-kappa	B
B	O
activation	O
by	O
TNF	B
alpha	O
in	O
a	O
human	B
T	O
cell	O
line	O
(	O
Jurkat	B
)	O
and	O
its	O
subclone	O
JCT6	B
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	B
transduction	O
pathway	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	B
lines,	O
both	O
phorbol	O
ester	O
and	O
TNF	B
alpha	O
were	O
able	O
to	O
activate	O
NF-kappa	B
B	O
.	O

Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2+	O
influx	O
while	O
TNF	B
alpha	O
activation	O
was	O
not.	O

Furthermore,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	B
inhibitor	O
staurosporin	O
,	O
the	O
TNF	B
alpha	O
effect	O
was	O
unchanged.	O

TNF	B
alpha	O
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O

Moreover,	O
cAMP	O
activators	O
did	O
not	O
activate	O
NF-kappa	B
B	O
in	O
Jurkat	B
cells	O
.	O

Thus,	O
TNF	B
alpha	O
-induced	O
NF-kappa	B
B	O
activation	O
was	O
found	O
to	O
be	O
mediated	O
by	O
none	O
of	O
the	O
major	O
signal-mediating	B
kinases	O
such	O
as	O
protein	B
kinase	O
C	O
(	O
PKC	B
),	O
protein	B
kinase	O
A	O
,	O
or	O
Ca(2+)-regulated	B
kinases	O
.	O

Furthermore,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	B
B	O
activation	O
by	O
both	O
TNF	B
alpha	O
and	O
PKC	B
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	B
B	O
/I	O
kappa	O
B	O
dissociation	O
without	O
affecting	O
the	O
NF-kappa	B
B	O
translocation	O
step	O
.	O

The	O
functional	O
domains	O
of	O
the	O
murine	B
Thy-1	O
gene	O
promoter	O
.	O

The	O
Thy-1	B
gene	O
promoter	O
resembles	O
a	O
"housekeeping"	O
promoter	O
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation-free	B
island	O
,	O
lacks	O
a	O
canonical	O
TATA	B
box	O
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	B
termini	O
of	O
the	O
mRNA	B
.	O

Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	O
does	O
not	O
confer	O
any	O
tissue	O
specificity	O
and	O
is	O
active	O
only	O
in	O
a	O
position-dependent	O
manner	O
.	O

It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	B
site	O
.	O

We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	O
Thy-1	B
promoter	O
and	O
show	O
that	O
the	O
dominant	B
promoter	O
elements	O
consist	O
of	O
multiple	O
binding	B
sites	O
for	O
the	O
transcription	B
factor	O
Sp1	B
,	O
an	O
inverted	O
CCAAT	B
box	O
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	B
start	O
site	O
.	O

DNase	B
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	B
factors	O
to	O
these	O
elements	O
,	O
including	O
Sp1	B
and	O
CP1	B
.	O

Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	B
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	B
factors	O
Sp1	B
and	O
CP1	B
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	B
sequences	O
.	O

Nuclear	B
factor	O
kappa	O
B	O
activates	O
proenkephalin	B
transcription	O
in	O
T	B
lymphocytes	O
.	O

Upon	O
activation,	O
T	B
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B
mRNA	O
in	O
the	O
cells.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes.	O

The	O
proenkephalin	B
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	B
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	B
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	B
site	O
of	O
the	O
transcription	B
factor	O
nuclear	B
factor	O
(NF)-kappa	O
B	O
.	O

Activation	O
of	O
T	B
lymphocytes	O
induces	O
an	O
NF-kappa	B
B	O
-like	O
binding	O
activity	O
to	O
the	O
B2	B
site,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B
promoter	O
.	O

Mutations	O
at	O
the	O
B2	B
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	B
homodimer	O
(two	O
p50s	B
)	O
of	O
the	O
DNA-binding	B
subunit	O
of	O
NF-kappa	B
B	O
binds	O
the	O
B2	B
site	O
of	O
proenkephalin	B
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(two	O
p65s	B
plus	O
two	O
p50s	B
)	O
form	O
of	O
the	O
factor.	O

Thus,	O
it	O
appears	O
that	O
the	O
T-cell-specific	O
activation	O
of	O
the	O
proenkephalin	B
promoter	O
is	O
mediated	O
by	O
NF-kappa	B
B	O
.	O

However,	O
as	O
NF-kappa	B
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	B
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T-cell-specific	B
factor	O
which	O
synergizes	O
with	O
NF-kappa	B
B	O
should	O
be	O
considered.	O

Induction	O
of	O
NF-KB	B
during	O
monocyte	O
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O

The	O
production	O
of	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	B
promonocytic	O
cell	O
line	O
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	B
human	O
monocytes	B
and	O
macrophages	B
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	B
transactivation	O
factor	O
NF-KB	B
to	O
the	O
double	B
repeat-KB	O
enhancer	O
sequence	O
located	O
in	O
the	O
long	B
terminal	O
repeat	O
.	O

PMA	O
treatment	O
,	O
and	O
not	O
retinoic	O
acid	O
treatment	O
of	O
the	O
U937	B
cells	O
acts	O
in	O
inducing	O
NF-KB	B
expression	O
in	O
the	O
nuclei	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	B
or	O
macrophages	B
,	O
induction	O
of	O
NF-KB	B
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O

When	O
U937	B
cells	O
were	O
infected	O
with	O
HIV-1	O
,	O
no	O
induction	O
of	O
NF-KB	B
factor	O
was	O
detected,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced,	O
suggesting	O
that	O
this	O
factor	O
was	O
not	O
required	O
for	O
viral	O
replication	O
.	O

These	O
results	O
indicate	O
that	O
in	O
monocytic	B
cell	O
lineage	O
,	O
HIV-1	O
could	O
mimic	O
some	O
differentiation/activation	O
stimuli	O
allowing	O
nuclear	O
NF-KB	B
expression	O
.	O

Disruption	O
of	O
the	O
human	B
SCL	O
locus	O
by	O
"	O
illegitimate"	O
V-(D)-J	B
recombinase	O
activity	O
.	O

A	O
fusion	B
complementary	O
DNA	O
in	O
the	O
T	B
cell	O
line	O
HSB-2	B
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	B
hematopoietic	O
transcription	O
factor	O
SCL	B
.	O

The	O
fusion	B
cDNA	O
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	O
locus	O
,	O
SIL	B
(	O
SCL	B
interrupting	O
locus	O
),	O
and	O
the	O
5'	B
untranslated	O
region	O
of	O
SCL	B
.	O

Similar	O
to	O
1;14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	B
5'	O
regulatory	O
region	O
.	O

This	O
event	O
is	O
probably	O
mediated	O
by	O
V-(D)-J	B
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	B
or	O
a	O
T	B
cell	O
receptor	O
.	O

Two	O
other	O
T	B
cell	O
lines	O
,	O
CEM	B
and	O
RPMI	B
8402	O
,	O
have	O
essentially	O
identical	O
deletions.	O

Thus,	O
in	O
lymphocytes	B
,	O
growth-affecting	B
genes	O
other	O
than	O
immune	B
receptors	O
risk	O
rearrangements	O
.	O

Thyroid	B
hormone	O
receptors	O
form	O
distinct	O
nuclear	B
protein-	O
dependent	O
and	O
independent	O
complexes	O
with	O
a	O
thyroid	B
hormone	O
response	O
element	O
.	O

We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	B
proteins	O
and	O
recombinant	B
thyroid	B
hormone	O
receptors	O
(	O
TRs	B
)	O
to	O
the	O
palindromic	B
thyroid	O
hormone	O
responsive	O
element	O
AGGTCATGACCT	O
(	O
TREp	B
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Four	O
specific	O
protein-DNA	B
complexes	O
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	B
pituitary	O
(GH3)	O
cells	O
with	O
a	O
TREp	B
-containing	O
DNA	O
fragment	O
.	O

This	O
was	O
compared	O
with	O
the	O
TREp	B
binding	O
of	O
reticulocyte	B
lysate-synthesized	O
TRs	B
.	O

TR	B
alpha	O
1	O
and	O
TR	B
beta	O
2	O
each	O
formed	O
a	O
single	O
major	O
TR	B
:	O
TREp	B
complex	O
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	B
NE	O
,	O
while	O
TR	B
beta	O
1	O
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	B
as	O
an	O
oligomer	O
.	O

Interestingly,	O
coincubation	O
of	O
35S-	B
TR	B
alpha	O
1	O
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	B
TREp	B
resulted	O
in	O
not	O
only	O
the	O
35S-TR:	B
TREp	B
complex	O
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S-	B
TR	B
alpha	O
1	O
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone.	O

Incubation	O
of	O
each	O
of	O
the	O
TRs	B
with	O
NE	B
from	O
COS-7	B
cells	O
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	B
TRs	O
to	O
mediate	O
T3-responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new,	O
more	O
greatly	O
shifted	O
complex	O
.	O

A	O
similar,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR:TRE	B
complex	O
was	O
also	O
present	O
in	O
NE	B
from	O
T3-unresponsive	B
JEG-3	B
cells	O
.	O

At	O
high	O
concentration	O
of	O
NE	B
,	O
all	O
of	O
the	O
TR	B
bound	O
to	O
TREp	B
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	B
.	O

Truncation	O
of	O
TR	B
alpha	O
1	O
at	O
amino	B
acid	O
210	O
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	B
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl-terminus	B
of	O
the	O
TRs	B
is	O
essential	O
for	O
interaction	O
with	O
nuclear	B
proteins	O
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

Cell-specific	O
differences	O
in	O
activation	O
of	O
NF-kappa	B
B	O
regulatory	O
elements	O
of	O
human	B
immunodeficiency	O
virus	O
and	O
beta	O
interferon	O
promoters	O
by	O
tumor	B
necrosis	O
factor	O
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B
necrosis	O
factor	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined.	O

Tumor	B
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	B
)	O
mRNA	O
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	B
U937	B
cells	O
and	O
in	O
a	O
chronically	B
HIV	O
infected	O
U937	B
cell	O
line	O
(	O
U9-IIIB	B
).	O

TNF-alpha	B
RNA	O
was	O
undetectable	O
in	O
U937	B
cells	O
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	B
cells	O
.	O

Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	B
RNA	O
in	O
U9-IIIB	B
cells	O
compared	O
with	O
U937	B
cells	O
,	O
suggesting	O
that	O
HIV-infected	B
monocytic	B
cells	O
produced	O
higher	O
levels	O
of	O
TNF-alpha	B
than	O
did	O
normal	B
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O

The	O
effects	O
of	O
TNF-alpha	B
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	B
chloramphenicol	O
acetyltransferase	O
plasmids	O
linked	O
to	O
regulatory	B
elements	O
from	O
the	O
HIV	B
long	O
terminal	O
repeat	O
(	O
LTR	B
)	O
and	O
the	O
beta	B
interferon	O
promoter	O
.	O

In	O
U937	B
and	O
Jurkat	B
T	O
lymphoid	O
cells	O
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	B
promoters	O
by	O
TNF-alpha	B
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context-specific	O
manner;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF-kappa	B
B	O
-containing	O
plasmids	O
correlated	O
directly	O
with	O
induction	O
of	O
NF-kappa	B
B	O
DNA-binding	O
activity	O
.	O

Although	O
the	O
intact	O
beta	B
interferon	O
promoter	O
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF-alpha	B
,	O
multimers	O
of	O
the	O
PRDII	B
NF-kappa	B
B	O
-binding	O
domain	O
were	O
inducible	O
by	O
both	O
agents.	O

TNF-alpha	B
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	B
LTR	O
in	O
T	B
cells	O
,	O
but	O
in	O
monocytic	B
cells	O
,	O
TNF-alpha	B
did	O
not	O
induce	O
the	O
HIV	B
LTR	O
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O

This	O
level	O
of	O
NF-kappa	B
B	O
-independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF-alpha	B
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
viral	B
RNA	O
production	O
in	O
U937	B
cells	O
.	O

However,	O
in	O
Jurkat	B
cells	O
,	O
TNF-alpha	B
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV-1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	B
RNA	O
synthesis	O
,	O
indicating	O
that	O
in	O
T	B
cells	O
HIV-1	O
multiplication	O
was	O
stimulated	O
by	O
TNF-alpha	B
treatment	O
.	O

Functional	O
analysis	O
of	O
cis-linked	B
regulatory	O
sequences	O
in	O
the	O
HLA	B
DRA	O
promoter	O
by	O
transcription	O
in	O
vitro.	O

Two	O
consensus	B
sequences,	O
called	O
X	B
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	B
proteins	O
and	O
regulating	O
expression	O
in	O
B	B
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	B
histocompatibility	O
complex	O
(MHC)	O
class	O
II	O
promoters	O
.	O

Unlike	O
other	O
class	B
II	O
promoters	O
,	O
the	O
HLA-DR	B
alpha	O
(DRA)	O
promoter	O
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
"octamer"	O
motif	O
of	O
immunoglobulin	B
variable	O
region	O
promoters	O
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O

This	O
"	O
octamer	B
"	O
in	O
the	O
context	O
of	O
DRA	B
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	B
(	O
OTF-1	B
)	O
and	O
lymphoid-specific	B
(	O
OTF-2	O
)	O
"octamer"	O
binding	O
proteins	O
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
"octamer"	B
complex	O
was	O
found.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis-acting	B
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	B
promoter	O
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	B
cells	O
than	O
in	O
extracts	O
from	O
class	B
II-negative	O
HeLa	O
cells	O
.	O

5'	B
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	B
box	O
,	O
but	O
retained	O
the	O
"octamer"	B
motif	O
and	O
TATA	B
box	O
were	O
completely	O
inactive,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	B
box	O
reduced	O
transcription	O
by	O
95%.	O

Using	O
supercoiled,	O
but	O
not	O
linear	B
templates,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	B
consensus	O
element	O
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	B
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	B
box	O
in	O
this	O
system	O
suggests	O
that,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	B
promoter	O
,	O
the	O
DRA	B
"octamer"	O
does	O
not	O
utilize	O
OTF-2	B
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	B
promoters	O
in	O
B	B
cells	O
.	O

Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte/macrophage-specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	B
immunodeficiency	O
virus	O
type	O
1-long	O
terminal	O
repeat	O
(	O
HIV-1-LTR	B
)	O
CAT	O
constructs	O
transfected	O
into	O
monocyte/macrophage-like	B
cell	O
lines	O
but	O
not	O
a	O
T	B
cell	O
line	O
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
).	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B
B	O
in	O
U937	B
and	O
THP-1	B
cells	O
.	O

LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	B
infected	O
monocyte/macrophage-like	O
cloned	O
cell	O
line	O
,	O
U1	B
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
before	O
treatment	O
with	O
LPS	O
.	O

This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	B
RNA	O
and	O
and	O
activation	O
of	O
NF-kappa	B
B	O
.	O

LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	B
T	O
cell	O
line	O
.	O

The	O
effect	O
of	O
LPS	O
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O

Steroid	O
dose	O
sparing	O
:	O
pharmacodynamic	O
responses	O
to	O
single	O
versus	O
divided	O
doses	O
of	O
methylprednisolone	O
in	O
man.	O

Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O

This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses.	O

Two	O
types	O
of	O
responses	O
were	O
compared	O
after	O
a	O
single	O
MP	O
dose	O
(40	O
mg	O
bolus)	O
and	O
a	O
divided	O
regimen	O
(20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O

The	O
suppression	O
of	O
basophils	B
measured	O
as	O
whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours.	O

The	O
37.5%	O
reduction	O
in	O
dose	O
produced	O
a	O
23%	O
overall	O
decreased	O
blood	O
histamine	O
response	O
.	O

A	O
pharmacodynamic	O
model	O
for	O
basophil	B
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens.	O

A	O
slower	O
initial	O
decline	O
in	O
blood	O
histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	O
cell	O
return	O
to	O
blood	O
.	O

The	O
50%	O
inhibitory	O
concentrations	O
of	O
MP	O
of	O
about	O
5	O
ng/ml	O
were	O
similar	O
for	O
both	O
regimens.	O

The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours.	O

The	O
50%	O
inhibitory	O
concentrations	O
of	O
MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng/ml.	O

Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O
corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
"dose-sparing"	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O

This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized.	O

1,25(OH)2D2	O
production	O
by	O
T	B
lymphocytes	O
and	O
alveolar	B
macrophages	O
recovered	O
by	O
lavage	O
from	O
normocalcemic	O
patients	O
with	O
tuberculosis.	O

To	O
compare	O
extra-renal	O
1,25(OH)2D3	O
production	O
in	O
different	O
types	O
of	O
granulomatous	O
disease	O
,	O
and	O
to	O
identify	O
the	O
cell	O
types	O
responsible,	O
we	O
have	O
evaluated	O
the	O
conversion	O
of	O
25(OH)D3	O
in	O
1,25(OH)2D3	O
by	O
uncultured	B
cells	O
recovered	O
by	O
bronchoalveolar	O
lavage	O
and	O
blood	B
mononuclear	O
cells	O
from	O
normocalcemic	O
patients	O
with	O
sarcoidosis	O
and	O
tuberculosis.	O

1,25(OH)2D3	O
was	O
produced	O
both	O
by	O
lavage	B
cells	O
(12/12	O
tuberculosis	O
patients	O
,	O
2/6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	B
mononuclear	O
cells	O
(3/5	O
tuberculosis	O
patients	O
,	O
0/3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	B
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(P	O
less	O
than	O
0.001).	O

1,25(OH)2D3	O
production	O
by	O
lavage	B
cells	O
from	O
tuberculosis	O
patients	O
correlated	O
with	O
the	O
number	O
of	O
CD8+	B
T	O
lymphocytes	O
present	O
but	O
not	O
other	O
cell	O
types.	O

T	B
lymphocytes	O
appeared	O
to	O
be	O
an	O
important	O
source	O
of	O
1,25(OH)2D3	O
production	O
,	O
since	O
purified	B
T	B
lymphocytes	O
from	O
all	O
patients	O
with	O
tuberculosis	O
produced	O
1,25(OH)2D3	O
,	O
and	O
1,25(OH)2D3	O
production	O
by	O
these	O
cells	O
correlated	O
closely	O
with	O
that	O
produced	O
by	O
unseparated	B
lavage	B
cells	O
.	O

Because	O
1,25(OH)2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	B
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage-lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1,25(OH)2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O

Megakaryocytic	B
and	O
erythrocytic	O
lineages	O
share	O
specific	O
transcription	B
factors	O
.	O

Erythroid-specific	B
genes	O
contain	O
binding	O
sites	O
for	O
NF-E1	B
(also	O
called	O
GF-1	B
and	O
Eryf-1	B
;	O
refs	B
1-3	O
respectively),	O
the	O
principal	O
DNA-binding	B
protein	O
of	O
the	O
erythrocytic	B
lineage	O
.	O

NF-E1	B
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	B
lineage	O
.	O

A	O
closely	O
related	O
(if	O
not	O
identical)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	B
megakaryocytic	O
cell	O
line	O
and	O
purified	B
human	O
megakaryocytes	O
;	O
it	O
binds	O
to	O
promoter	B
regions	O
of	O
two	O
megakaryocytic-specific	B
genes	O
.	O

The	O
binding	B
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	B
protein	O
;	O
also,	O
NF-E1	B
messenger	O
RNA	O
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	B
and	O
erythroid	O
cell	O
lines	O
.	O

Furthermore,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF-E1	B
result	O
in	O
a	O
70%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic-specific	B
promoter	O
.	O

We	O
also	O
find	O
that	O
NF-E2	B
,	O
another	O
trans-acting	B
factor	O
of	O
the	O
erythrocytic	B
lineage	O
,	O
is	O
present	O
in	O
megakaryocytes	B
.	O

Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O
mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans-acting	B
factors	O
.	O

Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	B
and	O
the	O
megakaryocytic	B
lineages	O
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	B
and	O
megakaryocytic	O
lineages	O
in	O
most	O
erythroblastic	B
and	O
megakaryoblastic	O
permanent	O
cell	O
lines	O
.	O

Transcriptional	O
down-regulation	O
of	O
c-myc	B
expression	O
by	O
protein	O
synthesis	O
-dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	B
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
.	O

We	O
show	O
that	O
in	O
the	O
human	B
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
Molt4	O
c-myc	B
mRNA	O
and	O
protein	O
expression	O
is	O
down-regulated	O
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O

A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c-myc	B
transcription	O
.	O

Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O

The	O
calcium	O
ionophore-induced	O
c-myc	B
suppression	O
,	O
however,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O

Therefore,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c-myc	B
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium	B
-dependent	O
induced	O
gene	O
product	O
.	O

Oestrogen	B
receptor	O
(	O
ER	B
)	O
analysis	O
in	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
:	O
correlation	O
of	O
biochemical	O
and	O
immunocytochemical	O
methods	O
.	O

Oestrogen	B
receptors	O
(	O
ER	B
)	O
are	O
present	O
in	O
neoplastic	B
lymphoid	O
cells	O
and	O
have	O
been	O
considered	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
differentiation.	O

Tamoxifen	O
,	O
an	O
oestrogen	O
antagonist	O
,	O
has	O
been	O
given	O
in	O
some	O
patients	O
with	O
CLL	O
and	O
Hodgkin's	O
disease	O
,	O
with	O
dramatic	O
response	O
in	O
single	O
cases.	O

Until	O
now,	O
ER	B
status	O
has	O
been	O
assessed	O
using	O
a	O
steroid	O
binding	O
assay	O
(	O
SBA	O
)	O
which	O
has	O
many	O
inherent	O
problems.	O

Recently,	O
the	O
development	O
of	O
monoclonal	B
antibodies	O
directed	O
against	O
ER	B
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	O
carcinomas	O
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O

We	O
studied	O
49	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O

In	O
30	O
of	O
these	O
cases	O
ER	B
enzyme	O
immunoassay	O
(	O
ER	B
-EIA	O
)	O
was	O
also	O
performed.	O

Cultured	B
MCF-7	O
cells	O
,	O
derived	O
from	O
a	O
pleural	O
effusion	O
of	O
a	O
breast	O
cancer	O
patient	O
,	O
known	O
to	O
contain	O
high	O
levels	O
of	O
ER	B
were	O
used	O
as	O
a	O
positive	O
control	O
(40-48%	O
ER	B
positive	O
cells	O
by	O
immunocytochemistry;	O
200	O
fmol/mg	O
protein	O
by	O
EIA).	O

All	O
of	O
the	O
CLL	O
cases	O
except	O
two	O
(96%)	O
were	O
negative	O
for	O
ER	B
(less	O
than	O
1%	O
staining;	O
less	O
than	O
4	O
fmol/mg	O
protein).	O

The	O
two	O
positive	O
cases	O
expressed	O
granular	O
ER	B
staining	O
over	O
the	O
nucleus	O
(9.2	O
and	O
12.1%	O
positive	O
cells)	O
and	O
were	O
positive	O
by	O
EIA	O
and	O
SBA	O
.	O

It	O
is	O
concluded	O
that	O
(i)	O
patients	O
with	O
CLL	O
rarely	O
express	O
ER	B
and	O
(ii)	O
immunocytochemical	O
staining	O
of	O
cytospin	O
preparations	O
is	O
a	O
valid	O
technique	O
for	O
the	O
measurement	O
of	O
ER	B
.	O

It	O
is	O
of	O
interest	O
that	O
one	O
of	O
the	O
positive	O
cases	O
was	O
diagnosed	O
as	O
CLL	O
with	O
Richter's	O
transformation	O
confirming	O
earlier	O
findings.	O

Type-II	B
estrogen	O
binding	O
sites	O
in	O
a	O
lymphoblastoid	B
cell	O
line	O
and	O
growth-inhibitory	O
effect	O
of	O
estrogen	O
,	O
anti-estrogen	O
and	O
bioflavonoids	O
.	O

Type-II	B
estrogen	O
-binding	O
sites	O
(	O
type-II	B
EBS	O
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	B
lymphoblastoid	O
cell	O
line	O
IM-9	O
using	O
a	O
whole-cell	O
assay	O
with	O
(6,7-3H)	O
estradiol	O
(	O
3H-E2	O
)	O
as	O
tracer.	O

Competition	O
analysis	O
showed	O
that	O
the	O
anti-estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(3H)-E2	O
binding	O
to	O
type-II	B
EBS	O
.	O

Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
),	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose-dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM.	O

The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type-II	B
EBS	O
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O

Moreover,	O
hesperidin,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O
type-II	B
EBS	B
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O

Cell-cycle	O
analysis	O
showed	O
that	O
the	O
growth-inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases.	O

Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti-estrogen	O
concentrations	O
and	O
flavonoids	O
may	O
regulate	O
IM-9	B
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type-II	B
EBS	O
.	O

[	O
Glucocorticoid	B
receptors	O
in	O
peripheral	B
blood	O
lymphocytes	O
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O

Quantitation	O
of	O
glucocorticoid	B
receptors	O
(	O
GCR	B
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	B
blood	O
lymphocytes	O
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	B
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O

It	O
is	O
stated	O
that	O
GCR	B
of	O
healthy	O
controls	O
and	O
GCS	O
-untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol-dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O

Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	B
count	O
in	O
cortisol	O
-dependent	O
BA	O
tends	O
to	O
rise.	O

Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	B
level	O
estimated	O
by	O
3H-triamcinolone	O
acetonide	O
.	O

Two	O
glucocorticoid	B
binding	O
sites	O
on	O
the	O
human	B
glucocorticoid	O
receptor	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	B
cells	O
via	O
interactions	O
with	O
the	O
glucocorticoid	B
receptor	O
(	O
GR	B
).	O

Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	B
with	O
one-site	O
kinetics	O
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A-ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	B
C7	O
cells	O
(a	O
human	B
acute	O
lymphoblastic	O
T-cell	O
line	O
).	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O

The	O
higher	O
affinity	B
sites	O
bind	O
CVZ	O
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
's	O
enhanced	O
biological	O
effects	O
.	O

In	O
mutant	B
leukemic	O
cells	O
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	B
affinity	O
site	O
in	O
CEM	B
C7	O
cells	O
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	B
affinity	O
CVZ	B
binding	O
site	O
.	O

We	O
now	O
show	O
that:	O
1)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	B
site	O
in	O
a	O
second,	O
independent,	O
B-cell	B
line	O
,	O
IM-9	B
;	O
2)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	B
's	O
higher	O
and	O
lower	O
affinity	O
sites;	O
3)	O
all	O
of	O
CVZ	B
's	O
binding	B
sites	O
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	B
GR	O
;	O
and	O
4)	O
freshly	O
isolated	O
clones	O
of	O
CVZ	O
-resistant	O
cells	O
have	O
lost	O
all	O
binding	B
sites	O
for	O
CVZ	O
.	O

These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	B
binding	O
sites	O
on	O
the	O
human	B
GR	O
or	O
a	O
protein	O
very	O
similar	O
to	O
it.	O

Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	B
genes	O
in	O
primary	B
lymphoid	O
cells	O
:	O
assaying	O
for	O
a	O
viral	O
transactivator	B
activity	O
in	O
normal	B
and	O
malignant	O
cells	O
.	O

In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	B
promoter	O
in	O
primary	B
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O

The	O
infection	O
of	O
a	O
variety	O
of	O
cultured	O
and	O
primary	B
lymphoid	O
cells	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
a	O
histone	B
promoter-driven	O
beta-galactosidase	B
gene	O
is	O
shown	O
to	O
result	O
in	O
the	O
expression	O
of	O
beta-galactosidase	B
in	O
50%	O
to	O
100%	O
of	O
the	O
cells.	O

A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta-galactosidase	B
gene	O
with	O
an	O
adenovirus	B
E2	O
promoter	O
,	O
results	O
in	O
beta-galactosidase	B
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	B
and	O
primary	O
cells	O
.	O

Since	O
the	O
adenovirus	B
E2	O
promoter	O
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	B
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	B
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B
gene	O
products	O
.	O

[The	O
effect	O
of	O
24,25-dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O

Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R,25	O
(OH)2D3	O
(	O
dioxyvit	O
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O

The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	O
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	B
and	O
0-	O
lymphocytes	O
.	O

Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1,25(OH)2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	B
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression,	O
after	O
the	O
dioxyvit	O
action,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O

Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	O
with	O
simultaneous	O
correction	O
of	O
vitamin	O
D	O
deficiency	O
were	O
apparently	O
responsible	O
for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	O
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	O
kidney	O
insufficiency	O
.	O

[The	O
role	O
of	O
glucocorticoid	B
receptors	O
and	O
HLA	B
antigens	O
in	O
the	O
pathogenesis	O
of	O
Cushing's	O
syndrome	O
]	O

Lymphocytic	O
levels	O
of	O
glucocorticoid	B
receptors	O
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko-	O
Cushing's	O
syndrome	O
.	O

Incidence	O
of	O
HLA	B
antigens	O
was	O
determined	O
in	O
94	O
of	O
them.	O

A	O
significant	O
rise	O
of	O
A10	B
and	O
B27	B
antigen	O
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko-	O
Cushing's	O
syndrome	O
.	O

The	O
levels	O
of	O
glucocorticoid	B
receptors	O
in	O
lymphocytes	B
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O

The	O
patients	O
carrying	O
B27	B
antigen	O
had	O
lymphocytic	B
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage.	O

Antigen	B
B27	O
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B
receptors	O
in	O
blood	B
lymphocytes	O
.	O

Effects	O
of	O
1	O
alpha,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	B
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
RWLeu-4	B
.	O

The	O
effects	O
of	O
1	O
alpha,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	B
chromosome-positive	O
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
,	O
RWLeu-4	B
,	O
were	O
investigated.	O

Binding	O
of	O
[3H]VD3	O
was	O
saturable,	O
with	O
approximately	O
2000-3000	O
sites/cell,	O
and	O
half-maximal	O
binding	O
occurring	O
at	O
0.21-0.33	O
nM.	O

Treatment	O
of	O
RWLeu-4	B
cells	O
with	O
VD3	O
induced	O
24R-hydroxylase	B
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues.	O

Exposure	O
of	O
RWLeu-4	B
cells	O
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50%	O
effective	O
dose	O
of	O
3.5-10	O
nM	O
within	O
72	O
h;	O
in	O
addition,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O

Exposure	O
of	O
RWLeu-4	B
cells	O
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage/monocyte	B
type	O
cells	O
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic.	O

Progressive	O
expression	O
of	O
cell	B
surface	O
maturation-specific	O
antigens	O
of	O
the	O
monocyte/macrophage	B
lineage	O
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	B
cells	O
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O

c-myc	B
RNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	B
cells	O
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment.	O

Finally,	O
the	O
in	O
vitro	O
tyrosine	B
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr-abl	B
oncogene	O
product	O
was	O
decreased	O
approximately	O
50%	O
by	O
VD3	O
treatment	O
.	O

Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor-effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

A	O
new	O
member	O
of	O
the	O
leucine	B
zipper	O
class	O
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	B
DR	O
alpha	O
promoter	O
.	O

Several	O
mutants	O
derived	O
from	O
transformed	B
human	O
B	O
cell	O
lines	O
are	O
defective	O
in	O
expressing	O
major	B
histocompatibility	O
complex	O
(MHC)	O
class	O
II	O
genes	O
.	O

The	O
failure	O
to	O
express	O
a	O
class	B
II	O
gene	O
in	O
at	O
least	O
one	O
such	O
mutant	B
line	O
has	O
been	O
mapped	O
to	O
the	O
MHC	B
class	O
II	O
X	O
box	O
,	O
a	O
conserved	B
transcriptional	O
element	O
in	O
the	O
promoter	B
region	O
.	O

A	O
complementary	B
DNA	O
encoding	O
a	O
DNA-binding	B
protein	O
(	O
human	B
X	O
box	O
binding	O
protein	O
,	O
hXBP-1	B
)	O
whose	O
target	O
is	O
the	O
human	B
DR	O
alpha	O
X	O
box	O
and	O
the	O
3'	B
flanking	O
region	O
has	O
now	O
been	O
cloned.	O

This	O
complementary	B
DNA	O
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c-jun	B
proto-oncogene	O
product	O
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	B
target	O
sequence	O
of	O
c-jun	B
.	O

Mutation	O
of	O
the	O
hXBP-1	B
DNA	O
target	O
sequence	O
decreased	O
DR	B
alpha	O
promoter	O
activity	O
in	O
vivo.	O

These	O
studies	O
suggest	O
that	O
the	O
hXBP-1	B
protein	O
acts	O
as	O
a	O
transcription	B
factor	O
in	O
B	B
cells	O
.	O

Pseudohypoaldosteronism	O
in	O
eight	O
families:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

Pseudohypoaldosteronism	O
is	O
a	O
rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	O
and	O
hyperkalemia	O
despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	O
.	O

The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O

Absent	O
or	O
greatly	O
diminished	O
type	B
I	O
aldosterone	O
receptors	O
in	O
peripheral	B
mononuclear	O
leucocytes	O
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O

We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O

There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O

In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	O
receptor	O
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced,	O
but	O
hormone	O
levels	O
were	O
normal.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	B
mononuclear	O
leucocytes	O
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

It,	O
therefore,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O

Perceived	O
social	O
support	O
and	O
tumor	B
estrogen/progesterone	O
receptor	O
status	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
breast	O
cancer	O
patients	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	B
killer	O
(NK)	O
cell	O
activity	O
in	O
61	O
Stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70,	O
who	O
were	O
accrued	O
to	O
this	O
project.	O

All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital,	O
or	O
at	O
their	O
first	O
outpatient	O
visit,	O
within	O
two	O
weeks	O
of	O
discharge.	O

A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support,	O
as	O
a	O
potential	O
"stress"	O
buffer,	O
related	O
to	O
NK	O
activity	O
.	O

In	O
the	O
main	O
model	O
reported	O
here,	O
we	O
found	O
that	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
could	O
be	O
explained	O
by	O
five	O
variables.	O

Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O
,	O
perceived	O
social	O
support	O
from	O
the	O
patient's	O
physician	O
,	O
estrogen	B
receptor	O
-negative	O
tumor	O
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(R2	O
=	O
0.33,	O
F(5,55)	O
=	O
5.5,	O
p	O
less	O
than	O
0.0004).	O

Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	O
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O
play	O
in	O
modulating	O
such	O
activity.	O

[	O
Estrogen	B
receptor	O
content	O
of	O
peripheral	B
blood	O
lymphocytes	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O

ER	B
content	O
in	O
lymphocytes	B
of	O
peripheral	O
blood	O
from	O
27	O
SLE	O
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran-coated	O
charcoal	O
assay	O
.	O

ER	B
content	O
in	O
lymphocytes	B
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol/mg	O
of	O
lymphocyte	B
cytosolic	O
protein	O
and	O
fmol/micrograms	O
of	O
lymphocyte	B
DNA	O
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	B
content	O
of	O
lymphocytes	B
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	O
.	O

But	O
the	O
logarithmic	O
mean	O
of	O
ER	B
content	O
in	O
lymphocytes	B
,	O
expressed	O
by	O
fmol/mg	O
of	O
cytosolic	B
protein	O
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(0.9356	O
+/-	O
0.31)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(0.2979	O
+/-	O
0.23,	O
P	O
less	O
than	O
0.001)	O
and	O
in	O
the	O
controls	O
(0.6204	O
+/-	O
0.52,	O
P	O
less	O
than	O
0.001).	O

The	O
normal	O
upper	O
limit	O
of	O
ER	B
content	O
in	O
lymphocytes	B
,	O
expressed	O
by	O
fmol/micrograms	O
of	O
DNA,	O
was	O
0.136.	O

The	O
elevated	O
rate	O
of	O
ER	B
content	O
in	O
lymphocytes	B
in	O
14	O
active	O
SLE	O
(92.9%)	O
was	O
also	O
higher	O
than	O
that	O
in	O
quieiescent	O
patients	O
(23.1%,	O
P	O
less	O
than	O
0.001)	O
and	O
in	O
the	O
controls	O
(10%,	O
P	O
less	O
than	O
0.001).	O

Moreover,	O
the	O
elevated	O
level	O
of	O
ER	B
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	B
antibody	O
and	O
hypocomplementemia	O
.	O

An	O
in	O
vitro	O
globin	O
gene	O
switching	O
model	O
based	O
on	O
differentiated	B
embryonic	O
stem	O
cells	O
.	O

We	O
used	O
mouse	B
embryonic	O
stem	O
(ES)	O
cells	O
to	O
study	O
globin	B
gene	O
expression	O
and	O
switching	O
in	O
vitro.	O

We	O
show	O
that	O
ES-derived	B
embryoid	O
bodies	O
express	O
the	O
full	O
complement	O
of	O
mouse	B
embryonic	O
globin	O
genes	O
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	B
genes	O
.	O

In	O
addition,	O
the	O
erythroid-specific	B
transcription	O
factor	O
NF-E1	B
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	B
in	O
embryoid	O
bodies	O
.	O

We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	B
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O

When	O
the	O
human	B
epsilon-	O
or	O
beta-	O
globin	O
genes	O
driven	O
by	O
the	O
dominant	B
control	O
region	O
(	O
DCR	B
)	O
are	O
introduced	O
into	O
this	O
system,	O
the	O
human	B
epsilon-	O
globin	O
gene	O
,	O
in	O
contrast	O
to	O
the	O
beta-	B
globin	O
gene	O
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	B
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	B
gene	O
.	O

We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon-	B
globin	O
gene	O
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	B
beta-globin	O
locus	O
.	O

Cloning	O
of	O
a	O
mitogen-inducible	B
gene	O
encoding	O
a	O
kappa	B
B	O
DNA-binding	O
protein	O
with	O
homology	O
to	O
the	O
rel	B
oncogene	O
and	O
to	O
cell-cycle	B
motifs	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen-inducible	B
gene	O
isolated	O
from	O
human	B
T	B
cells	O
that	O
predicts	O
a	O
protein	O
of	O
968	O
amino	O
acids	O
.	O

The	O
amino-terminal	B
domain	O
has	O
regions	O
homologous	O
to	O
the	O
oncogene	B
rel	O
and	O
to	O
the	O
developmentally	B
important	O
gene	O
dorsal	O
of	O
Drosophila	O
.	O

The	O
carboxy-terminal	B
domain	O
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell-cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	B
human	O
oncogene	B
bcl-3	O
and	O
in	O
the	O
ankyrin	B
protein	O
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA-binding	B
protein	O
which	O
interacts	O
specifically	O
with	O
the	O
kappa	B
B	O
binding	O
site	O
found	O
in	O
many	O
inducible	B
genes	O
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	B
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

Extrarenal	O
receptor-effector-mechanisms	O
for	O
aldosterone	O
:	O
the	O
sequence	O
of	O
effects	O
on	O
the	O
cellular	O
electrolyte	O
transport	O
in	O
human	B
lymphocytes	O
and	O
their	O
implications	O
for	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balances	O
.	O

High	O
affinity	O
aldosterone	O
binding	O
sites	O
have	O
not	O
only	O
been	O
described	O
in	O
the	O
classic	O
target	O
tissues	O
such	O
as	O
the	O
renal	O
tubules	O
,	O
but	O
also	O
in	O
non-classic	O
target	O
tissues	O
such	O
as	O
the	O
hippocampus	O
,	O
mammary	B
gland	O
,	O
endothelial	B
cells	O
and,	O
recently,	O
human	B
mononuclear	O
leukocytes	O
.	O

An	O
in	O
vitro	O
effect	O
of	O
aldosterone	O
on	O
intracellular	O
sodium	O
,	O
potassium	O
and	O
calcium	O
concentrations	O
and	O
cell	O
volume	O
was	O
shown	O
in	O
human	B
mononuclear	O
leukocytes	O
.	O

In	O
the	O
absence	O
of	O
aldosterone	O
,	O
the	O
intracellular	O
Na+	O
,	O
K+	O
and	O
Ca2+	O
concentrations	O
and	O
the	O
cell	O
volume	O
decreased	O
significantly,	O
but	O
remained	O
constant	O
when	O
aldosterone	O
(1.4	O
nmol/l)	O
was	O
added	O
to	O
the	O
incubation	O
medium	O
.	O

These	O
effects	O
of	O
aldosterone	O
were	O
blocked	O
by	O
the	O
aldosterone	O
antagonist	O
canrenone	O
(140	O
nmol/l).	O

The	O
sodium/proton	B
exchanger	O
of	O
the	O
cell	O
membrane	O
could	O
be	O
identified	O
as	O
the	O
primary	O
target	O
of	O
the	O
aldosterone	O
action,	O
possibly	O
non-genomically	O
mediated	O
through	O
membrane	B
receptors	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
model	O
was	O
underlined	O
by	O
the	O
demonstration	O
of	O
absent	O
or	O
a	O
decreased	O
number	O
of	O
mineralocorticoid	B
receptors	O
and	O
the	O
lack	O
of	O
electrolyte	O
response	O
to	O
aldosterone	O
in	O
human	B
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
pseudohypoaldosteronism	O
and	O
aldosteronism	O
.	O

Additionally,	O
an	O
abnormal	O
effector	O
mechanism	O
could	O
be	O
demonstrated	O
in	O
human	B
mononuclear	O
leukocytes	O
from	O
essential	O
hypertensives	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
significance	O
of	O
extrarenal,	O
nonepithelial	O
mineralocorticoid	B
receptors	O
and	O
the	O
related	O
effector	O
mechanism	O
in	O
different	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balance	O
in	O
man	O
.	O

Immunohistochemical	O
study	O
of	O
steroid	O
hormones	O
and	O
an	O
estrogen	O
binding	O
assay	O
in	O
malignant	O
soft	O
tissue	O
tumors	O
.	O

Immunohistochemically,	O
the	O
immunoreaction	O
against	O
5	O
steroid	O
hormone	O
anti-sera	O
(	O
estradiol	O
,	O
estriol	O
,	O
cortisol	O
,	O
progesterone	O
and	O
testosterone	O
)	O
was	O
examined	O
in	O
39	O
cases	O
with	O
the	O
malignant	O
soft	O
tissue	O
tumors	O
(	O
fibrosarcoma	O
:	O
8,	O
malignant	O
fibrous	O
histiocytoma	O
:	O
6,	O
rhabdomyosarcoma	O
:	O
10,	O
leiomyosarcoma	O
:	O
10,	O
liposarcoma	O
:	O
5).	O

Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O

Immunostained	O
tumor	B
cells	O
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive.	O

The	O
majority	O
of	O
the	O
positive	O
cases	O
occurred	O
in	O
female	O
cases.	O

Furthermore,	O
the	O
existence	O
of	O
estrogen	B
receptor	O
(estrogen	O
binding	O
activity)	O
was	O
examined	O
histochemically	O
in	O
39	O
cases	O
and	O
it	O
was	O
detected	O
in	O
8.	O

We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	O
soft	O
tissue	O
tumors	O
.	O

Involvement	O
of	O
cyclic	B
AMP-dependent	O
protein	O
kinases	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	B
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	B
AMP-dependent	O
protein	O
kinases	O
in	O
interleukin-1	B
(IL-1)-responsive	O
cells	O
blocked	O
IL-1-induced	O
gene	O
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	B
immunoglobulin	O
enhancer	O
or	O
the	O
human	B
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

This	O
inhibitor	O
did	O
not	O
affect	O
protein	B
kinase	O
C	O
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	B
AMP-dependent	O
protein	O
kinases	O
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL-1	B
in	O
a	O
number	O
of	O
responsive	O
cell	O
types	O
.	O

The	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)	O
ORI1yt	O
enhancer	O
is	O
not	O
B-cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	B
transcription	O
factors	O
R	B
and	O
Z	B
.	O

The	O
Epstein-Barr	O
virus	O
DR	O
promoter	O
is	O
located	O
upstream	O
of	O
the	O
PstI	B
repeats	O
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	B
box	O
,	O
it	O
contains	O
an	O
upstream	B
region	O
(positions	O
-69	O
to	O
-220)	O
responsive	O
to	O
EB1	B
(Z)	O
(the	O
BZLF1-encoded	B
transcription	O
factor	O
)	O
and	O
an	O
enhancer	B
with	O
two	O
functionally	O
distinct	O
domains,	O
A	B
and	O
B	B
.	O

Domain	B
B	O
has	O
been	O
described	O
as	O
a	O
B-cell-specific	B
EB1	B
-responsive	O
element	O
(P.M.Lieberman,	O
J.M.Hardwick,	O
and	O
S.D.Hayward,	O
J.Virol.63:3040-3050,	O
1989)	O
activated	O
synergistically	O
by	O
EB1	B
and	O
R	B
,	O
an	O
EBV	B
early	O
product	O
encoded	O
by	O
the	O
open	B
reading	O
frame	O
BRLF1	B
(M.A.	O
Cox,	O
J.Leahy,	O
and	O
J.M.Hardwick,	O
J.Virol.64:313-321,	O
1990).	O

We	O
show	O
here	O
that	O
domain	B
B	O
is	O
an	O
R-responsive	B
element	O
in	O
HeLa	B
cells	O
and	O
is	O
therefore	O
not	O
an	O
EB1	B
-responsive	O
B-cell-specific	O
element	O
.	O

However,	O
there	O
is	O
an	O
EB1	B
-binding	O
site	O
(	O
ZRE-B	B
)	O
located	O
within	O
the	O
R-responsive	B
enhancer	O
region	O
.	O

ZRE-B	B
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R-dependent	B
enhancer	O
activity	O
.	O

Moreover,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	B
and	O
EB1	B
when	O
activating	O
the	O
B	B
domain	O
(	O
ZRE-B	B
plus	O
the	O
R-responsive	B
element	O
)	O
positioned	O
as	O
an	O
enhancer	O
.	O

ZRE-B	B
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	B
inducible	O
enhancer	O
.	O

We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	B
enhancer	O
B	O
domain	O
,	O
either	O
alone	O
or	O
in	O
combination,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R-activating	O
signal	O
to	O
the	O
rabbit	B
beta-globin	O
promoter	O
.	O

We	O
found	O
that	O
the	O
R-responsive	B
element	O
is	O
composed	O
of	O
four	O
protoenhancers	O
that	O
span	O
the	O
whole	O
B	B
domain	O
.	O

These	O
protoenhancers	B
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B
.	O

One	O
of	O
the	O
protoenhancers	B
contains	O
the	O
overlapping	O
palindromes	B
5'-TTGTCCcgtGGACAAaTGTCC-3'	O
.	O

However,	O
one	O
palindrome	B
,	O
either	O
alone	O
or	O
duplicated,	O
or	O
the	O
overlapping	O
palindromes	B
did	O
not	O
respond	O
to	O
R.	O

Nuclear	B
3,5,3'-triiodothyronine	O
receptors	O
(	O
T3R	B
)	O
of	O
circulating	B
human	O
lymphocytes	O
in	O
hyper-	O
and	O
hypo	O
thyroidism	O
and	O
nonthyroidal	O
diseases	O
.	O

The	O
clinical	O
implications	O
of	O
nuclear	O
T3R	B
alterations	O
of	O
circulating	B
lymphocytes	O
in	O
hyperthyroidism	O
,	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
were	O
investigated.	O

Nuclear	B
T3R	O
in	O
lymphocytes	B
was	O
determined	O
by	O
radio-ligand	O
binding	O
analysis	O
.	O

The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypo	O
thyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O

In	O
hyperthyroidism	O
nuclear	O
T3	O
maximal	O
binding	O
capacity	O
(	O
MBC	O
)	O
was	O
unaltered,	O
whereas	O
in	O
hypothyroidism	O
the	O
MBC	O
was	O
significantly	O
increased.	O

In	O
the	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
chronic	O
renal	O
failure	O
and	O
hepatic	O
cirrhosis	O
,	O
the	O
nuclear	O
T3R	B
MBC	O
of	O
lymphocytes	B
was	O
about	O
1.5-1.6	O
times	O
of	O
the	O
normal	O
controls	O
.	O

It	O
was	O
concluded	O
that	O
there	O
existed	O
hormonal	O
regulation	O
of	O
nuclear	B
T3R	B
,	O
and	O
up-regulation	O
was	O
seen	O
in	O
hypothyroidism	O
and	O
low	O
T3	O
syndrome	O
.	O

Lymphocyte	B
cell	O
lines	O
from	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B
alpha,25-dihydroxyvitamin	O
D3	O
receptor	O
.	O

Lymphocyte	B
cell	O
lines	O
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	O
D-dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR-II	O
).	O

These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T-lymphotrophic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
).	O

Binding	O
of	O
[3H]1	O
alpha,25-dihydroxyvitamin	O
D3	O
(	O
1,25(OH)2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T-lymphocyte	B
cell	O
line	O
(	O
S-LB1	B
)	O
from	O
a	O
normal	O
individual.	O

The	O
1,25(OH)2D3	B
receptor	O
of	O
S-LB1	B
was	O
comparable	O
to	O
the	O
well-characterized	O
chick	B
intestinal	O
1,25(OH)2D3	O
receptor	O
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity,	O
its	O
mobility	O
on	O
5-20%	O
sucrose	O
gradients,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA-cellulose	O
.	O

Three	O
cell	B
lines	O
established	O
from	O
patients	O
with	O
VDDR-II	O
(	O
Rh-	B
VDR	O
,	O
Sh-	B
VDR	O
,	O
and	O
Ab-	B
VDR	O
)	O
showed	O
no	O
specific	O
binding	O
of	O
1,25(OH)2D3	O
to	O
a	O
receptor	O
and	O
treatment	O
of	O
the	O
cultured	B
cells	O
with	O
1,25(OH)2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24,25-dihydroxy-vitamin	O
D3	O
(	O
24,25(OH)2D3	O
),	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	O
1,25(OH)2D3	B
receptor	O
.	O

In	O
a	O
fourth	B
cell	O
line	O
,	O
A1-VDR	B
,	O
the	O
receptor	O
for	O
1,25(OH)2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25(OH)D3-24-hydroxylase	B
activity	O
was	O
not	O
detectable.	O

Induction	O
of	O
24,25-(OH)2D3	O
synthesis	O
by	O
1,25(OH)2D3	O
was	O
observed	O
in	O
the	O
fifth	B
cell	O
line	O
,	O
designated	O
Ro-VDR	B
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	B
cell	O
line	O
from	O
a	O
normal	O
donor	O
.	O

The	O
capacity	O
of	O
the	O
receptor	O
for	O
1,25(OH)2D3	O
was	O
low	O
in	O
Ro-VDR	B
.	O

In	O
all	O
cell	B
lines	O
where	O
1,25(OH)2D3	O
binding	O
to	O
a	O
receptor	O
was	O
detectable,	O
the	O
receptor	O
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3.7	O
S	O
on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O

Binding	O
and	O
elution	O
properties	O
to	O
DNA-cellulose	B
,	O
however,	O
differed	O
from	O
normal	O
in	O
both	O
Ro-VDR	B
and	O
A1-VDR	B
cells	O
where	O
elution	O
from	O
DNA-cellulose	B
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1,25(OH)2D3	B
receptor	O
.	O

While	O
Ro-VDR	B
cells	O
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	B
1,25(OH)2D3	O
receptor	O
,	O
neither	O
the	O
unoccupied	B
nor	O
the	O
occupied	O
receptor	O
from	O
A1-VDR	B
cells	O
was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O

In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	B
coding	O
for	O
both	O
the	O
c-myc	B
oncogene	O
and	O
the	O
growth	B
factor	O
known	O
as	O
granulocyte-monocyte	B
colony	O
stimulating	O
activity	O
by	O
1,25(OH)2D3	O
correlated	O
with	O
the	O
1,25(OH)2D3	B
receptor	O
status	O
of	O
these	O
cells.	O

Use	O
of	O
these	O
cell	B
lines	O
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect(s)	O
in	O
the	O
receptor	O
for	O
1,25(OH)2D3	O
in	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O

Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	B
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	B
myeloid	O
leukemic	O
cells	O
.	O

AP-1	B
,	O
the	O
polypeptide	B
product	O
of	O
c-jun	B
,	O
recognizes	O
and	O
binds	O
to	O
specific	B
DNA	B
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	O
responsive	O
to	O
certain	O
growth	B
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
).	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	B
gene	O
expression	O
in	O
HL-60	B
cells	O
during	O
monocytic	O
differentiation	O
.	O

Low	O
levels	O
of	O
c-jun	B
transcripts	O
were	O
detectable	O
in	O
untreated	O
HL-60	B
leukemic	O
cells	O
,	O
increased	O
significantly	O
by	O
6	O
h,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O

Similar	O
kinetics	O
of	O
c-jun	B
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	B
U-937	O
and	O
THP-1	B
monocytic	O
leukemia	O
cells	O
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(10	O
nM),	O
another	O
activator	O
of	O
protein	B
kinase	O
C	O
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore,	O
1,25-dihydroxyvitamin	O
D3	O
(0.5	O
microM),	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	B
expression	O
.	O

TPA	O
treatment	O
of	O
HL-60	B
cells	O
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c-jun	B
transcripts.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	B
gene	O
transcription	O
in	O
untreated	O
HL-60	B
cells	O
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3.3-fold.	O

Treatment	O
of	O
HL-60	B
cells	O
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c-jun	B
transcription	O
.	O

The	O
half-life	O
of	O
c-jun	B
RNA	O
as	O
determined	O
by	O
treating	O
HL-60	B
cells	O
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min.	O

In	O
contrast,	O
the	O
half-life	O
of	O
c-jun	B
RNA	O
in	O
TPA	B
-treated	O
HL-60	B
cells	O
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c-jun	B
RNA	O
observed	O
during	O
TPA	O
-induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	B
receptors	O
in	O
patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O

As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	O
were	O
examined.	O

Four	O
variants	O
of	O
changes	O
in	O
the	O
thyroid	O
status	O
,	O
characteristic	O
of	O
children	O
with	O
different	O
variants	O
of	O
nephrotic	O
syndrome	O
were	O
distinguished:	O
1)	O
biochemical	O
signs	O
of	O
primary	O
hypothyroidism	O
,	O
2)	O
biochemical	O
signs	O
of	O
secondary	O
hypothyroidism	O
,	O
3)	O
low	O
content	O
of	O
T3,	O
4)	O
dysfunction	O
of	O
the	O
hypophyseal	O
and	O
thyroid	O
system	O
.	O

It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	B
receptors	O
,	O
thyroid	O
hormones	O
that	O
the	O
low	O
level	O
of	O
steroid	B
receptors	O
,	O
thyroid	O
hormones	O
(T3	O
and	O
T4)	O
and	O
cortisol	O
is	O
typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	O
dysplasia	O
.	O

It	O
is	O
assumed	O
that	O
superaddition	O
under	O
such	O
conditions	O
of	O
immune	O
glomerulopathy	O
(	O
glomerulonephritis	O
and	O
nephrotic	O
syndrome	O
)	O
gives	O
rise	O
to	O
the	O
resistance	O
to	O
the	O
treatment	O
with	O
glucocorticoids	O
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	B
early	O
region	O
3	O
promoter	O
is	O
mediated	O
by	O
NF-kappa	B
B	O
binding	O
motifs	O
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	B
cells	O
.	O

However,	O
analysis	O
of	O
the	O
viral	B
control	O
elements	O
and	O
the	O
cellular	B
factors	O
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	B
has	O
not	O
been	O
reported.	O

The	O
adenovirus	B
early	O
region	O
3	O
(	O
ES	O
)	O
gene	O
products	O
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	B
I	O
MHC	O
antigens	O
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O

To	O
determine	O
whether	O
different	O
cellular	B
factors	O
were	O
involved	O
in	O
E3	B
regulation	O
in	O
lymphocytes	B
as	O
compared	O
with	O
HeLa	B
cells	O
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	B
promoter	O
in	O
both	O
cell	O
types	O
were	O
performed.	O

These	O
studies	O
detected	O
two	O
novel	O
domains	B
referred	O
to	O
as	O
L1	B
and	O
L2	B
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	B
factor	O
NF-kappa	B
B	O
.	O

Transfections	O
of	O
E3	B
constructs	O
linked	O
to	O
the	O
chloramphenicol	B
acetyltransferase	O
gene	O
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	B
NF-kappa	B
B	O
motif	O
(	O
L2	B
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	B
cells	O
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	B
cells	O
.	O

In	O
contrast,	O
mutagenesis	O
of	O
proximal	B
NF-kappa	B
B	O
motif	O
(	O
L1	B
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	B
cells	O
and	O
lymphoid	B
cells	O
but	O
resulted	O
in	O
a	O
small,	O
but	O
reproducible,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	B
cells	O
when	O
coupled	O
to	O
the	O
L2	B
mutation	O
.	O

Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	B
and	O
L2	O
domains	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	B
promoter	O
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

Characterization	O
of	O
defensin	B
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	B
virulence	O
regulon	O
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	B
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP/phoQ	B
two-component	O
virulence	O
regulon	O
were	O
tested	O
by	O
using	O
purified	O
defensins	B
NP-1	B
and	O
NP-2	B
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	B
pair	O
(	O
phoP	B
[	O
transcriptional	B
activator	O
]	O
or	O
phoQ	B
[	O
membrane	B
sensor	O
kinase	O
])	O
had	O
increased	O
sensitivities	O
to	O
defensin	B
.	O

The	O
predicted	O
periplasmic	B
domain	O
of	O
the	O
PhoQ	B
protein	O
contained	O
a	O
markedly	O
anionic	B
domain	O
that	O
could	O
interact	O
with	O
cationic	B
proteins	O
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	B
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	B
are	O
polar	O
on	O
phoQ	B
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	B
protein	O
in	O
the	O
absence	O
of	O
PhoP	B
to	O
test	O
whether	O
resistance	O
to	O
defensin	B
requires	O
only	O
the	O
phoQ	B
gene	O
product	O
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	B
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	B
without	O
PhoP	B
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	B
.	O

This	O
implied	O
that	O
a	O
pag	B
(	O
phoP	B
-activated	O
gene	O
)	O
product	O
is	O
responsible	O
for	O
defensin	B
resistance	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	B
NP-1	B
,	O
NP-5	B
,	O
and	O
HNP-1	B
to	O
activate	O
pag	B
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect.	O

Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP	B
-PhoQ	O
regulon	O
because	O
mutations	O
in	O
pagC	B
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	B
locus	O
that	O
resulted	O
in	O
constitutive	O
pag	B
activation	O
(phenotype	O
PhoPc	B
),	O
had	O
no	O
effect	O
on	O
defensin	B
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	B
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	B
-phoQ	O
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	B
proteins	O
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	B
.	O

Stimulation	O
of	O
a	O
human	B
T-cell	O
clone	O
with	O
anti-CD3	B
or	O
tumor	B
necrosis	O
factor	O
induces	O
NF-kappa	B
B	O
translocation	O
but	O
not	O
human	B
immunodeficiency	O
virus	O
1	O
enhancer-dependent	O
transcription	O
.	O

The	O
expression	O
of	O
transiently	B
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	B
terminal	O
repeat	O
(	O
LTR	B
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	B
sequence	O
and	O
the	O
translocation	O
of	O
the	O
HIV	B
enhancer-binding	O
protein	O
NF-kappa	B
B	O
were	O
analyzed	O
in	O
two	O
human	B
T-cell	O
clones	O
stimulated	O
through	O
their	O
T-cell	B
receptor	O
complex	O
or	O
by	O
tumor	B
necrosis	O
factor	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B
B	O
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	B
LTR	O
or	O
the	O
HIV	B
enhancer	O
.	O

Interleukin	B
2	O
induced	O
proliferation	O
but	O
not	O
NF-kappa	B
B	O
translocation	O
or	O
LTR	B
transactivation	O
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	B
LTR	B
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	B
did	O
not.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B
B	O
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	B
B	O
by	O
tumor	B
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	B
is	O
not	O
sufficient	O
to	O
induce	O
HIV	B
enhancer	O
-dependent	O
transcription	O
in	O
cloned	B
T	O
cells	O
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	B
T-cell	O
lines	O
and	O
indicates	O
that	O
normal	B
T	O
lymphocytes	O
differ	O
from	O
tumoral	B
T	O
cells	O
in	O
terms	O
of	O
requirements	O
for	O
HIV	B
LTR	O
activation	O
.	O

Furthermore,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B
B	O
translocation	O
per	O
se,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B
B	O
complex	O
with	O
the	O
HIV	B
enhancer	O
.	O

Decreased	O
concentration	O
of	O
1,25-dihydroxyvitamin	B
D3	O
receptors	O
in	O
peripheral	B
mononuclear	O
cells	O
of	O
patients	O
with	O
X-linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O

Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X-linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
).	O

However,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
cannot	O
be	O
explained	O
by	O
hypophosphatemia	O
alone.	O

Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	B
(	O
VDR	B
),	O
abnormalities	O
of	O
VDR	B
have	O
been	O
postulated	O
in	O
XLH	O
.	O

In	O
order	O
to	O
investigate	O
this	O
possibility,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B
in	O
PHA-activated	B
peripheral	O
mononuclear	O
cells	O
from	O
10	O
XLH	O
patients	O
.	O

Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(21.7	O
+/-	O
5.1	O
fmol/mg	O
protein,	O
mean	O
+/-	O
SEM)	O
compared	O
to	O
the	O
normal	O
controls	O
(60.7	O
+/-	O
4.0).	O

On	O
the	O
contrary,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate-supplemented	O
patients	O
(58.3	O
+/-	O
2.7)	O
and	O
controls	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B
concentration	O
and	O
serum	O
phosphate	O
(P	O
less	O
than	O
0.05).	O

In	O
two	O
patients	O
,	O
VDR	B
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started.	O

These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O

Two	O
distinct	O
forms	O
of	O
active	O
transcription	O
factor	O
CREB	B
(	O
cAMP	B
response	O
element	O
binding	O
protein	O
).	O

Mammalian	B
cells	O
express	O
two	O
distinct	O
forms	O
of	O
transcription	B
factor	O
CREB	B
(	O
cAMP	B
response	O
element	O
binding	O
protein	O
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	B
gene	O
transcript	O
.	O

The	O
two	O
proteins	O
differ	O
by	O
a	O
14-amino	B
acid	O
serine-rich	O
insertion	O
present	O
in	O
one	O
of	O
the	O
CREB	B
isoforms	O
.	O

We	O
show	O
that	O
both	O
CREB	B
isoforms	O
are	O
expressed	O
in	O
many	O
cell	O
types	O
and	O
mammalian	O
species	O
.	O

Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	B
response	O
element	O
in	O
vitro	O
.	O

As	O
expected	O
for	O
proteins	O
of	O
this	O
class,	O
the	O
CREB	B
proteins	O
bind	O
DNA	O
as	O
dimers.	B

Both	O
proteins	O
impart	O
cAMP	O
-regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	B
DNA-binding	O
domain	O
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	B
.	O

The	O
presence	O
of	O
multiple	O
CREB	B
isoforms	O
with	O
identical	O
DNA-binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	B
domain	O
raises	O
the	O
possibility	O
that	O
CREB	B
proteins	O
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Human	B
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion-associated	B
regulatory	O
protein	O
.	O

The	O
vpr	B
product	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	B
cells	O
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	B
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	B
protein	O
.	O

The	O
vpr	B
product	O
is	O
the	O
first	O
regulatory	B
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	B
particle	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	B
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	B
protein	O
synthesis	O
occurs.	O

A	O
novel	O
B-cell	B
lineage-specific	O
transcription	O
factor	O
present	O
at	O
early	O
but	O
not	O
late	O
stages	O
of	O
differentiation	O
.	O

A	O
novel	O
B-cell-specific	B
transcription	O
factor	O
,	O
BSAP	B
,	O
was	O
identified	O
as	O
a	O
mammalian	O
homolog	O
of	O
the	O
sea	B
urchin	O
protein	O
TSAP	B
,	O
which	O
interacts	O
with	O
the	O
promoters	B
of	O
four	O
tissue-specific	B
late	O
histone	O
H2A-2	O
and	O
H2B-2	O
genes	O
.	O

As	O
shown	O
by	O
mobility-shift	O
,	O
methylation	O
interference	O
,	O
and	O
mutational	O
analyses	O
,	O
the	O
mammalian	B
protein	O
BSAP	B
recognizes	O
all	O
four	O
sea	B
urchin	O
binding	O
sites	O
in	O
a	O
manner	O
indistinguishable	O
from	O
TSAP	B
;	O
however,	O
the	O
two	O
proteins	O
differ	O
in	O
molecular	O
weight.	O

BSAP	B
is	O
exclusively	O
restricted	O
to	O
the	O
B-cell	B
lineage	O
of	O
lymphoid	O
differentiation	O
.	O

Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro-B-cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre-B-	O
and	O
mature	O
B-	O
cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	B
differentiated	O
plasma	O
cells	O
.	O

Moreover,	O
BSAP	B
is	O
clearly	O
a	O
B-cell-specific	B
transcription	O
factor	O
,	O
as	O
a	O
wild-type	B
but	O
not	O
a	O
mutant	O
TSAP	B
-binding	O
site	O
of	O
the	O
sea	O
urchin	O
functions	O
only	O
in	O
transfected	B
B	O
cells	O
as	O
an	O
upstream	B
promoter	O
element	O
.	O

Competition	O
experiments	O
did	O
not	O
reveal	O
any	O
high-affinity	B
binding	O
site	O
for	O
BSAP	B
in	O
known	O
regulatory	B
regions	O
of	O
immunoglobulin	B
and	O
class	O
II	O
major	O
histocompatibility	O
(MHC)	O
genes	O
,	O
suggesting	O
that	O
BSAP	B
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O
B-lymphoid-specific	B
genes	O
.	O

Octamer	B
transcription	B
factors	O
and	O
the	O
cell	O
type-specificity	O
of	O
immunoglobulin	B
gene	O
expression	O
.	O

Antibodies	B
are	O
produced	O
exclusively	O
in	O
B	B
lymphocytes	O
.	O

The	O
expression	O
of	O
the	O
antibody-encoding	B
genes	O
,	O
the	O
immunoglobulin	B
(Ig)	O
genes	O
,	O
is	O
also	O
restricted	O
to	O
B	B
cells	O
.	O

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	B
and	O
the	O
enhancer	B
of	O
Ig	B
genes	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O

This	O
sequence	O
motif	O
is	O
a	O
binding	B
site	O
for	O
nuclear	B
proteins	O
,	O
the	O
so-called	O
octamer	B
transcription	B
factors	O
(	O
Oct	B
or	O
OTF	O
factors	O
).	O

The	O
Oct-1	B
protein	O
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far,	O
whereas	O
Oct-2A	B
and	O
Oct-2B	B
are	O
found	O
mainly	O
in	O
B	B
lymphocytes	O
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell-specific	O
expression	O
of	O
Ig	B
genes	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	B
type-specific	O
Oct	O
factors	O
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	B
and	O
Oct-2	O
factors	O
.	O

Recently,	O
a	O
number	O
of	O
other	O
octamer	B
factor	O
variants	O
were	O
identified.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	B
transcript	O
of	O
one	O
Oct	B
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	B
Ig	O
heavy	O
chain	O
enhancer	O
only	O
in	O
lymphocytes	B
is	O
a	O
ubiquitously	B
active	O
transcription	O
factor	O
.	O

The	O
transcriptional	B
enhancer	O
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	B
heavy	O
chain	O
constant	O
region	O
is	O
a	O
major	O
determinant	O
of	O
B-cell-specific	O
expression	O
of	O
immunoglobulin	B
genes	O
.	O

Like	O
other	O
enhancers	O
,	O
the	O
Ig	B
heavy	O
chain	O
enhancer	O
contains	O
several	O
short	O
sequence	O
motifs	O
that	O
bind	O
specific	O
transcription	B
factors	O
.	O

Each	O
binding	B
site	O
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	B
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	B
heavy	O
chain	O
enhancer	O
components	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	O
elements	O
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	B
enhancer	O
motif	O
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	O
transcription	B
factor	O
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	B
cells	O
and	O
non-	B
B	B
cells	O
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo.	O

However,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	B
reporter	O
gene	O
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non-	B
lymphoid	O
cells	O
:	O
In	O
previous	O
experiments	O
by	O
others,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor,	O
designated	O
NF-muE3	B
,	O
was	O
detected	O
in	O
B	B
cells	O
but	O
not	O
in	O
non-B	B
cells	O
.	O

From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell-type-specific	O
transcription	O
in	O
B	B
lymphocytes	O
:	O
(a)	O
cell-specific	B
factors	O
such	O
as	O
Oct-2A	B
and	O
Oct-2B	B
that	O
are	O
not	O
expressed	O
in	O
most	O
other	O
cell	O
types:	O
(b)	O
ubiquitous	B
factors	O
such	O
as	O
NF-kappa	B
B	O
that	O
are	O
constitutively	O
active	O
in	O
B	B
cells	O
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells;	O
(c)	O
ubiquitously	B
active	O
factors	O
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	B
sequence	O
motif	O
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	B
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non-B	B
cells	O
,	O
perhaps	O
due	O
to	O
a	O
non-permissive	B
chromatin	O
structure	O
of	O
the	O
Ig	B
heavy	O
chain	O
locus	O
.	O

[	O
Endocrine	O
status	O
changes	O
in	O
children	O
with	O
bronchial	O
asthma	O
]	O

A	O
study	O
was	O
made	O
of	O
adrenocortical	O
function	O
by	O
measuring	O
blood	O
plasma	O
cortisol	O
concentration	O
and	O
amount	O
of	O
glucocorticoid	B
receptors	O
in	O
lymphocytes	B
as	O
well	O
as	O
thyroid	O
function	O
by	O
measuring	O
blood	O
plasma	O
triidothyronine	O
and	O
thyroxine	O
concentration	O
in	O
58	O
bronchial	O
asthma	O
children	O
aged	O
1	O
to	O
14	O
years.	O

The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out.	O

TAR	B
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	B
ester	O
stimulated	O
T	B
lymphocytes	O
.	O

Multiple	O
regulatory	B
elements	O
in	O
the	O
human	B
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
(	O
HIV	B
LTR	O
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O

Previous	O
transfection	O
studies	O
of	O
HIV	B
LTR	O
constructs	O
linked	O
to	O
the	O
chloramphenicol	B
acetyltransferase	O
gene	O
indicated	O
that	O
multiple	O
regulatory	B
regions	O
including	O
the	O
enhancer	B
,	O
SP1	B
,	O
TATA	B
and	O
TAR	B
regions	O
were	O
important	O
for	O
HIV	O
gene	O
expression	O
.	O

To	O
characterize	O
these	O
regulatory	B
elements	O
further,	O
mutations	O
in	O
these	O
regions	O
were	O
inserted	O
into	O
both	O
the	O
5'	B
and	O
3'	O
HIV	O
LTRs	O
and	O
infectious	B
proviral	O
constructs	O
were	O
assembled.	O

These	O
constructs	O
were	O
transfected	O
into	O
either	O
HeLa	B
cells	O
,	O
Jurkat	B
cells	O
or	O
U937	B
cells	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
phorbol	O
esters	O
which	O
have	O
previously	O
been	O
demonstrated	O
to	O
activate	O
HIV	O
gene	O
expression	O
.	O

Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O
of	O
p24	B
gag	O
protein	O
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	B
constructs	O
.	O

Results	O
in	O
all	O
cell	B
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	B
,	O
TATA	B
and	O
the	O
TAR	B
loop	O
and	O
stem	B
secondary	O
structure	O
resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	B
motif	O
or	O
TAR	B
primary	O
sequence	O
resulted	O
in	O
only	O
slight	O
decreases.	O

However,	O
viruses	O
containing	O
mutations	O
in	O
either	O
the	O
TAR	B
loop	O
sequences	O
or	O
stem	B
secondary	O
structure	O
which	O
were	O
very	O
defective	O
for	O
gene	O
expression	O
in	O
untreated	O
Jurkat	B
cells	O
,	O
gave	O
nearly	O
wild-type	O
levels	O
of	O
gene	O
expression	O
in	O
phorbol	B
ester	O
-treated	O
Jurkat	B
cells	O
but	O
not	O
in	O
phorbol	B
ester	O
-treated	O
HeLa	B
or	O
U937	B
cells	O
.	O

High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	B
mutant	O
constructs	O
in	O
phorbol	B
ester	O
-treated	O
Jurkat	B
cells	O
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	B
region	O
or	O
by	O
disruption	O
of	O
the	O
tat	B
gene	O
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

A	O
case	O
of	O
hypersensitivity	O
to	O
thyroid	O
hormones	O
with	O
normally	O
functioning	O
thyroid	O
gland	O
and	O
increased	O
nuclear	B
triiodothyronine	O
receptors	O
.	O

A	O
52-year-old	O
male	O
presented	O
himself	O
with	O
tachycardia	O
crises	O
which	O
appeared	O
first	O
during	O
childhood,	O
increased	O
in	O
frequency	O
without	O
goiter	O
or	O
exophthalmos	O
.	O

Cardiac	O
and	O
adrenergic	O
diseases	O
were	O
excluded.	O

The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	O
,	O
free	O
T4	O
and	O
T3	O
,	O
TBG	O
,	O
radioiodine	O
uptake	O
,	O
TSH	O
and	O
T3	O
suppressibility	O
;	O
however	O
the	O
TSH	O
response	O
to	O
TRH	B
was	O
decreased.	O

The	O
lymphocyte	B
nuclear	O
T3	O
receptor	O
was	O
found	O
with	O
an	O
affinity	O
close	O
to	O
that	O
of	O
normal	O
volunteers	O
(Ka:	O
1.42	O
x	O
10(10)	O
M-1	O
vs	O
1.95	O
+/-	O
0.35	O
x	O
10(10)	O
M-1)	O
and	O
a	O
binding	O
capacity	O
markedly	O
increased	O
(9.9	O
vs	O
3.7	O
+/-	O
0.4	O
fmol	O
T3	O
/100	O
micrograms	O
DNA).	O

Pindolol	O
was	O
inefficient	O
on	O
the	O
dysrhythmia	O
which	O
disappeared	O
with	O
carbimazole	O
and	O
relapsed	O
after	O
withdrawal	O
of	O
the	O
antithyroid	O
drug.	O

Under	O
carbimazole	O
,	O
the	O
plasma	O
T4	O
markedly	O
decreased	O
(27.7	O
+/-	O
3.6	O
nmol/l)	O
but	O
the	O
patient	O
remained	O
euthyroid	O
.	O

The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B
nuclear	O
receptor	O
sites	O
in	O
lymphocytes	B
.	O

Induction	O
of	O
immediate	B
early	O
response	O
genes	O
by	O
macrophage	B
colony-stimulating	O
factor	O
in	O
normal	B
human	O
monocytes	O
.	O

A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	B
,	O
cytoskeletal	B
,	O
and	O
extracellular	O
matrix	O
genes	O
have	O
been	O
termed	O
immediate	B
early	O
response	O
genes	O
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	B
factor	O
-stimulated	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage-CSF	B
(	O
M-CSF	B
)	O
in	O
human	B
monocytes	O
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M-CSF	B
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O

Normal	O
human	B
monocytes	O
were	O
isolated,	O
carefully	O
washed,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum-containing	O
medium	O
.	O

At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	B
cells	O
were	O
stimulated	O
with	O
M-CSF	B
,	O
and	O
RNA	B
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
control	O
resting	B
cells	O
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c-jun	B
,	O
fibronectin	B
receptor	O
,	O
and	O
actin	O
mRNA	O
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	B
,	O
however,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes.	O

The	O
c-jun	B
gene	O
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M-CSF	B
addition	O
.	O

In	O
contrast,	O
the	O
expression	O
of	O
actin	B
and	O
fibronectin	O
receptor	O
mRNA	O
was	O
more	O
sustained,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M-CSF	B
addition	O
.	O

We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	B
specific	O
tyrosine	O
kinase	O
hck	B
gene	O
simultaneously	O
with	O
the	O
other	O
immediate	B
early	O
response	O
genes	O
.	O

The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes,	O
and	O
in	O
fact,	O
super-induced	O
the	O
expression	O
of	O
c-jun	B
and	O
hck	B
.	O

Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c-jun	B
,	O
hck	O
,	O
and	O
actin	O
genes	O
.	O

Therefore,	O
in	O
normal	B
human	B
monocytes	O
M-CSF	B
induces	O
immediate	B
early	O
response	O
genes	O
without	O
inducing	O
cell	O
proliferation.	O

These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	B
.	O

Inducible	O
nuclear	B
factor	O
binding	O
to	O
the	O
kappa	B
B	O
elements	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
enhancer	O
in	O
T	B
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal-dependent	O
manner	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	B
genes	O
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	B
.	O

In	O
addition,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B
factors	O
in	O
T	B
cells	O
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	B
DNA-binding	O
complexes	O
,	O
the	O
kappa	B
B	O
complex	O
within	O
the	O
HIV	B
enhancer	O
and	O
the	O
NFAT-1	B
complex	O
within	O
the	O
interleukin-2	B
enhancer	O
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	B
enhancer	O
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	B
phytohemagglutinin	O
whereas	O
phorbol	O
myristate	O
acetate	O
-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B
B	O
complexes	O
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O

Purification	O
of	O
TCF-1	B
alpha	O
,	O
a	O
T-cell-specific	B
transcription	O
factor	O
that	O
activates	O
the	O
T-cell	B
receptor	O
C	O
alpha	O
gene	O
enhancer	O
in	O
a	O
context-dependent	O
manner.	O

The	O
differentiation	O
of	O
T	B
cells	O
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O

We	O
have	O
purified	O
a	O
new	O
T-cell-specific	B
factor	O
,	O
TCF-1	B
alpha	O
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	B
T-cell	O
receptor	O
(	O
TCR	B
).	O

TCF-1	B
alpha	O
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	B
sites	O
on	O
the	O
HIV-1	B
promoter	O
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	B
alpha	O
enhancer	O
and	O
to	O
promoters	O
for	O
several	O
genes	O
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T-cell	O
development	O
than	O
the	O
TCR	B
alpha	O
gene	O
(e.g.,	O
p56lck	B
and	O
CD3	B
delta	O
).	O

Sequences	O
related	O
to	O
the	O
TCF-1	B
alpha	O
binding	B
motif	O
(	O
5'-GGCACCCTTTGA-3'	B
)	O
are	O
also	O
found	O
in	O
the	O
human	B
TCR	O
delta	O
(and	O
possibly	O
TCR	B
beta	O
)	O
enhancers	O
.	O

Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF-1	B
alpha	O
activity	O
is	O
derived	O
from	O
a	O
family	O
of	O
57-	B
to	O
53-kD	O
proteins	O
that	O
are	O
abundantly	O
expressed	O
in	O
mature	B
and	O
immature	O
T-cell	O
lines	O
(	O
Jurkat	B
,	O
CCRF-CEM	B
)	O
and	O
not	O
in	O
mature	B
B	O
cells	O
(	O
JY	B
,	O
Namalwa	B
)	O
or	O
nonlymphoid	B
(HeLa)	O
cell	O
lines	O
.	O

A	O
small	O
95-bp	B
fragment	O
of	O
the	O
TCR	B
alpha	O
control	O
region	O
that	O
contains	O
the	O
TCF-1	B
alpha	O
binding	B
site	O
juxtaposed	O
between	O
a	O
cAMP-response	B
element	O
(the	O
CRE	B
or	O
T	B
alpha	O
1	O
motif	O
)	O
and	O
the	O
binding	B
site	O
for	O
a	O
distinct	O
lymphoid-specific	B
protein	O
(	O
TCF-2	B
alpha	O
)	O
behaved	O
as	O
a	O
potent	O
T-cell-specific	B
enhancer	O
in	O
vivo.	O

Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	B
(Jurkat)	O
T-cell	O
lines	O
as	O
well	O
as	O
resting	B
and	O
activated	O
immature	O
(CCRF-CEM)	O
T-cell	O
lines	O
.	O

Mutation	O
of	O
the	O
TCF-1	B
alpha	O
binding	O
site	O
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	B
enhancer	O
repeats	O
.	O

The	O
TCF-1	B
alpha	O
binding	O
site	O
was	O
also	O
required	O
for	O
TCR	B
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	B
but	O
not	O
HeLa	B
cells	O
,	O
confirming	O
that	O
TCF-1	B
alpha	O
is	O
a	O
T-cell-specific	B
transcription	O
factor	O
.	O

Curiously,	O
the	O
TCF-1	B
alpha	O
binding	B
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	B
alpha	O
enhancer	O
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	B
promoter	O
.	O

Thus,	O
the	O
transcriptional	O
activity	O
of	O
TCF-1	B
alpha	O
appears	O
to	O
depend	O
on	O
the	O
TCF-2	B
alpha	O
and	O
T	B
alpha	O
1	O
(	O
CREB	O
)	O
transcription	O
factors	O
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	B
alpha	O
enhancer	O
.	O

Tandem	O
AP-1-binding	B
sites	O
within	O
the	O
human	B
beta-globin	O
dominant	O
control	O
region	O
function	O
as	O
an	O
inducible	B
enhancer	O
in	O
erythroid	B
cells	O
.	O

A	O
powerful	O
enhancer	B
has	O
been	O
mapped	O
to	O
an	O
18-bp	B
DNA	O
segment	O
located	O
11	B
kb	O
5'	O
to	O
the	O
human	B
epsilon-globin	O
gene	O
within	O
the	O
dominant	B
control	O
or	O
locus-activating	B
region	O
.	O

This	O
enhancer	B
is	O
inducible	O
in	O
K562	B
human	O
erythroleukemia	O
cells	O
,	O
increasing	O
linked	O
gamma-globin	B
promoter	O
/luciferase	B
gene	O
expression	O
to	O
170-fold	O
over	O
an	O
enhancerless	B
construct	O
.	O

The	O
enhancer	B
consists	O
of	O
tandem	O
AP-1-binding	B
sites	O
,	O
phased	O
10	O
bp	O
apart,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity.	O

DNA-protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	B
molecular	O
weight	O
complex	O
on	O
the	O
enhancer	B
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	B
sites	O
and	O
correlates	O
with	O
maximal	O
enhancer	O
activity	O
.	O

Induction	O
of	O
the	O
enhancer	B
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	B
gene	O
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	B
and	O
fos	O
families	O
to	O
tandem	O
AP-1	B
consensus	O
sequences	O
.	O

Identification	O
of	O
a	O
novel	O
factor	O
that	O
interacts	O
with	O
an	O
immunoglobulin	B
heavy-chain	O
promoter	O
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B
cell-specific	O
factor	O
OTF2	B
.	O

The	O
tissue-specific	O
expression	O
of	O
the	O
MOPC	B
141	O
immunoglobulin	B
heavy-chain	O
gene	O
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O

B-cell-specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	B
element	O
5'-ATGCAAAG-3'	O
,	O
located	O
in	O
the	O
upstream	B
region	O
of	O
this	O
promoter	B
and	O
in	O
the	O
promoters	B
of	O
all	O
other	O
immunoglobulin	B
heavy-	O
and	O
light-	O
chain	O
genes	O
.	O

The	O
interaction	O
of	O
purified	B
octamer	O
transcription	B
factors	O
1	O
and	O
2	O
(	O
OTF1	B
and	O
OTF2	B
)	O
with	O
the	O
MOPC	B
141	O
promoter	O
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	B
I	O
footprinting	O
.	O

Purified	B
OTF1	B
from	O
HeLa	B
cells	O
and	O
OTF1	B
and	O
OTF2	B
from	O
B	B
cells	O
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy-chain	B
promoter	O
.	O

The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	B
element	O
5'-CTCAGGA-3'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B
factors	O
involves	O
cooperation	O
between	O
octamer	B
and	O
heptamer	O
sites	O
in	O
this	O
promoter	B
.	O

In	O
addition	O
to	O
these	O
elements,	O
we	O
identified	O
a	O
second	O
regulatory	B
element	O
,	O
the	O
N	B
element	O
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3'	O
.	O

The	O
N	B
element	O
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B-cell	O
and	O
HeLa-cell	O
extracts	O
,	O
and,	O
in	O
conjunction	O
with	O
the	O
octamer	B
element	O
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B-cell	O
extracts	O
.	O

The	O
N	B
element	O
bound	O
a	O
transcription	B
factor	O
,	O
NTF	B
,	O
that	O
is	O
ubiquitous	O
in	O
cell-type	O
distribution	O
,	O
and	O
NTF	B
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	O
described	O
proteins	O
that	O
bind	O
to	O
similar	O
sequences.	O

Based	O
on	O
these	O
results,	O
we	O
propose	O
that	O
NTF	B
and	O
OTF2	B
interactions	O
(both	O
with	O
their	O
cognate	O
DNA	B
elements	O
and	O
possibly	O
at	O
the	O
protein-protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell-specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O

NF-kappa	B
B	O
as	O
inducible	B
transcriptional	B
activator	O
of	O
the	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
gene	O
.	O

The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte-	B
macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	B
cells	O
with	O
phytohemagglutinin	B
and	O
active	O
phorbolester	O
and	O
upon	O
expression	O
of	O
tax1	B
,	O
a	O
transactivating	B
protein	O
of	O
the	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O

The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	B
receptor	O
alpha-chain	O
and	O
interleukin-2	B
genes	O
,	O
depending	O
on	O
promoter	B
elements	O
that	O
bind	O
the	O
inducible	O
transcription	B
factor	O
NF-kappa	B
B	O
(or	O
an	O
NF-kappa	B
B	O
-like	O
factor	O
).	O

We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM-CSF	B
gene	O
is	O
also	O
regulated	O
by	O
a	O
cognate	B
motif	O
for	O
the	O
NF-kappa	B
B	O
transcription	B
factor	O
.	O

A	O
recent	O
functional	O
analysis	O
by	O
Miyatake	O
et	O
al.	O
(S.	O
Miyatake,	O
M.	O
Seiki,	O
M.	O
Yoshida,	O
and	O
K.	O
Arai,	O
Mol.	O
Cell.	O
Biol.	O
8:5581-5587,	O
1988)	O
described	O
a	O
short	O
promoter	B
region	O
in	O
the	O
GM-CSF	B
gene	O
that	O
conferred	O
strong	O
inducibility	O
by	O
T-cell-activating	O
signals	O
and	O
tax1	B
,	O
but	O
no	O
NF-kappa	B
B	O
-binding	O
motifs	O
were	O
identified.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	B
human	O
NF-kappa	B
B	O
and	O
of	O
the	O
NF-kappa	B
B	O
activated	O
in	O
Jurkat	B
T	O
cells	O
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM-CSF	B
promoter	O
element	O
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T-cell-activating	O
signals	O
and	O
tax1	B
.	O

As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O
and	O
oligonucleotide	O
competition	O
experiments,	O
purified	O
NF-kappa	B
B	O
binds	O
at	O
positions	O
-82	O
to	O
-91	O
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM-CSF	B
promoter	O
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	O
functional	O
kappa	B
B	O
motif	O
in	O
the	O
beta	B
interferon	O
promoter	O
(	O
GGGAAATTCC	O
).	O

Two	O
kappa	B
B-like	O
motifs	O
at	O
positions	O
-98	B
to	O
-108	O
of	O
the	O
GM-CSF	B
promoter	O
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities.	O

Our	O
data	O
provide	O
strong	O
evidence	O
that	O
the	O
expression	O
of	O
the	O
GM-CSF	B
gene	O
following	O
T-cell	O
activation	O
is	O
controlled	O
by	O
binding	O
of	O
the	O
NF-kappa	B
B	O
transcription	B
factor	O
to	O
a	O
high-affinity	B
binding	O
site	O
in	O
the	O
GM-CSF	B
promoter	O
.	O

Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	O
action	O
in	O
human	B
tonsillar	O
T-	O
lymphocytes	O
.	O

The	O
treatment	O
of	O
human	B
tonsillar	O
T-	O
lymphocytes	O
with	O
4-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
),	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	B
receptor	O
(	O
GR	B
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O

This	O
increase	O
disappeared	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O

Alone,	O
PMA	O
and	O
calcium	O
ionophore	O
A23187	O
did	O
not	O
affect,	O
but	O
together	O
stimulated,	O
like	O
phytohaemagglutinin	B
(	O
PHA	B
),	O
leucine	O
and,	O
in	O
particular,	O
thymidine	O
incorporation	O
.	O

PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	B
.	O

Alone,	O
these	O
agents	O
failed	O
to	O
alter	O
the	O
suppressive	O
effect	O
of	O
dexamethasone	O
on	O
thymidine	O
and	O
leucine	O
incorporation	O
;	O
however,	O
PMA	O
-A23187	O
and	O
PMA	O
-PHA	B
combinations	O
appeared	O
to	O
antagonize	O
the	O
suppression	O
by	O
dexamethasone	O
.	O

To	O
be	O
or	O
not	O
to	O
be	O
a	O
responder	O
in	O
T-cell	O
responses	O
:	O
ubiquitous	O
oligopeptides	O
in	O
all	O
proteins.	O

Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language.	O

Accordingly,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O

The	O
reason	O
that	O
only	O
certain	O
individuals	O
of	O
particular	O
major	B
histocompatibility	O
complex	O
(MHC)	O
haplotypes	O
can	O
mount	O
T-cell	O
responses	O
against	O
a	O
given	O
antigen	O
of	O
pathogens	O
is	O
found	O
in	O
the	O
fact	O
that	O
T-cell	B
receptors	O
are	O
designed	O
to	O
recognize	O
18-20	O
residue-long	O
peptide	O
fragments	O
sandwiched	O
between	O
two	O
alpha-helices	B
of	O
class	B
I	O
or	O
class	O
II	O
MHC	B
molecules	O
.	O

At	O
this	O
range	O
of	O
peptide	O
lengths	O
,	O
most	O
would	O
appear	O
as	O
self,	O
while	O
nonselfness	O
of	O
the	O
remainders	O
are	O
destined	O
to	O
be	O
quite	O
ambiguous,	O
hence	O
creating	O
responders	O
and	O
nonresponders.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	B
lymphocytes	O
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	B
lymphocytes	O
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B
receptor	O
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog,	O
rapamycin	O
.	O

On	O
the	O
other	O
hand,	O
interleukin	B
2	O
(	O
IL-2	B
)-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O

Remarkably,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other's	O
actions,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	B
(	O
immunosuppressant	B
binding	O
protein	O
).	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	B
binding	O
protein	O
FKBP	B
(Kd	O
=	O
0.2	O
nM)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	B
(Kd	O
=	O
0.4	O
nM)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

However,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O
to	O
revert	O
FK506	O
-mediated	O
inhibition	O
of	O
IL-2	B
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF-AT	B
,	O
a	O
T-cell-specific	B
transcription	O
factor	O
necessary	O
for	O
IL-2	B
gene	O
activation	O
.	O

Similarly,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin	O
-mediated	O
inhibition	O
of	O
IL-2	B
-induced	O
proliferation	O
.	O

The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to,	O
and	O
by	O
the	O
abundance	O
of,	O
the	O
immunophilin	B
FKBP	O
.	O

FKBP	B
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans-	O
rotamers	O
of	O
the	O
peptidyl-prolyl	B
amide	O
bond	O
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	B
(Ki	O
=	O
0.2	O
nM).	O

Neither	O
FKBP	B
binding	O
nor	O
inhibition	O
of	O
rotamase	B
activity	O
of	O
FKBP	B
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs.	O

Rather,	O
these	O
findings	O
suggest	O
that	O
immunophilin	B
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	B
receptor	O
-induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	B
interferes	O
with	O
IL-2	B
-induced	O
signals	O
.	O

Adherence-dependent	O
increase	O
in	O
human	B
monocyte	O
PDGF(B)	B
mRNA	O
is	O
associated	O
with	O
increases	O
in	O
c-fos	B
,	O
c-jun	O
,	O
and	O
EGR2	O
mRNA	O
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	B
monocyte	O
to	O
a	O
tissue	B
macrophage	O
.	O

This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	B
factors	O
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	O
encoding	O
profibrotic	B
growth	B
factors	O
such	O
as	O
platelet-derived	B
growth	O
factor	O
B	O
subunit	O
(	O
PDGF[B]	B
)	O
and	O
transforming	B
growth	O
factor-beta	O
(	O
TGF-beta	B
).	O

After	O
in	O
vitro	O
adherence,	O
human	B
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF(B)	B
mRNA	O
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d.	O

No	O
increase	O
in	O
TGF-beta	B
mRNA	O
was	O
observed.	O

The	O
6-h	O
increase	O
in	O
PDGF(B)	B
mRNA	O
was	O
adherence	O
dependent,	O
and	O
in	O
addition,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O

The	O
6-h	O
increase	O
in	O
PDGF(B)	B
mRNA	O
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O

Adherence	O
to	O
either	O
fibronectin	B
or	O
collagen-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF(B)	B
mRNA	O
accumulation	O
.	O

The	O
increased	O
PDGF(B)	B
mRNA	O
observed	O
in	O
adherent	O
monocytes	O
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	B
of	O
the	O
early	B
growth	O
response	O
genes	O
c-fos	B
(maximal	O
at	O
20	O
min),	O
c-jun,	B
and	O
EGR2	B
(maximal	O
at	O
6-24	O
h).	O

The	O
increase	O
in	O
c-jun	B
and	O
EGR2,	B
but	O
not	O
c-fos	B
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	B
,	O
c-jun	O
,	O
EGR2	O
,	O
and	O
PDGF(B)	B
mRNA	O
.	O

In	O
addition,	O
the	O
increases	O
in	O
c-jun	B
,	O
EGR2	B
,	O
and	O
PDGF(B)	B
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O

Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	B
factor	O
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T-cell	B
antigen	O
receptor	O
.	O

Stimulation	O
of	O
T	B
lymphocytes	O
through	O
their	O
antigen	B
receptor	O
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	B
factors	O
,	O
including	O
NF-AT	B
and	O
NF-kappa	B
B	O
,	O
which	O
are	O
involved	O
in	O
regulating	B
genes	O
required	O
for	O
immunologic	O
activation.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	B
factor	O
in	O
individual	O
viable	O
cells	O
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence-activated	O
cell	O
sorter	O
to	O
quantitate	O
beta-galactosidase	B
(	O
beta-gal	B
).	O

We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF-AT	B
transcriptional	O
activity	O
among	O
T	B
cells	O
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF-AT	B
-binding	O
site	O
directs	O
transcription	O
of	O
the	O
lacZ	B
gene	O
.	O

Unexpectedly,	O
stimulation	O
of	O
cloned	O
stably	B
transfected	O
Jurkat	B
T	B
cells	O
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	B
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta-gal	B
and	O
others	O
express	O
high	O
levels.	O

This	O
expression	O
pattern	O
cannot	O
be	O
accounted	O
for	O
by	O
cell-cycle	O
position	O
or	O
heritable	O
variation.	O

Further	O
results,	O
in	O
which	O
beta-gal	B
activity	O
is	O
correlated	O
with	O
NF-AT	B
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	B
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	B
concentration-dependent	O
assembly	O
of	O
transcription	B
complexes	O
at	O
the	O
promoter	B
.	O

Similar	O
constructs	O
controlled	O
by	O
NF-kappa	B
B	O
or	O
the	O
entire	O
interleukin-2	B
enhancer	O
show	O
bimodal	O
expression	O
patterns	O
during	O
induction,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	B
factors	O
may	O
be	O
a	O
common	O
property	O
of	O
inducible	B
genes	O
.	O

The	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)	O
BMRF1	O
promoter	O
for	O
early	B
antigen	O
(	O
EA-D	B
)	O
is	O
regulated	O
by	O
the	O
EBV	B
transactivators	O
,	O
BRLF1	B
and	O
BZLF1	B
,	O
in	O
a	O
cell-specific	O
manner	O
.	O

The	O
Epstein-Barr	B
virus	O
early	O
antigen	O
diffuse	O
component	O
(	O
EA-D	B
)	O
is	O
essential	O
for	O
Epstein-Barr	B
virus	O
DNA	O
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection.	O

We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	B
(	O
BMRF1	B
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate-early	B
viral	O
transactivators	O
,	O
BZLF1	B
(	O
Z	B
)	O
and	O
BRLF1	B
(	O
R	B
),	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	B
cells	O
and	O
epithelial	B
cells	O
.	O

In	O
lymphoid	B
cells	O
,	O
Z	B
or	O
R	B
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA-D	B
promoter	O
activity	O
,	O
whereas	O
both	O
transactivators	O
together	O
produced	O
a	O
large	O
stimulatory	O
effect.	O

In	O
epithelial	B
cells	O
,	O
the	O
Z	B
transactivator	O
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA-D	B
promoter	O
;	O
the	O
effect	O
of	O
R	B
and	O
Z	B
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	B
alone.	O

Deletional	O
analysis	O
and	O
site-directed	O
mutagenesis	O
of	O
the	O
EA-D	B
promoter	O
demonstrated	O
that	O
in	O
epithelial	B
cells	O
the	O
potential	O
AP-1	B
binding	O
site	O
plays	O
an	O
essential	O
role	O
in	O
Z	B
responsiveness,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important.	O

In	O
lymphoid	B
cells	O
,	O
only	O
the	O
upstream	B
sequences	O
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z/R	B
combination,	O
and	O
the	O
AP-1	B
site	O
is	O
dispensable.	O

These	O
data	O
suggest	O
that	O
EA-D	B
(	O
BMRF1	B
)	O
promoter	O
regulation	O
by	O
Z	B
and	O
R	O
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type.	O

Complementary	B
DNA	O
encoding	O
the	O
human	B
T-cell	O
FK506	O
-binding	O
protein	O
,	O
a	O
peptidylprolyl	B
cis-trans	O
isomerase	O
distinct	O
from	O
cyclophilin	B
.	O

The	O
recently	O
discovered	O
macrolide	O
FK506	O
has	O
been	O
demonstrated	O
to	O
have	O
potent	O
immunosuppressive	O
activity	O
at	O
concentrations	O
100-fold	O
lower	O
than	O
cyclosporin	O
A	O
,	O
a	O
cyclic	O
undecapeptide	O
that	O
is	O
used	O
to	O
prevent	O
rejection	O
after	O
transplantation	O
of	O
bone	O
marrow	O
and	O
organs	O
,	O
such	O
as	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
.	O

After	O
the	O
recent	O
discovery	O
that	O
the	O
cyclosporin	B
A	O
-binding	O
protein	O
cyclophilin	B
is	O
identical	O
to	O
peptidylprolyl	B
cis-trans	O
isomerase	O
,	O
a	O
cellular	B
binding	O
protein	O
for	O
FK506	O
was	O
found	O
to	O
be	O
distinct	O
from	O
cyclophilin	B
but	O
to	O
have	O
the	O
same	O
enzymatic	O
activity	O
.	O

In	O
this	O
study,	O
we	O
isolated	O
a	O
cDNA	B
coding	O
for	O
FK506	B
-binding	O
protein	O
(	O
FKBP	B
)	O
from	O
human	B
peripheral	O
blood	O
T	O
cells	O
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence,	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	B
,	O
reported	O
for	O
bovine	B
FKBP	B
.	O

The	O
DNA	O
isolated	O
contained	O
an	O
open	B
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O

The	O
first	O
40	O
residues	O
of	O
the	O
deduced	O
amino	B
acid	O
sequence	O
were	O
identical	O
to	O
those	O
of	O
the	O
reported	O
amino-terminal	B
sequence	O
of	O
bovine	B
FKBP	B
,	O
indicating	O
that	O
the	O
DNA	O
sequence	O
isolated	O
represents	O
the	O
gene	O
coding	O
for	O
FKBP	B
.	O

Computer-assisted	O
analysis	O
of	O
the	O
deduced	O
amino	B
acid	O
sequence	O
indicates	O
that	O
FKBP	B
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	B
acid	O
sequences	O
of	O
known	O
proteins,	O
including	O
cyclophilin	B
.	O

This	O
result	O
suggests	O
that	O
two	O
catalytically	O
similar	O
proteins,	O
cyclophilin	B
and	O
FKBP	B
,	O
evolved	O
independently.	O

In	O
Northern	O
blot	O
analysis	O
,	O
mRNA	B
species	O
of	O
approximately	O
1.8	O
kilobases	O
that	O
hybridized	O
with	O
human	B
FKBP	B
cDNA	O
were	O
detected	O
in	O
poly(A)+	B
RNAs	O
from	O
brain	O
,	O
lung	O
,	O
liver	O
,	O
and	O
placental	B
cells	O
and	O
leukocytes	B
.	O

Induction	O
of	O
Jurkat	B
leukemic	O
T	O
cells	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	B
mRNA	O
.	O

Southern	O
blot	O
analysis	O
of	O
human	B
genomic	O
DNA	O
digested	O
with	O
different	O
restriction	B
enzymes	O
suggests	O
the	O
existence	O
of	O
only	O
a	O
few	O
copies	O
of	O
the	O
DNA	B
sequence	O
encoding	O
FKBP	B
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
result	O
that	O
as	O
many	O
as	O
20	O
copies	O
of	O
the	O
cyclophilin	B
gene	O
and	O
possible	O
pseudogenes	O
may	O
be	O
present	O
in	O
the	O
mammalian	B
genome	O
.	O

Involvement	O
of	O
a	O
second	O
lymphoid-specific	B
enhancer	O
element	O
in	O
the	O
regulation	O
of	O
immunoglobulin	B
heavy-chain	O
gene	O
expression	O
.	O

To	O
determine	O
whether	O
enhancer	O
elements	O
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	B
(OCTA)-nucleotide	O
motif	O
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	B
heavy-chain	O
(IgH)	O
gene	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	B
site	O
for	O
a	O
putative	O
additional	O
lymphoid-specific	B
transcription	O
factor	O
,	O
designated	O
NF-microB	B
,	O
in	O
the	O
murine	B
IgH	B
enhancer	O
.	O

We	O
demonstrate	O
that	O
the	O
NF-microB-binding	B
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	B
enhancer	O
,	O
because	O
mutation	O
of	O
the	O
microB	B
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	B
enhancer	O
in	O
cells	O
of	O
the	O
B-cell	B
lineage	O
but	O
not	O
in	O
nonlymphoid	B
cells	O
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	B
site	O
.	O

Moreover,	O
combined	O
mutation	O
of	O
both	O
microB	B
and	O
OCTA	B
sites	O
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	B
cells	O
.	O

Interestingly,	O
alteration	O
of	O
either	O
the	O
microB	B
or	O
E3	O
site	O
in	O
a	O
70-base-pair	B
fragment	O
of	O
the	O
IgH	B
enhancer	O
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	B
abolished	O
enhancer	O
activity	O
in	O
lymphoid	B
cells	O
completely.	O

Nevertheless,	O
a	O
multimer	O
of	O
the	O
microB	B
motif	O
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

DNase	B
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	B
protein	O
binds	O
to	O
the	O
microB	B
DNA	O
motif	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	B
element	O
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
IgH	B
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	B
element	O
is	O
essential	O
for	O
its	O
activity.	O

Stimulation	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	B
and	O
HIV-2	O
transactivator	O
gene	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection.	O

Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis.	O

The	O
transactivator	B
(IE-2)	O
gene	O
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro.	O

This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV-2	B
tat	O
gene	O
and	O
T-cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	B
CD4+	O
lymphocytes	O
.	O

While	O
the	O
HIV-2	B
and	O
HIV-1	O
tat	O
genes	O
and	O
T-cell	B
activators	O
apparently	O
employ	O
independent	O
modes	O
of	O
action,	O
the	O
CMV	B
transactivator	O
in	O
combination	O
with	O
the	O
HIV-2	B
tat	O
or	O
T-cell	B
activators	O
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components.	O

Both	O
HIV-2	B
and	O
CMV	O
transactivators	O
enhance	O
HIV-2	B
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	B
transactivator	O
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

A	O
significant	O
proportion	O
of	O
transcripts	O
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	B
.	O

Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	B
long	O
terminal	O
repeat	O
(	O
LTR	B
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	B
CD4+	O
lymphocytes	O
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	B
enhancer	O
element	O
.	O

Quantitative	O
immunohistochemical	O
analysis	O
of	O
mononuclear	O
infiltrates	O
in	O
breast	O
carcinomas	O
--correlation	O
with	O
tumour	O
differentiation	O
.	O

Inflammatory	O
infiltrates	O
were	O
analysed	O
in	O
tissue	O
sections	O
of	O
76	O
breast	O
carcinomas	O
by	O
counting	O
the	O
percentage	O
of	O
macrophages	B
,	O
IgA+	B
and	O
IgG+	O
plasma	O
cells	O
,	O
T	B
cells	O
with	O
their	O
subpopulations,	O
and	O
natural	B
killer	O
cells	O
,	O
and	O
by	O
measuring	O
postcapillary	B
venules	O
(	O
PCVs	O
,	O
found	O
in	O
12	O
cases)	O
within	O
the	O
infiltrates.	O

These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	B
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
extent	O
of	O
inflammation	O
and	O
nuclear	O
grade	O
(P	O
less	O
than	O
0.0001),	O
and	O
an	O
inverse	O
correlation	O
between	O
inflammation	O
and	O
oestrogen	B
receptor	O
(	O
OR	B
)	O
positivity	O
(P	O
less	O
than	O
0.05)	O
as	O
well	O
as	O
inflammation	O
and	O
progesterone	B
receptor	O
(	O
PR	B
)	O
positivity	O
(P	O
less	O
than	O
0.05).	O

The	O
percentage	O
of	O
the	O
OKT8+	B
suppressor/cytotoxic	O
T	O
cells	O
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(P	O
less	O
than	O
0.02).	O

The	O
diameter	O
of	O
the	O
PCVs	B
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(P	O
less	O
than	O
0.02).	O

In	O
addition,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	B
and	O
both	O
the	O
percentage	O
of	O
the	O
OKT8+	B
T	O
cells	O
(P	O
less	O
than	O
0.04)	O
and	O
the	O
Leu-7+	B
natural	O
killer	O
cells	O
(P	O
less	O
than	O
0.03).	O

Reactivity	O
of	O
lymphocytes	B
to	O
a	O
progesterone	B
receptor-specific	O
monoclonal	O
antibody	O
.	O

In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O
of	O
pregnancy	B
lymphocytes	O
,	O
but	O
not	O
nonpregnancy	B
lymphocytes	O
,	O
with	O
the	O
progesterone	B
receptor-specific	O
monoclonal	O
antibody	O
mPRI	B
.	O

Using	O
an	O
avidin	B
-biotin	B
peroxidase	O
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+/-	O
3.7%	O
(mean	O
+/-	O
SEM,	O
N	O
=	O
27)	O
of	O
pregnancy	B
lymphocytes	O
,	O
while	O
only	O
0.47	O
+/-	O
0.33%	O
(mean	O
+/-	O
SEM,	O
N	O
=	O
15)	O
of	O
nonpregnancy	B
lymphocytes	O
reacted	O
with	O
the	O
antibody.	O

To	O
characterize	O
the	O
receptor-bearing	B
subset,	O
CD8+	B
and	O
CD4+	B
cells	O
were	O
depleted	O
by	O
complement-dependent	O
lysis.	O

Depletion	O
of	O
CD8+	B
cells	O
was	O
accompanied	O
by	O
62	O
+/-	O
18%	O
loss	O
of	O
progesterone	B
receptor	O
-bearing	O
cells	O
,	O
while	O
depletion	O
of	O
CD4+	B
cells	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	B
staining	O
lymphocytes	O
.	O

In	O
nonpregnancy	B
lymphocytes	O
a	O
3-day	O
PHA	B
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor-containing	B
cells	O
.	O

These	O
results	O
suggest	O
that	O
pregnancy	O
,	O
but	O
not	O
nonpregnancy	O
,	O
lymphocytes	B
contain	O
progesterone	B
binding	O
structures	O
,	O
and	O
that	O
these	O
are	O
inducible	O
by	O
mitogenic	O
or	O
alloantigenic	O
stimuli	O
.	O

Activation	O
of	O
human	B
CD4	O
T	O
lymphocytes	O
.	O

Interaction	O
of	O
fibronectin	B
with	O
VLA-5	B
receptor	O
on	O
CD4	B
cells	O
induces	O
the	O
AP-1	B
transcription	B
factor	O
.	O

Fibronectin	B
synergized	O
with	O
anti-CD3	B
antibody	O
to	O
promote	O
CD4	B
cell	O
proliferation	O
in	O
a	O
serum-free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	B
cells	O
were	O
cultured	O
with	O
anti-CD3	B
alone	O
or	O
fibronectin	B
alone.	O

In	O
addition,	O
anti-CD29	B
(	O
integrin	B
beta	O
1	O
)	O
as	O
well	O
as	O
anti-VLA-5	B
(	O
human	B
fibronectin	O
receptor	O
)	O
antibodies	O
blocked	O
this	O
CD4	B
cell	O
activation	O
in	O
this	O
system.	O

Although	O
anti-CD3	B
alone	O
or	O
fibronectin	B
alone	O
cannot	O
induce	O
IL-2	B
message	O
by	O
CD4	B
cells	O
,	O
the	O
combination	O
of	O
anti-CD3	B
plus	O
fibronectin	B
induced	O
IL-2	B
message	O
by	O
CD4	B
cells	O
.	O

In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B
message	O
was	O
generated,	O
we	O
showed	O
that	O
a	O
fibronectin	B
-VLA-5	B
fibronectin	B
receptor	O
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B
transcriptional	O
factor	O
.	O

Thus	O
the	O
VLA-5	B
fibronectin	O
receptor	O
on	O
CD4	B
cells	O
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	B
-	O
TCR	B
-mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B
.	O

Glucocorticoid	B
receptors	O
on	O
mononuclear	B
leukocytes	O
in	O
Alzheimer's	O
disease	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer's	O
disease	O
(	O
AD	O
).	O

In	O
an	O
exploration	O
of	O
the	O
potential	O
role	O
of	O
the	O
glucocorticoid	B
receptor	O
(GR)	O
in	O
AD	O
,	O
GR	B
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	B
leukocytes	O
of	O
12	O
AD	O
patients	O
and	O
12	O
healthy	O
controls	O
.	O

GR	B
binding	O
characteristics	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
or	O
between	O
patients	O
subdivided	O
according	O
to	O
diagnosis	O
or	O
associated	O
clinical	O
features.	O

These	O
data	O
suggest	O
that	O
the	O
abnormalities	O
of	O
the	O
HPA	O
system	O
in	O
AD	O
are	O
not	O
related	O
to	O
a	O
GR	B
deficiency	O
.	O

Oncogene	O
amplification	O
correlates	O
with	O
dense	O
lymphocyte	O
infiltration	O
in	O
human	O
breast	O
cancers	O
:	O
a	O
role	O
for	O
hematopoietic	B
growth	O
factor	O
release	O
by	O
tumor	B
cells	O
?	O

One	O
hundred	O
six	O
primary	O
breast	O
cancer	O
samples	O
were	O
analysed	O
for	O
c-erbB2	O
,	O
int-2	O
,	O
and	O
c-myc	O
gene	O
amplification	O
.	O

Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42%.	O

Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O
blot	O
techniques	O
.	O

Amplified	O
c-erbB2	B
gene	O
sequences	O
were	O
present	O
in	O
21.5%	O
of	O
all	O
samples.	O

Int-2	B
was	O
amplified	O
in	O
13.1%	O
and	O
c-myc	B
was	O
amplified	O
in	O
10.3%.	O

In	O
a	O
non-parametric	O
test	O
(Kruskal-Wallis)	O
a	O
strong	O
negative	O
association	O
was	O
found	O
between	O
high	O
levels	O
of	O
c-erbB2	B
amplification	O
and	O
absence	O
of	O
estrogen	B
receptor	O
(ER)	O
(P	O
=	O
.0009)	O
or	O
progesterone	B
receptor	O
(	O
PR	B
)	O
(P	O
=	O
.011)	O
expression.	O

No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	B
separately	O
or	O
combined	O
with	O
T,	O
N,	O
grade,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ.	O

There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c-erbB2	B
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(P	O
=	O
0.09).	O

A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	B
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(P	O
=	O
.05).	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered,	O
either	O
for	O
each	O
oncogene	B
separately	O
(P	O
=	O
.0048)	O
or	O
in	O
combination	O
(P	O
=	O
.0007).	O

We	O
propose	O
that	O
malignant	O
cell	O
cytokine	B
production	O
may	O
help	O
explain	O
this	O
observation.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B
factor	O
NF-kappa	B
B	O
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	B
Tax	O
protein	O
.	O

Transient	O
short-term	O
expression	O
of	O
the	O
Tax	B
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	B
transcription	O
factor	O
NF-kappa	B
B	O
.	O

Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	B
factor	O
NF-kappa	B
B	O
in	O
the	O
nucleus	O
of	O
Namalwa	B
B	O
lymphoid	O
cells	O
,	O
which	O
constitutively	O
express	O
Tax	B
.	O

In	O
contrast,	O
NF-kappa	B
B	O
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long-term	O
expression	O
of	O
Tax	B
in	O
Jurkat	B
T	O
lymphocytes	O
.	O

The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	B
to	O
activate	O
NF-kappa	B
B	O
was	O
also	O
blocked	O
in	O
Jurkat	B
cells	O
constitutively	O
expressing	O
Tax	B
.	O

However,	O
the	O
activation	O
of	O
other	O
mitogen-inducible	B
transcription	B
factors	O
,	O
such	O
as	O
Fos	B
and	O
Jun	B
,	O
was	O
unaffected.	O

Thus,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	B
expression	O
can	O
be	O
quite	O
different.	O

Consequently,	O
one	O
function	O
of	O
Tax	B
in	O
cells	O
infected	O
with	O
HTLV-I	O
might	O
involve	O
cell-type-specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation,	O
of	O
distinct	O
signal	O
pathways	O
.	O

The	O
cells	B
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

Interferon-gamma	B
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years.	O

In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	B
interferon-gamma	B
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O

Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule,	O
as	O
well	O
as	O
other	O
cytokines	B
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O

Cloning	O
of	O
a	O
transcriptionally	B
active	O
human	O
TATA	O
binding	O
factor	O
.	O

Transcription	B
factor	O
IID	O
(	O
TFIID	B
)	O
binds	O
to	O
the	O
TATA	B
box	O
promoter	O
element	O
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	B
genes	O
transcribed	O
by	O
RNA	B
polymerase	O
II	O
.	O

Complementary	B
DNA	O
(	O
cDNA	B
)	O
encoding	O
a	O
human	B
TFIID	B
protein	O
has	O
been	O
cloned.	O

The	O
human	B
TFIID	B
polypeptide	O
has	O
339	O
amino	O
acids	O
and	O
a	O
molecular	O
size	O
of	O
37,745	O
daltons	O
.	O

The	O
carboxyl-terminal	B
181	O
amino	O
acids	O
of	O
the	O
human	B
TFIID	B
protein	O
shares	O
80%	O
identity	O
with	O
the	O
TFIID	B
protein	O
from	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
amino	B
terminus	O
contains	O
an	O
unusual	O
repeat	O
of	O
38	O
consecutive	O
glutamine	O
residues	O
and	O
an	O
X-Thr-Pro	B
repeat	O
.	O

Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O
coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O

A	O
novel	O
T-cell	B
trans-activator	O
that	O
recognizes	O
a	O
phorbol	B
ester-inducible	O
element	O
of	O
the	O
interleukin-2	B
promoter	O
.	O

The	O
interleukin	B
2	O
(	O
IL-2	B
)	O
gene	O
promoter	O
is	O
recognized	O
by	O
several	O
cell-type-specific	B
and	O
ubiquitous	O
transcriptional	O
regulators	O
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL-2	B
production	O
and	O
T-cell	O
activation	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	O
T-cell-specific	B
transcriptional	O
activator	O
TCF-1	B
(for	O
T-Cell	B
Factor-1	O
),	O
which	O
recognizes	O
a	O
T-cell-specific	B
response	O
element	O
(	O
TCE	B
)	O
located	O
within	O
the	O
IL-2	B
promoter	O
.	O

Although	O
the	O
TCE	B
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	B
NF	B
kappa	O
B	O
site	O
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	B
is	O
distinct	O
from	O
NF	B
kappa	O
B	O
.	O

However,	O
like	O
NF	B
kappa	O
B	O
,	O
TCF-1	B
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T-cell	O
activators	O
.	O

Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	O
treated	O
by	O
conservation	O
therapy	O
.	O

Risk	O
factors	O
for	O
local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I-II	O
patients	O
with	O
infiltrating	O
ductal	O
carcinomas	O
(median	O
follow-up,	O
71	O
months)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk:	O
moderate/marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
),	O
high	O
histologic	O
grade	O
(G),	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
),	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	B
receptor	O
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years,	O
and	O
vascular	O
invasion	O
.	O

Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O

These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40.	O

Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR	O
/EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins:	O
tumors	O
with	O
MCR	O
had	O
a	O
28%,	O
and	O
with	O
EIC	O
a	O
22%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years.	O

Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(2.6%	O
at	O
5	O
years),	O
regardless	O
of	O
age.	O

For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O
recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	O
with	O
positive	O
or	O
indeterminate	O
margins	O
(31%	O
at	O
5	O
years).	O

The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O

High-risk	O
patients	O
can	O
be	O
recognized	O
morphologically.	O

The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40.	O

Tax	B
-independent	O
binding	O
of	O
multiple	B
cellular	B
factors	O
to	O
Tax	B
-response	O
element	O
DNA	O
of	O
HTLV-I	O
.	O

The	O
human	B
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
promoter	O
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	B
pair	O
sequence	O
designated	O
here	O
as	O
TRE	B
(	O
Tax	B
-response	O
element	O
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	B
encoded	O
transactivator	O
protein	O
Tax	B
.	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B
proteins	O
from	O
C81-66-45	B
cells,	O
an	O
HTLV-I	B
immortalized	O
Tax	B
-expressing	O
human	O
T-lymphocyte	O
line	O
(Salahuddin	O
et	O
al.,	O
1983),	O
that	O
interact	O
with	O
the	O
TRE	B
-DNA	O
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax	B
-protein	O
.	O

The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32,	O
36	O
to	O
42,	O
50	O
and	O
110	O
kD.	O

Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins.	O

First,	O
from	O
different	O
cell	B
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	B
proteins	O
were	O
specifically	O
cross-linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	B
labeled	O
TRE	B
-DNA	O
fragment	O
.	O

Second,	O
TRE	B
-DNA	O
binding	O
proteins	O
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD.	O

Third,	O
only	O
the	O
50	B
kD	O
protein	O
was	O
retained	O
on	O
a	O
biotinylated	O
DNA-streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE	B
-DNA	O
.	O

Fourth,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	B
-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	B
,	O
36	O
to	O
42	O
and	O
110	O
kD	O
proteins	O
and	O
to	O
less	O
extent	O
the	O
50	B
kD	O
factor	O
.	O

Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly[d(I-C)]	B
in	O
all	O
reactions.	O

The	O
cAMP-response	B
element	O
CRE	B
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	B
base-pair	O
sequence	O
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	B
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	B
response	O
element	O
binding	O
protein	O
,	O
CREB	B
,	O
is	O
involved	O
in	O
the	O
protein-	B
TRE	B
-DNA	O
complex	O
and	O
in	O
mediating	O
the	O
Tax	B
response	O
.	O

Two	O
distinct	O
transcription	B
factors	O
that	O
bind	O
the	O
immunoglobulin	B
enhancer	O
microE5/kappa	B
2	O
motif	O
.	O

Activity	O
of	O
the	O
immunoglobulin	B
heavy	O
and	O
kappa	O
light	O
chain	O
gene	O
enhancers	O
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	B
and	O
developmentally	O
regulated	O
proteins	O
.	O

Two	O
complementary	B
DNAs	O
were	O
isolated	O
that	O
encode	O
proteins,	O
denoted	O
ITF-1	B
and	O
ITF-2	B
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5/kappa	B
2	O
motif	O
found	O
in	O
both	O
heavy	B
and	O
kappa	O
light	O
chain	O
enhancers	O
.	O

The	O
complementary	B
DNAs	O
are	O
the	O
products	O
of	O
distinct	O
genes,	O
yet	O
both	O
ITF-1	B
and	O
ITF-2	B
are	O
structurally	O
and	O
functionally	O
similar.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix-loop-helix	B
motifs	O
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

Elevated	O
glucocorticoid	B
receptor	O
concentrations	O
before	O
and	O
after	O
glucocorticoid	O
therapy	O
in	O
peripheral	B
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	O
dermatitis	O
.	O

The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	B
binding	O
sites	O
in	O
peripheral	B
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O

Patients	O
with	O
AD	O
(n	O
=	O
15)	O
exhibited	O
significantly	O
more	O
glucocorticoid	B
receptors	O
(	O
GR	B
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(n	O
=	O
22),	O
while	O
the	O
GR	B
affinity	O
did	O
not	O
differ.	O

Methylprednisolone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	B
sites	O
per	O
cell	O
in	O
the	O
steroid-treated	O
control	O
group	O
(n	O
=	O
10)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O

The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group.	O

In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	O
in	O
AD	O
and	O
findings	O
of	O
abnormal	O
cAMP	O
and	O
cAMP-phosphodiesterase	B
activity	O
,	O
the	O
elevated	O
GR	B
concentrations	O
in	O
AD	O
lend	O
support	O
to	O
the	O
hypothesis	O
of	O
a	O
compensatory	O
GR	B
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	O
or	O
to	O
altered	O
cAMP	O
-induced	O
GR	B
expression	O
.	O

The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	B
lymphocytes	O
.	O

Cyclosporin	O
A	O
and	O
FK506	O
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	B
produced	O
by	O
T	B
lymphocytes	O
.	O

Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	B
protein	O
,	O
cyclophilin	B
and	O
FKBP	B
respectively,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action.	O

Using	O
constructs	O
in	O
which	O
mRNA	B
production	O
controlled	O
by	O
a	O
specific	O
transcription	B
factor	O
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF-AT	B
,	O
NFIL2	B
A	O
,	O
NFIL2	B
B	O
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	B
kappa	O
B	O
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O

However,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2+	O
mobilization	O
dependent	O
expression	O
of	O
c-fos	B
mRNA	O
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2+	O
is	O
sensitive	O
to	O
these	O
drugs.	O

Furthermore,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	B
factors	O
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	B
factors	O
.	O

The	O
internal	B
methionine	O
codons	O
of	O
human	B
T-cell	O
leukemia	O
virus	O
type	O
II	O
rex	B
gene	O
are	O
not	O
required	O
for	O
p24rex	B
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV-I	O
)	O
and	O
II	O
(	O
HTLV-II	O
)	O
have	O
two	O
nonstructural	B
trans-acting	O
regulatory	O
genes	O
,	O
tax	B
and	O
rex	B
,	O
located	O
in	O
the	O
3'	B
region	O
of	O
the	O
viral	B
genome	O
.	O

The	O
tax	B
gene	O
product	O
(	O
HTLV-I	B
p40tax	O
and	O
HTLV-II	B
p37tax	O
)	O
is	O
the	O
transcriptional	B
activator	O
of	O
the	O
viral	B
long	O
terminal	O
repeat	O
.	O

The	O
rex	B
gene	O
encodes	O
two	O
protein	B
products,	O
p27rex	B
/p21rex	O
and	O
p26rex	B
/p24rex	B
in	O
HTLV-I	O
and	O
HTLV-II	O
,	O
respectively.	O

Rex	B
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full-length	B
gag/pol	O
and	O
singly	O
spliced	O
env	B
mRNA	O
in	O
the	O
cytoplasm	O
of	O
HTLV-infected	B
cells	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	B
gene	O
is	O
critical	O
for	O
Rex	B
production	O
and	O
function.	O

The	O
importance	O
of	O
the	O
internal	B
ATGs	O
to	O
Rex	B
function	O
is	O
not	O
known.	O

However,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV-I	B
rex	B
gene	O
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	B
,	O
and	O
by	O
analogy	O
HTLV-II	B
p24rex	O
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	B
AUG	O
of	O
the	O
tax	B
/rex	O
mRNA	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV-II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	B
ATGs	O
of	O
the	O
rex	B
gene	O
on	O
Rex	B
protein	O
production	O
and	O
function.	O

Our	O
results	O
indicate	O
that	O
p24rex	B
of	O
HTLV-II	O
is	O
not	O
initiated	O
at	O
an	O
internal	B
AUG	O
and	O
that	O
the	O
internal	B
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	B
gene	O
and,	O
ultimately,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

Astrocytes	B
and	O
glioblastoma	B
cells	O
express	O
novel	O
octamer-DNA	B
binding	O
proteins	O
distinct	O
from	O
the	O
ubiquitous	B
Oct-1	B
and	O
B	B
cell	O
type	O
Oct-2	B
proteins	O
.	O

The	O
'octamer'	B
sequence	O
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	B
genes	O
in	O
B-lymphocytes	B
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	B
genes	O
in	O
all	O
cell	O
types.	O

In	O
lymphocytes	B
,	O
the	O
octamer-binding	B
protein	O
Oct-2A	B
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B-cell	O
specific	O
gene	O
expression	O
,	O
while	O
the	O
ubiquitous	B
protein	O
Oct-1	B
seems	O
to	O
control	O
general	O
octamer	B
site	O
-dependent	O
transcription	O
.	O

Various	O
other	O
genes,	O
for	O
example	O
interleukin-1	B
and	O
MHC	B
class	O
II	O
genes	O
,	O
contain	O
an	O
octamer	B
sequence	O
in	O
the	O
promoter	B
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer-binding	B
proteins	O
in	O
the	O
latter	O
cells.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	B
binding	O
proteins	O
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	B
mouse	O
astrocytes	B
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	B
glioblastoma	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O

The	O
nervous	B
system-derived	O
(N-Oct)	O
proteins	O
bound	O
to	O
the	O
octamer	B
DNA	O
sequence	O
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	B
and	O
Oct-2A	B
proteins	O
.	O

The	O
relationship	O
of	O
the	O
N-Oct	B
proteins	O
to	O
Oct-1	B
and	O
Oct-2A	B
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	B
Oct-1	B
and	O
Oct-2A	B
proteins.	O

On	O
the	O
basis	O
of	O
these	O
assays,	O
all	O
N-Oct-factors	B
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	B
Oct-1	B
and	O
the	O
lymphoid-specific	B
Oct-2A	B
proteins.	O

In	O
melanoma	B
cells	O
that	O
contain	O
the	O
N-Oct-3	B
factor	O
,	O
a	O
transfected	O
lymphocyte-specific	B
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct-2A	B
expression	O
vector	O
.	O

We	O
therefore	O
speculate	O
that	O
N-Oct-3	B
and	O
other	O
N-Oct	B
factors	O
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Detection	O
in	O
non-erythroid	B
cells	O
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	B
cell	O
transcription	B
factor	O
EF1	B
.	O

The	O
erythroid	B
transcription	B
factor	O
erythroid	B
factor-1	O
(	O
EF1	B
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid-specific	B
genes	O
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence-specific	O
DNA-binding	O
characteristics	O
of	O
EF1	B
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non-erythroid	B
cell	O
types	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	B
-like	O
activity	O
in	O
non-erythroid	B
cells	O
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
expressed	O
in	O
such	O
cells.	O

Protein	O
kinase	O
inhibitor	O
H-7	O
blocks	O
accumulation	O
of	O
unspliced	B
mRNA	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
).	O

Rex	B
,	O
the	O
post-transcriptional	B
regulator	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
),	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O
unspliced	B
viral	O
gag-pol	O
mRNA	O
.	O

Rex	B
is	O
a	O
phosphoprotein	B
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H-7	O
[	O
1-(5-isoquinolinyl-sulfonyl)-2-methylpiperazine	O
].	O

Treatment	O
of	O
an	O
HTLV-I	B
infected	O
human	O
T-cell	O
line	O
with	O
H-7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	B
gag-pol	O
mRNA	O
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B
protein	O
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B
.	O

In	O
contrast,	O
other	O
viral	B
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H-7	O
used.	O

Therefore,	O
the	O
phosphorylation	O
of	O
Rex	B
is	O
required	O
for	O
the	O
viral	B
RNA	O
partition	O
of	O
HTLV-I	O
.	O

Increased	O
glucocorticoid	O
responsiveness	O
of	O
CD4+	B
T-cell	O
clonal	O
lines	O
grown	O
in	O
serum-free	O
media	O
.	O

CEM-C7	B
,	O
a	O
human	B
leukemic	O
CD4+	O
T-lymphocyte	O
cell	O
line	O
and	O
three	O
of	O
its	O
subclones,	O
CEM-4R4	B
,	O
CEM-3R43	B
,	O
and	O
ICR-27	B
,	O
previously	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
5	O
to	O
10%	O
fetal	O
bovine	O
serum	O
,	O
have	O
been	O
adapted	O
to	O
serum-free	O
media	O
.	O

The	O
best	O
medium	O
of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms/ml	O
each	O
transferrin	B
and	O
insulin	O
+	O
5	O
ng/ml	O
sodium	O
selenite	O
+/-	O
0.1%	O
bovine	B
serum	O
albumin	O
.	O

While	O
growing	O
either	O
with	O
or	O
without	O
albumin,	B
the	O
several	O
clonal	O
lines	O
of	O
CEM	B
cells	O
displayed	O
growth	O
similar	O
to	O
serum-supplemented	B
cultures.	O

Cell	O
proliferation	O
of	O
CEM-C7	B
cells	O
cultured	O
in	O
both	O
serum-free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo.	O

with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O
both	O
serum-supplemented	B
and	O
serum-free	O
cultures	O
(viability	O
greater	O
than	O
or	O
equal	O
to	O
90%).	O

Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum-free	O
or	O
serum	O
containing	O
media	O
.	O

The	O
expression	O
of	O
CD4	B
,	O
a	O
marker	O
for	O
T-derived	B
lymphoid	O
cells	O
,	O
was	O
not	O
significantly	O
different	O
in	O
serum-free	O
medium	O
.	O

When	O
grown	O
in	O
serum-free	O
medium,	O
CEM-C7	B
cells	O
exhibited	O
increased	O
steroid	O
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	B
receptor	O
binding	O
sites	O
,	O
increased	O
induction	O
of	O
glutamine	B
synthetase	O
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	O
.	O

Receptor	B
mutant	O
subclones	O
of	O
CEM-C7	B
,	O
which	O
are	O
proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	O
when	O
grown	O
in	O
serum-supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium.	O

The	O
increased	O
sensitivity	O
of	O
CEM-C7	B
cells	O
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum-free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum-containing	O
medium	O
.	O

Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium.	O

[	O
Glucocorticoid	B
receptors	O
on	O
human	B
peripheral	O
mononuclear	O
and	O
polymorphonuclear	O
leucocytes	O
:	O
changes	O
in	O
patients	O
with	O
yang-deficiency	O
]	O

It	O
was	O
found	O
that,	O
in	O
former	O
works,	O
the	O
glucocorticoid	B
receptors	O
(	O
GCR	B
)	O
on	O
peripheral	B
mixed	B
leucocytes	O
in	O
patients	O
with	O
Yang-deficiency	O
were	O
decreased.	O

In	O
this	O
work,	O
the	O
mixed	B
leucocytes	O
were	O
further	O
separated	O
into	O
mononuclear	B
(MNL)	O
and	O
polymorphonuclear	O
(PML)	O
leucocytes	O
,	O
and	O
GCR	B
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	B
.	O

GCR	B
on	O
MNL	B
and	O
PML	B
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+/-	O
413	O
and	O
4433	O
+/-	O
651	O
sites/cell	O
respectively,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(4462	O
+/-	O
962	O
and	O
5622	O
+/-	O
782	O
sites/cell	O
respectively,	O
P	O
less	O
than	O
0.05).	O

GCR	O
on	O
MNL	B
,	O
PML	B
and	O
mixed	B
leucocytes	O
in	O
5	O
patients	O
were	O
determined	O
simultaneously,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+/-	O
370,	O
4986	O
+/-	O
419	O
and	O
4524	O
+/-	O
852	O
sites/cell	O
respectively,	O
with	O
the	O
lowest	O
GCR	B
on	O
MNL	B
and	O
highest	O
on	O
PML	B
.	O

The	O
ubiquitous	B
octamer-binding	O
protein	O
(s)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B
genes	O
.	O

All	O
immunoglobulin	B
genes	O
contain	O
a	O
conserved	O
octanucleotide	B
promoter	O
element	O
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell-specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified,	O
and	O
cDNAs	B
encoding	O
octamer-binding	B
proteins	O
have	O
been	O
cloned.	O

Some	O
of	O
these	O
proteins	O
(referred	O
to	O
as	O
OTF-2	B
)	O
are	O
lymphoid	O
specific,	O
whereas	O
at	O
least	O
one	O
other,	O
and	O
possibly	O
more	O
(referred	O
to	O
as	O
OTF-1	B
),	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types.	O

The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue-specific	O
expression	O
of	O
immunoglobulin	B
genes	O
is	O
unclear.	O

We	O
have	O
identified	O
two	O
human	B
pre-B-cell	O
lines	O
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	B
yet	O
still	O
express	O
high	O
levels	O
of	O
steady-state	O
immunoglobulin	B
heavy-chain	O
mRNA	O
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	B
gene	O
in	O
vitro.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	B
made	O
from	O
one	O
of	O
these	O
pre-B	B
cells	O
or	O
from	O
HeLa	B
cells	O
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	B
gene	O
.	O

Furthermore,	O
OFT-1	B
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	B
when	O
normalized	O
for	O
binding	O
activity.	O

These	O
results	O
suggest	O
that	O
OTF-1	B
,	O
without	O
OTF-2	B
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	B
genes	O
and	O
that	O
OTF-2	B
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	B
gene	O
expression	O
.	O

Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O

In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	B
receptors	O
on	O
human	B
mononuclear	O
leukocytes	O
(	O
HML	B
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	B
have	O
already	O
been	O
described.	O

In	O
the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	O
.	O

In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	B
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O

A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(P	O
less	O
than	O
0.02).	O

The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	O
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O

Plasma	O
renin	B
activity	O
and	O
aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits.	O

The	O
number	O
of	O
mineralocorticoid	B
receptors	O
/cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(n	O
=	O
9).	O

The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	B
receptors	O
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O
mechanism	O
in	O
the	O
HML	B
of	O
patients	O
with	O
essential	O
hypertension	O
.	O

[Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1,25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
determination	O
in	O
lymphocytes	B
of	O
children	O
with	O
rickets	O
and	O
rickets	O
-like	O
diseases	O
]	O

The	O
authors	O
provide	O
the	O
results	O
of	O
studying	O
1,25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
in	O
lymphocytes	B
of	O
children	O
with	O
rickets	O
and	O
rickets	O
-like	O
diseases	O
.	O

It	O
is	O
proposed	O
that	O
the	O
character	O
of	O
their	O
expression	O
under	O
the	O
influence	O
of	O
vitamin	O
D	O
may	O
be	O
used	O
with	O
differential	O
diagnostic	O
purposes	O
in	O
view.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double-stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	B
regulatory	O
proteins	O
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods,	O
each	O
with	O
specific	O
limitations.	O

Inhibition	O
of	O
sequence-specific	B
DNA-binding	O
proteins	O
was	O
achieved	O
with	O
double-stranded	O
(ds)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	B
or	O
kappa	O
B	O
consensus	O
sequences	O
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	B
transcription	O
factor	O
or	O
nuclear	B
factor	O
(NF)-kappa	O
B	O
.	O

The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner.	O

Octamer-dependent	O
activation	O
of	O
a	O
reporter	B
plasmid	O
or	O
NF-kappa	B
B	O
-dependent	O
activation	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	O
transfected	O
B	B
cell	O
line	O
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	B
consensus	O
to	O
Jurkat	B
T	O
leukemia	O
cells	O
inhibited	O
interleukin-2	B
(	O
IL-2	B
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	O
octamer	B
site	O
in	O
the	O
IL-2	B
enhancer	O
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	B
factors	O
and	O
may	O
provide	O
anti-viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

[Effect	O
of	O
the	O
regimen	O
of	O
kidney-tonifying	O
and	O
qi-invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B
receptor	O
]	O

The	O
plasma	O
cortisol	O
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B
receptor	O
(	O
GCR	B
)	O
in	O
the	O
peripheral	B
lymphocytes	O
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O

In	O
animal	O
experiment	O
,	O
GCR	B
of	O
spleen	B
lymphocytic	O
cell	O
was	O
also	O
measured	O
in	O
18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O

The	O
results	O
showed	O
that	O
GCR	B
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
didn't	O
change	O
with	O
aging.	O

So	O
we	O
think	O
that	O
GCR	B
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O

After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney-tonifying	O
and	O
Qi-invigorating	O
,	O
the	O
GCR	B
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced,	O
and	O
in	O
this	O
way,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved.	O

Interferon	B
affects	O
nuclear	B
proteins	O
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O

Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	B
myelogenous	O
leukemia	O
(	O
CML	O
)	O
cells	O
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	B
proteins	O
and	O
the	O
transcriptional	B
enhancers	O
of	O
interferon	B
(IFN)-inducible	O
genes.	O

Exposure	O
of	O
CML	B
cells	O
to	O
IFN-alpha	B
diminished	O
the	O
effect	O
of	O
the	O
CML	B
cytoplasmic	O
proteins	O
on	O
these	O
nuclear	B
protein-DNA	O
complexes	O
.	O

The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN-alpha	B
correlated	O
with	O
the	O
sensitivity	O
to	O
the	O
IFN	B
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	B
protein-DNA	O
complexes	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN-alpha	B
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	B
proteins	O
.	O

Epstein-Barr	B
virus	O
nuclear	O
antigen	O
2	O
transactivates	O
latent	B
membrane	O
protein	O
LMP1	B
.	O

Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)	O
nuclear	O
antigen	O
2	O
(	O
EBNA-2	B
)	O
or	O
leader	B
protein	O
(	O
EBNA-LP	B
)	O
affects	O
expression	O
of	O
the	O
EBV	B
latent	O
infection	O
membrane	O
protein	O
LMP1	B
.	O

We	O
now	O
demonstrate	O
the	O
following.	O

(i)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	B
under	O
control	O
of	O
simian	B
virus	O
40	O
or	O
Moloney	O
murine	O
leukemia	O
virus	O
promoters	O
resulted	O
in	O
increased	O
LMP1	B
expression	O
in	O
P3HR-1-infected	B
Burkitt's	O
lymphoma	O
cells	O
and	O
the	O
P3HR-1	B
or	O
Daudi	B
cell	O
line	O
.	O

(ii)	O
Transfection	O
and	O
expression	O
of	O
EBNA-LP	B
alone	O
had	O
no	O
effect	O
on	O
LMP1	B
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA-2	B
to	O
affect	O
LMP1	B
expression	O
.	O

(iii)	O
LMP1	B
expression	O
in	O
Daudi	B
and	O
P3HR-1-infected	B
cells	O
was	O
controlled	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
EBNA-2	B
expression	O
in	O
Daudi	B
cells	O
increased	O
LMP1	B
mRNA	O
.	O

(iv)	O
No	O
other	O
EBV	B
genes	O
were	O
required	O
for	O
EBNA-2	B
transactivation	O
of	O
LMP1	B
since	O
cotransfection	O
of	O
recombinant	B
EBNA-2	B
expression	O
vectors	O
and	O
genomic	B
LMP1	B
DNA	O
fragments	O
enhanced	O
LMP1	B
expression	O
in	O
the	O
EBV-negative	B
B-lymphoma	O
cell	O
lines	O
BJAB	B
,	O
Louckes	B
,	O
and	O
BL30	B
.	O

(v)	O
An	O
EBNA-2	B
-responsive	O
element	O
was	O
found	O
within	O
the	O
-512	O
to	O
+40	O
LMP1	B
DNA	O
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	B
acetyltransferase	O
reporter	O
gene	O
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA-2	B
expression	O
vector	O
.	O

(vi)	O
The	O
EBV	B
type	O
2	O
EBNA-2	B
transactivated	O
LMP1	B
as	O
well	O
as	O
the	O
EBV	B
type	O
1	O
EBNA-2	B
.	O

(vii)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	B
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B
,	O
whereas	O
a	O
transformation-competent	B
EBNA-2	B
deletion	O
mutant	O
did	O
transactivate	O
LMP1	B
.	O

LMP1	B
is	O
a	O
potent	O
effector	O
of	O
B-lymphocyte	B
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B
to	O
induce	O
cellular	O
CD23	B
gene	O
expression	O
.	O

Thus,	O
EBNA-2	B
transactivation	O
of	O
LMP1	B
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA-2	B
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV-induced	O
growth	O
transformation	O
.	O

The	O
expression	O
of	O
c-fos	B
,	O
c-jun	O
,	O
and	O
c-myc	O
genes	O
is	O
regulated	O
by	O
heat	O
shock	O
in	O
human	B
lymphoid	O
cells	O
.	O

The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	B
protooncogenes	O
c-fos	B
,	O
c-jun	B
,	O
and	O
c-myc	B
was	O
studied	O
in	O
human	B
lymphoid	O
cells	O
.	O

Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c-fos	O
and	O
c-jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c-myc	B
mRNA	O
levels	O
in	O
pre-B	B
(Hyon)	O
and	O
T	B
(DND-41)	O
cell	O
lines	O
as	O
well	O
as	O
in	O
freshly	B
isolated	O
normal	O
human	O
thymocytes.	O

The	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	B
in	O
Hyon	B
cells	O
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O

Altered	O
transcription	O
of	O
c-fos	B
and	O
c-myc	O
genes	O
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O

Secondarily,	O
heat	O
shock	O
of	O
Hyon	B
cells	O
stabilized	O
the	O
c-myc	B
mRNA	O
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min.	O

The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c-myc	B
mRNA	O
level	O
,	O
however,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	B
protooncogenes	O
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	B
protooncogenes	O
in	O
the	O
stress	O
response	O
of	O
lymphoid	B
cells	O
.	O

Mapping	O
of	O
B-cell	B
epitopes	O
of	O
the	O
human	B
hepatitis	O
B	O
virus	O
X	O
protein	O
.	O

The	O
immune	O
response	O
to	O
the	O
X	B
protein	O
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	B
fusion	O
proteins	O
and	O
synthetic	O
peptides	O
.	O

Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O

Each	O
serum	O
contained	O
antibodies	B
to	O
a	O
different	O
set	O
of	O
epitopes	B
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	B
sequence	O
.	O

Some	O
of	O
the	O
epitopes	B
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	B
proteins	O
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O

The	O
carboxy-terminal	B
half	O
of	O
the	O
HBx	B
protein	O
was	O
preferentially	O
recognized	O
by	O
antibodies	B
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	B
antigenic	O
region	O
with	O
at	O
least	O
two	O
major	O
nonoverlapping	O
epitopes	B
.	O

Anti-	O
HBx	B
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	O
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	B
-specific	O
peptide	O
ELISAs	O
.	O

Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O

[The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	B
leukocytes	O
]	O

Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	B
leukocytes	O
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O

Both	O
RM	O
and	O
ChtM	O
showed	O
circadian	O
rhythm	O
.	O

Leukocytes	B
migrated	O
most	O
rapidly	O
at	O
night.	O

The	O
difference	O
between	O
the	O
peak	O
(0:00)	O
and	O
trough	O
values	O
(8:00)	O
of	O
RM	O
and	O
ChtM	B
was	O
significant	O
statistically	O
(P	O
less	O
than	O
0.01).	O

ChtM	B
was	O
inhibited	O
by	O
hydrocortisone	O
(F)	O
of	O
physiological	O
concentration	O
(10(-9)-10(-7)	O
mol/L)	O
which	O
was	O
dose-dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O

The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(more	O
than	O
10(-5)	O
mol/L)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially.	O

It	O
is	O
suggested	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
may	O
be	O
a	O
physiological	O
regulator	O
of	O
the	O
activity	O
of	O
leukocytes	B
and	O
its	O
inhibitory	O
action	O
on	O
ChtM	B
may	O
be	O
involved	O
in	O
antiinflammatory	O
mechanisms	O
of	O
GC	O
of	O
pharmacological	O
doses	O
.	O

The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	O
may	O
be	O
mediated	O
by	O
low	O
affinity	O
specific	O
binding	O
sites	O
of	O
glucocorticoid	B
receptors	O
.	O

Heterogeneity	O
of	O
antigen	O
molecules	O
recognized	O
by	O
anti-tax1	B
monoclonal	O
antibody	O
Lt-4	B
in	O
cell	B
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O

Using	O
a	O
monoclonal	B
antibody	O
,	O
Lt-4	B
,	O
directed	O
against	O
human	B
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
trans-activator	O
(	O
tax1	B
)	O
antigen	O
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B
and	O
related	O
antigens	O
in	O
a	O
variety	O
of	O
T	B
cell	O
lines	O
bearing	O
HTLV-I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV-I	O
)	O
and	O
HTLV-II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O

Lt-4	B
reacted	O
with	O
all	O
HTLV-I	B
-bearing	O
cell	O
lines	O
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	B
cell	O
lines	O
bearing	O
STLV-I	O
,	O
but	O
not	O
with	O
an	O
HTLV-II	B
-bearing	O
cell	O
line	O
.	O

Lt-4	B
detected	O
40	B
kd	O
tax1	O
antigen	O
molecules	O
in	O
most	O
HTLV-I	B
-bearing	O
cell	O
lines	O
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	B
kd	O
tax1	O
antigen	O
.	O

In	O
the	O
STLV-I	B
-bearing	O
T	O
cell	O
lines	O
,	O
tax1	B
-related	O
antigen	O
molecules	O
detected	O
by	O
Lt-4	B
were	O
heterogeneous,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36-41	O
kd.	O

Characterization	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
-binding	O
proteins	O
from	O
the	O
human	B
T-cell	O
line	O
Jurkat	O
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	B
proteins	O
that	O
bind	O
to	O
the	O
viral	B
long	O
terminal	O
repeat	O
(	O
LTR	B
).	O

Among	O
the	O
protein-binding	B
regions	O
of	O
the	O
HIV-1	B
LTR	O
is	O
the	O
transcription-enhancer	B
region	O
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	O
,	O
C1	B
,	O
and	O
one	O
constitutive,	O
C2	B
,	O
protein	O
can	O
bind	O
to	O
the	O
HIV	B
enhancer	O
in	O
Jurkat	B
cells	O
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	B
domain	O
.	O

Both	O
C1	B
and	O
C2	B
proteins	O
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2	B
-receptor	O
alpha-subunit	O
enhancer	O
.	O

The	O
inducible	O
C1	B
protein	O
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross-linking	O
as	O
a	O
47	B
kDa	O
protein	O
.	O

Differences	O
in	O
transcriptional	B
enhancers	O
of	O
HIV-1	O
and	O
HIV-2	O
.	O

Response	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

T	O
cell	O
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	B
terminal	O
repeat	O
(	O
LTR	B
)	O
and	O
comprise	O
the	O
transcriptional	B
enhancer	O
,	O
which	O
contains	O
two	O
conserved	B
binding	O
sites	O
for	O
the	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF	B
kappa	O
B	O
).	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	B
kappa	O
B	O
binding	O
site	O
.	O

We	O
demonstrate	O
that	O
the	O
HIV-1	B
LTR	O
responds	O
better	O
than	O
the	O
HIV-2	B
LTR	O
to	O
T	O
cell	O
activation	O
signals.	O

These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	O
cell	O
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	B
or	O
HIV-2	O
enhancers	O
are	O
placed	O
upstream	O
of	O
a	O
heterologous	B
promoter	O
but	O
also	O
when	O
these	O
enhancers	O
are	O
switched	O
between	O
their	O
respective	O
LTR	B
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays,	O
NF	B
kappa	O
B	O
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	B
transcriptional	O
enhancer	O
and	O
only	O
to	O
the	O
single	O
conserved	B
site	O
in	O
the	O
HIV-2	B
transcriptional	O
enhancer	O
.	O

Instead	O
of	O
NF	B
kappa	O
B	O
,	O
the	O
activator	B
protein	O
3	O
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O

In	O
conclusion,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O

NF-X2	B
that	O
binds	O
to	O
the	O
DRA	B
X2-box	O
is	O
activator	B
protein	O
1	O
.	O

Expression	O
cloning	O
of	O
c-Jun	B
.	O

Human	B
class	O
II	O
MHC	O
Ag	O
are	O
a	O
family	O
of	O
cell	B
surface	O
glycoproteins	O
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	B
lymphocytes	O
and	O
thymic	B
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN-gamma	B
.	O

Conserved	B
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	B
II	O
genes	O
.	O

In	O
the	O
DRA	B
promoter	O
,	O
one	O
of	O
these	O
cis-acting	B
regulatory	O
motifs	O
is	O
the	O
X2-box	B
to	O
which	O
nuclear	B
factor	O
X2	O
(	O
NF-X2	B
)	O
binds.	O

Here,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full-length	O
cDNA	B
clone	O
encoding	O
NF-X2	B
.	O

This	O
cDNA	B
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	B
c-Jun	O
protein	O
,	O
which	O
together	O
with	O
c-Fos	B
forms	O
the	O
heterodimeric	B
activator	O
protein-1	O
transcription	O
complex	O
.	O

Whereas	O
c-Fos	B
/c-Jun	B
heterodimers	O
do	O
not	O
exist	O
in	O
B	B
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	B
in	O
class	B
II	O
nonexpressing	O
cells	O
.	O

Thus,	O
c-Fos	B
/c-Jun	B
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B
gene	O
expression	O
.	O

Synthesis	O
of	O
4,19-disubstituted	O
derivatives	O
of	O
DOC	O
.	O

Radioreceptor	O
assay	O
of	O
some	O
corticosteroid	O
derivatives	O
in	O
human	B
mononuclear	O
leukocytes	O
.	O

Several	O
new	O
4,19-substituted	O
steroids	O
and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	B
1	O
receptors	O
in	O
human	B
mononuclear	O
leukocytes	O
.	O

11	O
beta,19-epoxy-4,21-dihydroxypregn-4-ene-3,20-dione	O
(2)	O
was	O
hydrogenated	O
with	O
Pd-C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5,	O
accompanied	O
by	O
4,21-diacetoxy-11	O
beta,19-epoxy-3-hydroxypregnan-20-one	O
(6)	O
and	O
21-acetoxy-11	O
beta,19-epoxy-4-hydroxypregnane-3,20-dione	O
(7).	O

With	O
hot	O
acetic	O
+	O
p-toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta,19-epoxypregn-5-ene-4,20-dione	O
(8)	O
Pd-C	O
hydrogenation	O
of	O
3,21-diacetoxy-5	O
beta,19-cyclopregna-2,9(11)-diene-4,20-dione	O
(10)	O
gave	O
3,21-diacetoxy-5	O
beta,19-cyclopregn-5-ene-4,20-dione	O
(11)	O
and	O
the	O
9,11-dihydro	O
derivative	O
of	O
the	O
latter.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4,21-dihydroxypregna-4,9(11)-diene-3,20-dione	O
(13).	O

Pd-C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4,5-dihydro	O
derivative	O
18,	O
19-chloro-21-acetoxypregn-9(11)-en-20-one	O
(15),	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3,4-diacetoxy	O
derivative	O
17.	O

When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	B
mononuclear	O
leukocytes	O
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	B
1	O
receptor	O
,	O
the	O
highest	O
being	O
0.72%	O
for	O
13	O
(	O
aldosterone	O
=	O
100%).	O

For	O
comparison,	O
other	O
RBA	O
in	O
this	O
system	O
were:	O
19-noraldosterone	O
,	O
20%;	O
18-deoxyaldosterone	O
,	O
5.8%;	O
18-deoxy-19-noraldosterone	O
,	O
4.7%;	O
18,21-anhydroaldosterone	O
,	O
0.37%;	O
17-isoaldosterone	O
,	O
7.6%	O
and	O
apoaldosterone	O
,	O
4.3%	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	B
(	O
nuclear	B
factor	O
of	O
activated	O
T-cells	O
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B
factor	O
.	O

Nuclear	B
factor	O
of	O
activated	O
T-cells	O
(	O
NFAT-1	B
)	O
is	O
a	O
transcription	B
factor	O
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T-cell	O
activation	O
.	O

We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT-1	B
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	B
NFAT-1	B
binding	O
motif	O
that	O
directs	O
transcription	O
of	O
SV40	B
T-antigen	O
in	O
transgenic	O
mice	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	B
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

NFAT-1	B
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	O
T-lymphocytes	B
upon	O
release	O
of	O
intracellular	O
calcium	O
.	O

By	O
targeting	O
NFAT-1	B
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	B
activity	O
.	O

Besides	O
in	O
T-lymphocytes	B
NFAT-1	B
activity	O
could	O
also	O
be	O
induced	O
in	O
T-lymphocyte-depleted	B
spleen	O
cells	O
and	O
purified	B
B-lymphocytes	O
and	O
requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	B
kinase	O
C	O
.	O

A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	B
activity	O
between	O
T-lymphocytes	B
and	O
non-T-lymphocytes	B
was	O
revealed.	O

Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O

Interestingly,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT-1	B
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV-LTR/tat	B
transgenic	O
mice	O
(Vogel,	O
J.,	O
Hinrichs,	O
S.	O
H.,	O
Reynolds,	O
R.	O
K.,	O
Luciw,	O
P.	O
A.,	O
and	O
Jay,	O
G.	O
(1988)	O
Nature	O
335,	O
606-611).	O

This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT-1	B
has	O
been	O
shown	O
to	O
bind	O
functional	O
sequences	O
in	O
HIV-LTR	B
suggest	O
a	O
role	O
for	O
NFAT-1	B
in	O
dermal	O
activation	O
of	O
the	O
HIV-LTR	B
.	O

A	O
novel	O
T-cell	B
protein	O
which	O
recognizes	O
a	O
palindromic	B
sequence	O
in	O
the	O
negative	B
regulatory	O
element	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

Two	O
major	O
protein-binding	B
sites	O
within	O
the	O
negative	B
regulatory	O
element	O
of	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
have	O
been	O
identified.	O

One	O
(	O
site	B
B	O
)	O
contained	O
a	O
palindromic	B
sequence	O
with	O
homology	O
to	O
steroid/thyroid	B
hormone	O
response	O
elements	O
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	B
sites	O
of	O
this	O
class.	O

A	O
novel	O
T-cell	B
protein	O
recognized	O
the	O
palindromic	B
sequence	O
within	O
site	B
B	O
and	O
also	O
bound	O
estrogen-	B
or	O
thyroid	O
hormone-	O
response	O
elements	O
with	O
lower	O
affinity.	O

A	O
7-base-pair	B
mutation	O
in	O
the	O
site	B
B	O
palindrome	O
,	O
which	O
destroyed	O
protein	O
binding,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	B
cells	O
.	O

Progesterone	O
suppression	O
of	O
pregnancy	B
lymphocytes	O
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect.	O

This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	B
lymphocytes	O
is	O
mediated	O
by	O
specific	O
progesterone	B
receptors	O
.	O

The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	O
receptor	O
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	B
factor	O
by	O
progesterone	B
-treated	O
pregnancy	O
lymphocytes	O
.	O

RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	B
factor	O
,	O
while	O
RU	O
43044	O
was	O
without	O
effect.	O

These	O
data	O
suggest	O
that	O
in	O
pregnancy,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	B
receptors	O
and	O
glucocorticoid	B
binding	O
sites	O
are	O
not	O
involved.	O

The	O
56-59-kilodalton	B
protein	O
identified	O
in	O
untransformed	B
steroid	O
receptor	O
complexes	O
is	O
a	O
unique	O
protein	O
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70-	B
and	O
90-	O
kilodalton	O
heat	O
shock	O
proteins	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
9S	B
,	O
untransformed	O
progestin	B
,	O
estrogen	O
,	O
androgen	O
,	O
and	O
glucocorticoid	O
receptor	O
complexes	O
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	B
protein	O
[Tai,	O
P.K.,	O
Maeda,	O
Y.,	O
Nakao,	O
K.,	O
Wakim,	O
N.G.,	O
Duhring,	O
J.L.,	O
&amp;	O
Faber,	O
L.E.(1986)	O
Biochemistry	O
25,	O
5269-5275].	O

In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	B
antibody	O
KN	B
382/EC1	O
raised	O
against	O
the	O
rabbit	B
59-kDa	O
protein	O
reacts	O
with	O
9S	B
,	O
untransformed	O
glucocorticoid	B
receptor	O
complexes	O
in	O
cytosol	O
prepared	O
from	O
human	B
IM-9	O
lymphocytes	O
but	O
not	O
with	O
4S	B
salt-transformed	O
receptors	O
.	O

The	O
human	B
protein	O
recognized	O
by	O
the	O
EC1	B
antibody	O
is	O
a	O
56-kDa	B
protein	O
(	O
p56	B
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O

There	O
are	O
at	O
least	O
six	O
isomorphs	O
of	O
p56	B
by	O
two-dimensional	O
gel	O
analysis	O
.	O

N-Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	B
is	O
a	O
unique	B
human	O
protein	O
.	O

When	O
p56	B
is	O
immunoadsorbed	O
from	O
IM-9	O
cell	O
cytosol	O
,	O
both	O
the	O
70-	B
and	O
90-	O
kDa	O
heat	O
shock	O
proteins	O
are	O
coadsorbed	O
in	O
an	O
immune-specific	O
manner	O
.	O

Neither	O
heat	B
shock	O
protein	O
reacts	O
directly	O
with	O
the	O
EC1	B
antibody	O
.	O

We	O
conclude	O
that	O
p56	B
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B
and	O
hsp90	B
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	B
steroid	O
receptors	O
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
proto-oncoprotein	B
ets-1	O
defines	O
a	O
transcriptional	B
activator	O
sequence	O
within	O
the	O
long	B
terminal	O
repeat	O
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O

The	O
ets	B
proto-oncogene	O
family	O
is	O
a	O
group	O
of	O
sequence-related	O
genes	O
whose	O
normal	O
cellular	O
function	O
is	O
unknown.	O

In	O
a	O
study	O
of	O
cellular	B
proteins	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
murine	O
retroviruses	O
in	O
T	B
lymphocytes	O
,	O
we	O
have	O
discovered	O
that	O
a	O
member	O
of	O
the	O
ets	B
gene	O
family	O
encodes	O
a	O
sequence-specific	B
DNA-binding	O
protein	O
.	O

A	O
mouse	B
ets-1	O
cDNA	O
clone	O
was	O
obtained	O
by	O
screening	O
a	O
mouse	B
thymus	O
cDNA	O
expression	O
library	O
with	O
a	O
double-stranded	O
oligonucleotide	O
probe	O
representing	O
20	O
bp	O
of	O
the	O
Moloney	B
murine	O
sarcoma	O
virus	O
(	O
MSV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	B
).	O

The	O
cDNA	O
sequence	O
has	O
an	O
813-bp	B
open	O
reading	O
frame	O
(	O
ORF	B
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97.6%	O
identical	O
to	O
the	O
272	B
carboxy-terminal	O
amino	O
acids	O
of	O
the	O
human	B
ets-1	B
protein	O
.	O

The	O
ORF	B
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
30-kD	B
protein	O
product	O
was	O
shown	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
by	O
mobility-shift	O
assays	O
,	O
Southwestern	O
blot	O
analysis	O
,	O
and	O
methylation	O
interference	O
.	O

A	O
mutant	B
LTR	O
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets-1	B
binding	O
site	O
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro.	O

Transcriptional	O
efficiency	O
of	O
the	O
MSV	B
LTR	O
promoter	O
containing	O
this	O
disrupted	O
ets-1	B
binding	O
site	O
was	O
compared	O
to	O
the	O
activity	O
of	O
a	O
wild-type	B
promoter	O
in	O
mouse	B
T	O
lymphocytes	O
in	O
culture,	O
and	O
15-	O
to	O
20-fold	O
reduction	O
in	O
expression	O
of	O
a	O
reporter	B
gene	O
was	O
observed.	O

We	O
propose	O
that	O
ets-1	B
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type-C	O
retroviruses	O
and	O
speculate	O
that	O
ets-related	B
genes	O
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B
DNA-binding	O
proteins	O
.	O

Type	B
II	O
estrogen	O
binding	O
sites	O
in	O
human	B
peripheral	O
blood	O
mononuclear	O
cells	O
:	O
variations	O
during	O
the	O
menstrual	O
cycle	O
.	O

We	O
have	O
previously	O
reported	O
that	O
human	B
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	B
)	O
contain	O
type	B
II	O
estrogen	O
binding	O
sites	O
(	O
type	B
II	O
EBS	O
).	O

In	O
this	O
study,	O
the	O
fluctuations	O
of	O
type	B
II	O
EBS	O
during	O
the	O
menstrual	O
cycle	O
were	O
analyzed	O
in	O
6	O
normally	O
menstruating	O
women	O
.	O

Approximately	O
3	O
times	O
higher	O
levels	O
of	O
type	B
II	O
EBS	B
were	O
found	O
in	O
the	O
periovulatory	O
period	O
with	O
respect	O
to	O
both	O
follicular	O
and	O
luteal	O
phases	O
.	O

In	O
postmenopausal	O
women	O
the	O
mean	O
type	B
II	O
EBS	B
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle.	O

However,	O
in	O
3	O
postmenopausal	O
patients	O
a	O
short	O
course	O
of	O
estrogen	O
or	O
tamoxifen	O
resulted	O
in	O
a	O
marked	O
increase	O
of	O
type	B
II	O
EBS	B
levels.	O

Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O
17	O
beta-estradiol	O
for	O
type	B
II	O
EBS	O
in	O
PBMC	B
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O

Mononuclear	B
leukocyte	O
glucocorticoid	B
receptor	O
binding	O
characteristics	O
and	O
down-regulation	O
in	O
major	O
depression	O
.	O

Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
),	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O

To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[3H]-DEX-binding	O
assays	O
were	O
used	O
to	O
measure,	O
in	O
vitro,	O
the	O
GC	B
receptor	O
affinity	O
(1/Kd)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	B
leukocytes	O
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

DEX	O
(1.0	O
mg	O
orally)	O
was	O
administered	O
to	O
study	O
in	O
vivo	O
GC	B
receptor	O
down-regulation	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down-regulated	O
Bmax	O
after	O
DEX	O
.	O

By	O
paired	O
t-test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O

Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down-regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor-binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC	O
-mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect(s)	O
leading	O
to	O
GC	O
resistance	O
.	O

Ras-related	B
GTP-binding	O
proteins	O
and	O
leukocyte	O
signal	O
transduction	O
.	O

Many	O
aspects	O
of	O
leukocyte	O
function	O
are	O
regulated	O
by	O
both	O
heterotrimeric	B
and	O
Ras-related	O
GTP-binding	O
proteins	O
,	O
but	O
there	O
is	O
little	O
definite	O
information	O
about	O
their	O
roles	O
in	O
the	O
specialized	O
processes	O
utilized	O
by	O
leukocytes	B
for	O
cell	O
killing.	O

Recent	O
progress	O
in	O
understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	B
NADPH	O
oxidase	O
by	O
the	O
Rac	B
GTP-binding	O
proteins	O
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O

It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	B
oxidase	O
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP-GDP	B
state	O
of	O
Rac	B
.	O

Proteins	O
exist	O
in	O
leukocytes	B
able	O
to	O
modify	O
GTP-binding	B
protein	O
function	O
in	O
this	O
manner,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O

Proteins	O
of	O
the	O
Ras	B
superfamily	O
are	O
likely	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
normal	O
phagocyte	O
functions	O
through	O
their	O
ability	O
to	O
modulate	O
the	O
assembly	O
of	O
actin	B
filaments	O
,	O
direct	O
vesicle	O
trafficking	O
and	O
fusion,	O
and	O
so	O
forth.	O

BSAP	B
:	O
a	O
key	O
regulator	O
of	O
B-cell	O
development	O
and	O
differentiation	O
.	O

B-cell-specific	B
activator	O
protein	O
(	O
BSAP	B
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
Pax-gene	B
family	O
of	O
transcription	B
factors	O
;	O
in	O
the	O
lymphoid	O
system	O
,	O
BSAP	B
is	O
produced	O
only	O
in	O
B	B
cells	O
.	O

Here,	O
Markus	O
Neurath,	O
Eckhard	O
Stuber	O
and	O
Warren	O
Strober	O
describe	O
the	O
molecular	O
structure	O
of	O
BSAP	B
and	O
focus	O
on	O
the	O
ability	O
of	O
this	O
protein	O
to	O
regulate	O
the	O
expression	O
of	O
B-cell-specific	B
genes	O
.	O

They	O
propose	O
that	O
BSAP	B
is	O
a	O
key	O
protein	O
of	O
B	B
cells	O
and	O
that	O
it	O
not	O
only	O
influence	O
B-cell	O
development	O
but	O
also	O
influences	O
the	O
balance	O
between	O
B-cell	O
proliferation	O
and	O
immunoglobulin	B
secretion	O
at	O
later	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Down-regulation	O
of	O
NF-kappa	B
B	O
protein	O
levels	O
in	O
activated	B
human	O
lymphocytes	O
by	O
1,25-dihydroxyvitamin	O
D3	O
[published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9;93(1):524]	O

The	O
effect	O
of	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25(OH)2)D3	O
],	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties,	O
on	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
)	O
proteins	O
was	O
examined	O
in	O
in	O
vitro	O
activated	O
normal	B
human	O
lymphocytes	O
by	O
Western	O
blot	O
analysis	O
.	O

Over	O
a	O
72-hr	O
period	O
of	O
activation,	O
the	O
expression	O
of	O
the	O
50-kDa	B
NF-kappa	B
B	O
,	O
p50	B
,	O
and	O
its	O
precursor,	O
p105	B
,	O
was	O
increased	O
progressively.	O

When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1,25(OH)2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased.	O

The	O
effect	O
of	O
the	O
hormone	O
on	O
the	O
levels	O
of	O
p50	B
was	O
demonstrable	O
in	O
the	O
cytosolic	O
and	O
nuclear	O
compartments	O
;	O
it	O
required	O
between	O
4	O
and	O
8	O
hr	O
and	O
was	O
specific,	O
as	O
25-hydroxyvitamin	O
D3	O
and	O
24,25-dihydroxyvitamin	O
D3	O
were	O
ineffective.	O

Besides	O
p50	B
,	O
1,25(OH)2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	B
B	O
protein	O
,	O
namely	O
c-rel	B
.	O

In	O
addition,	O
1,25(OH)2D3	O
decreased	O
the	O
abundance	O
of	O
a	O
specific	O
DNA-protein	B
complex	O
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	B
lymphocytes	O
with	O
a	O
labeled	O
NF-kappa	B
B	O
DNA	O
binding	O
motif	O
.	O

Further,	O
1,25(OH)2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF-kappa	B
B	O
in	O
Jurkat	B
cells	O
transiently	O
transfected	O
with	O
a	O
construct	O
containing	O
four	O
tandem	O
repeats	O
of	O
the	O
NF-kappa	B
B	O
binding	O
sequence	O
of	O
the	O
immunoglobulin	B
kappa	O
light	O
chain	O
gene	O
linked	O
to	O
the	O
chloramphenicol	B
acetyltransferase	O
reporter	O
gene	O
.	O

These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF-kappa	B
B	O
during	O
human	O
lymphocyte	O
activation	O
and	O
suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated.	O

The	O
myeloid	B
zinc	O
finger	O
gene	O
,	O
MZF-1	B
,	O
regulates	O
the	O
CD34	B
promoter	O
in	O
vitro.	O

MZF-1	B
is	O
a	O
C2H2	B
zinc	O
finger	O
gene	O
encoding	O
a	O
putative	O
transcriptional	O
regulator	O
of	O
myeloid	O
differentiation	O
.	O

The	O
MZF-1	B
protein	O
contains	O
13	O
C2H2	B
zinc	O
fingers	O
arranged	O
in	O
bipartite	B
DNA	O
binding	O
domains	O
containing	O
zinc	B
fingers	O
through	O
4	O
and,	O
in	O
the	O
carboxy-terminus	B
,	O
5	B
through	O
13.	O

We	O
previously	O
identified	O
the	O
DNA	B
consensus	O
binding	O
site	O
recognized	O
by	O
the	O
two	O
DNA	B
binding	O
domains	O
.	O

To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF-1	B
,	O
the	O
full-length	O
MZF-1	B
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	B
binding	O
domain	O
of	O
the	O
yeast	B
transactivator	O
GAL4	B
.	O

The	O
expression	B
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	B
acetyl	O
transferase	O
(CAT)	O
reporter	O
gene	O
regulated	O
by	O
the	O
thymidine	B
kinase	O
promoter	O
containing	O
GAL4	B
DNA	O
binding	O
sites	O
into	O
NIH	B
3T3	O
,	O
293	O
,	O
K562	B
,	O
and	O
Jurkat	B
cell	O
lines	O
.	O

MZF-1	B
represses	O
CAT	B
reporter	O
gene	O
expression	O
via	O
GAL4	B
binding	O
sites	O
in	O
the	O
nonhematopoietic	B
cell	O
lines	O
NIH	B
3T3	O
and	O
293	B
.	O

In	O
contrast,	O
MZF-1	B
activates	O
CAT	B
reporter	O
gene	O
expression	O
in	O
the	O
hematopoietic	B
cell	O
lines	O
K562	B
and	O
Jurkat	B
.	O

The	O
MZF-1	B
binding	O
sites	O
are	O
present	O
in	O
the	O
promoters	O
of	O
several	O
genes	O
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	B
promoter	O
.	O

MZF-1	B
transcriptional	O
regulation	O
of	O
this	O
physiologically	O
relevant	O
promoter	O
was	O
assessed	O
in	O
both	O
hematopoietic	B
and	O
nonhematopoietic	O
cell	O
lines	O
.	O

Recombinant	B
MZF-1	B
protein	O
specifically	O
binds	O
to	O
the	O
consensus	B
binding	O
sites	O
in	O
the	O
CD34	B
promoter	O
in	O
mobility	O
shift	O
assays	O
.	O

MZF-1	B
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	B
reporter	O
plasmids	O
regulated	O
by	O
the	O
CD34	B
promoter	O
into	O
both	O
nonhematopoietic	B
and	O
hematopoietic	O
cell	O
lines	O
.	O

As	O
with	O
the	O
heterologous	B
DNA	O
binding	O
domain	O
,	O
MZF-1	B
represses	O
reporter	O
gene	O
expression	O
in	O
nonhematopoietic	B
cell	O
lines	O
and	O
activates	O
expression	O
in	O
hematopoietic	B
cell	O
lines	O
.	O

Activation	O
of	O
CD34	B
expression	O
in	O
hematopoietic	B
cell	O
lines	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF-1	B
binding	O
sites	O
.	O

The	O
cell	O
type-specific	O
regulation	O
of	O
the	O
CD34	B
promoter	O
by	O
MZF-1	B
suggests	O
the	O
presence	O
of	O
tissue-specific	B
regulators/adapters	O
or	O
differential	O
MZF-1	B
modifications	O
that	O
determine	O
MZF-1	B
transcriptional	O
regulatory	O
function	O
.	O

The	O
murine	B
BCL6	O
gene	O
is	O
induced	O
in	O
activated	B
lymphocytes	O
as	O
an	O
immediate	B
early	O
gene	O
.	O

The	O
chromosomal	O
translocation	O
involving	O
3q27	B
is	O
often	O
detected	O
in	O
human	O
B-cell	O
lymphomas	O
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O
large-cell	O
component	O
.	O

The	O
BCL6	B
gene	O
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O

Here	O
we	O
cloned	O
the	O
murine	B
BCL6	B
(mBCL6)	O
cDNA	O
from	O
the	O
muscle	B
cDNA	O
library	O
using	O
the	O
human	B
BCL6	B
(hBCL6)	O
cDNA	O
as	O
a	O
probe.	O

The	O
predicted	O
amino	B
acid	O
sequence	O
was	O
95%	O
identical	O
to	O
that	O
of	O
hBCL6	B
.	O

It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel-like	B
zinc-finger	O
motif	O
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	B
,	O
indicating	O
that	O
the	O
BCL6	B
gene	O
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O

Expression	O
of	O
the	O
mBCL6	B
gene	O
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O

Furthermore,	O
it	O
was	O
induced	O
in	O
lymphocytes	B
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation.	O

This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O

These	O
results	O
suggest	O
that	O
BCL6	B
plays	O
a	O
role	O
in	O
activated	B
lymphocytes	O
as	O
an	O
immediate	B
early	O
gene.	O

The	O
role	O
of	O
BSAP	B
(	O
Pax-5	B
)	O
in	O
B-cell	O
development	O
.	O

The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B-cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O

In	O
this	O
manner,	O
the	O
paired	B
box	O
containing	O
gene	O
Pax-5	B
,	O
encoding	O
the	O
B	B
cell	O
specific	O
transcription	O
factor	O
BSAP	B
,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O

Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	B
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	B
heavy-chain	O
gene	O
at	O
late	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

The	O
DNA-binding	O
properties	O
of	O
two	O
heat	B
shock	O
factors	O
,	O
HSF1	B
and	O
HSF3	B
,	O
are	O
induced	O
in	O
the	O
avian	B
erythroblast	O
cell	O
line	O
HD6	O
.	O

Avian	O
cells	O
express	O
three	O
heat	B
shock	O
transcription	B
factor	O
(	O
HSF	O
)	O
genes	O
corresponding	O
to	O
a	O
novel	B
factor	O
,	O
HSF3	B
,	O
and	O
homologs	O
of	O
mouse	B
and	O
human	O
HSF1	B
and	O
HSF2	B
.	O

Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	B
reveals	O
that	O
HSF3	B
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B
and	O
HSF2	B
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both.	O

HSF3	B
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	B
cell	O
line	O
HD6	O
,	O
the	O
lymphoblast	B
cell	O
line	O
MSB	O
,	O
and	O
embryo	B
fibroblasts	O
,	O
and	O
yet	O
its	O
DNA-binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	B
cells	O
to	O
heat	O
shock.	O

Acquisition	O
of	O
HSF3	B
DNA-binding	O
activity	O
in	O
HD6	B
cells	O
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non-DNA-binding	B
dimer	O
to	O
a	O
DNA-binding	B
trimer	O
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B
is	O
oligomerization	O
of	O
an	O
inert	O
monomer	O
to	O
a	O
DNA-binding	B
trimer	O
.	O

Induction	O
of	O
HSF3	B
DNA-binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	B
.	O

As	O
occurs	O
for	O
HSF1	B
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B
to	O
the	O
nucleus.	O

HSF	B
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	O
activator	O
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	O
overexpressed	O
HSF3	B
measured	O
by	O
using	O
a	O
heat	B
shock	O
element-containing	O
reporter	O
construct	O
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O
chimeric	B
GAL4	O
-HSF3	B
protein	O
on	O
a	O
GAL4	B
reporter	O
construct	O
.	O

These	O
results	O
reveal	O
that	O
HSF3	B
is	O
negatively	O
regulated	O
in	O
avian	B
cells	O
and	O
acquires	O
DNA-binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O

Direct	O
demonstration	O
of	O
NFATp	B
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	B
HT-2	O
cells	O
using	O
a	O
specific	O
NFATp	B
polyclonal	O
antibody	O
.	O

Nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	B
genes	O
,	O
and	O
NFAT	B
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	B
is	O
a	O
substrate	O
for	O
calcineurin	B
,	O
a	O
serine/threonine	B
phosphatase	O
.	O

Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	O
NFATp	B
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O
110-130-kDa	B
NFATp	B
protein	O
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O

Treatment	O
of	O
immunoprecipitated	B
NFATp	B
from	O
untreated	O
HT-2	B
cells	O
with	O
calcineurin	B
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	B
,	O
demonstrating	O
that	O
NFATp	B
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	B
.	O

NFATp	B
immunoprecipitated	O
from	O
32P-labeled	B
HT-2	O
cells	O
migrated	O
as	O
an	O
approximately	O
120-kDa	B
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells.	O

Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	B
dephosphorylation	O
.	O

The	O
dephosphorylation	O
of	O
NFATp	B
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	B
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	B
is	O
a	O
calcineurin	B
substrate	O
in	O
cells.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	B
factors	O
of	O
activated	O
T	O
cells	O
,	O
NFATp	B
and	O
NFATc	B
,	O
in	O
human	B
natural	O
killer	O
cells	O
:	O
regulation	O
upon	O
CD16	B
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	B
receptors	O
to	O
the	O
activation	O
of	O
cytokine	B
synthesis	O
in	O
natural	B
killer	O
(NK)	O
cells	O
have	O
not	O
been	O
elucidated.	O

We	O
report	O
here	O
that	O
the	O
nuclear	B
factor	O
of	O
activated	O
T	B
cells	O
(	O
NFATp	B
),	O
a	O
cyclosporin	B
A	O
(	O
CsA	O
)-sensitive	O
factor	O
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	B
,	O
mediates	O
CD16	B
-induced	O
activation	O
of	O
cytokine	B
genes	O
in	O
human	B
NK	O
cells	O
.	O

CD16	B
(	O
Fc	B
gamma	O
RIIIA	O
)-induced	O
expression	O
of	O
cytokine	B
mRNA	O
in	O
NK	B
cells	O
occurs	O
via	O
a	O
CsA	O
-sensitive	O
and	O
Ca(2+)-dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	B
cells	O
with	O
CD16	B
ligands	O
induces	O
NFAT	B
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation,	O
via	O
a	O
CsA	O
-sensitive	O
and	O
Ca(2+)-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis.	O

NK	B
cell	O
NFAT	B
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	B
cells	O
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation,	O
and	O
can	O
associate	O
with	O
AP-1	B
.	O

Two	O
distinct	O
molecules,	O
NFATp	B
and	O
NFATc	B
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	B
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	B
and	O
NFATc-	O
specific	O
antibodies	O
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	B
ligand	O
binding	O
involves	O
primarily,	O
if	O
not	O
exclusively,	O
NFATp	B
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(approximately	O
120	O
kD)	O
as	O
that	O
of	O
T	B
lymphocytes	O
.	O

NK	B
cells	O
do	O
not	O
express	O
NFATc	B
constitutively,	O
but	O
NFATc	B
mRNA	O
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	B
ligands	O
.	O

However,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	O
recognizing	O
the	O
T	B
cell	O
NFATc	B
revealed	O
no	O
detectable	O
NFATc	B
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	B
or	O
phorbol	O
ester	O
-stimulated	O
cells	O
at	O
any	O
time	O
tested,	O
up	O
to	O
4	O
h.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA	B
-sensitive	O
transcription	B
factors	O
,	O
NFATp	B
and	O
NFATc	B
,	O
are	O
expressed	O
in	O
human	B
NK	B
cells	O
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	B
cells	O
by	O
a	O
single	O
stimulus,	O
that,	O
in	O
the	O
case	O
of	O
CD16	B
in	O
NK	B
cells	O
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	B
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	B
mRNA	O
.	O

Interleukin	B
2	O
signaling	O
involves	O
the	O
phosphorylation	O
of	O
Stat	B
proteins	O
.	O

One	O
of	O
the	O
most	O
important	O
cytokines	B
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	B
2	O
(IL-2),	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	B
lymphocytes	O
and	O
natural	B
killer	O
cells	O
.	O

The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood.	O

While	O
the	O
binding	O
of	O
IL-2	B
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	B
,	O
Jak-1	B
and	O
Jak-3	B
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized.	O

Since	O
many	O
cytokines	B
that	O
activate	O
Jak	B
kinases	O
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	B
family	O
of	O
transcription	B
factors	O
,	O
the	O
ability	O
of	O
IL-2	B
to	O
trigger	O
Stat	B
phosphorylation	O
was	O
examined.	O

Exposure	O
of	O
activated	B
human	O
T	O
lymphocytes	O
or	O
of	O
a	O
natural	B
killer	O
cell	O
line	O
(	O
NKL	B
)	O
to	O
IL-2	B
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B
alpha	O
,	O
Stat1	B
beta	O
,	O
and	O
Stat3	B
,	O
as	O
well	O
as	O
of	O
two	O
Stat-related	B
proteins	O
,	O
p94	B
and	O
p95	B
.	O

p94	B
and	O
p95	B
share	O
homology	O
with	O
Stat1	B
at	O
the	O
phosphorylation	B
site	O
and	O
in	O
the	O
Src	B
homology	O
2	O
(SH2)	O
domain	O
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B
.	O

These	O
Stat	B
proteins	O
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	O
DNA	B
sequence	O
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL-2	B
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	O
genes	O
involved	O
in	O
immune	O
cell	O
function	O
.	O

Expression	O
of	O
c-fos	B
correlates	O
with	O
IFN-alpha	B
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(i)	O
constitutive	O
levels	O
of	O
oncogene	B
and	O
p53	O
transcripts	O
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(ii)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN-alpha	B
2c	O
.	O

Peripheral	B
blood	O
mononuclear	O
cells	O
(	O
pbmc	B
)	O
and	O
bone	B
marrow	O
cells	O
of	O
26	O
patients	O
were	O
examined	O
for	O
c-fos	B
,	O
c-myc	B
,	O
p53	B
and	O
the	O
hybrid	O
bcr/abl	O
mRNA	O
levels	O
.	O

Results	O
indicated	O
that	O
(i)	O
constitutive	O
c-fos	B
transcript	O
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN-alpha	B
therapy	O
(p	O
&lt;	O
0.01)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	B
(r	O
=	O
0.6895,	O
p	O
&lt;	O
0.01)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	B
cells	O
(r	O
=	O
-0.568,	O
p	O
&lt;	O
0.01)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested,	O
(ii)	O
constitutive	O
mRNA	O
levels	O
of	O
the	O
hybrid	O
bcr/abl	B
,	O
c-myc	B
and	O
p53	B
are	O
positively	O
correlated	O
with	O
each	O
other,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters,	O
and	O
(iii)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN-alpha	B
is	O
accompanied	O
by	O
upregulation	O
of	O
c-fos	B
and	O
downregulation	O
of	O
c-myc	B
mRNA	O
levels	O
in	O
responder	O
patients	O
.	O

Menopause	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
blood	B
monocyte	O
number	O
and	O
a	O
relative	O
decrease	O
in	O
the	O
expression	O
of	O
estrogen	B
receptors	O
in	O
human	B
peripheral	O
monocytes	O
.	O

PROBLEM:	O
The	O
clinical	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
estrogen	B
receptor	O
(	O
ER	B
)	O
in	O
human	B
monocytes	O
was	O
evaluated.	O

METHOD:	O
Two	O
color	O
flow	O
cytometry	O
analysis	O
was	O
used	O
on	O
peripheral	O
blood	O
samples	O
of	O
young	O
and	O
postmenopausal	O
females	O
and	O
postmenopausal	O
females	O
treated	O
with	O
estrogen	O
replacement	O
therapy	O
.	O

In	O
addition,	O
the	O
monocyte	O
and	O
lymphocyte	O
counts	O
and	O
the	O
blood	O
estrogen	O
levels	O
of	O
each	O
patient	O
were	O
determine.	O

RESULTS:	O
During	O
menopause	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
the	O
percentage	O
of	O
ER	B
positive	O
monocytes	B
,	O
and	O
an	O
increase	O
in	O
blood	O
monocyte	O
number	O
,	O
which	O
declines	O
following	O
estrogen	O
replacement	O
therapy	O
to	O
values	O
of	O
the	O
young.	O

CONCLUSIONS:	O
These	O
findings	O
suggest	O
that	O
estrogen	O
modulates	O
the	O
monocyte	O
numbers	O
and	O
its	O
effects	O
may	O
be	O
mediated	O
through	O
the	O
ER	B
in	O
the	O
monocytes	B
.	O

Staphylococcal	O
enterotoxins	O
modulate	O
interleukin	B
2	O
receptor	O
expression	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B
protein-	O
tyrosine	O
kinase	O
3	O
(	O
Jak3	B
)	O
and	O
signal	B
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	B
proteins	O
).	O

Staphylococcal	O
enterotoxins	O
(	O
SE	O
)	O
stimulate	O
T	B
cells	O
expressing	O
the	O
appropriate	O
variable	B
region	O
beta	O
chain	O
of	O
(	B
V	O
beta	O
)	O
T-cell	O
receptors	O
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O

Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	O
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	B
cells	O
.	O

In	O
addition,	O
SE	O
can	O
induce	O
an	O
interleukin-2	B
(	O
IL-2	B
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O

Here,	O
we	O
show	O
that	O
SE	O
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	B
receptor	O
(IL-2R)	O
beta	O
and	O
gamma	B
chains	O
(	O
IL-2R	B
beta	O
and	O
IL-2R	B
gamma	O
)	O
in	O
human	B
antigen-specific	O
CD4+	O
T-cell	O
lines	O
.	O

Thus,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B
and	O
SEB	B
,	O
the	O
expression	O
of	O
IL-2R	B
beta	O
was	O
down-regulated,	O
IL-2R	B
gamma	O
was	O
slightly	O
up-regulated,	O
while	O
IL-2R	B
alpha	O
remained	O
largely	O
unaffected.	O

The	O
changes	O
in	O
the	O
composition	O
of	O
IL-2Rs	B
were	O
accompanied	O
by	O
inhibition	O
of	O
IL-2	B
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B
protein-	O
tyrosine	O
kinase	O
3	O
(	O
Jak3	B
)	O
and	O
signal	B
transducers	O
and	O
activators	O
of	O
transcription	O
called	O
Stat3	B
and	O
Stat5	B
.	O

In	O
parallel	O
experiments,	O
IL-2	B
-driven	O
proliferation	O
was	O
inhibited	O
significantly.	O

After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	O
,	O
the	O
expression	O
of	O
IL-2R	B
beta	O
remained	O
low,	O
while	O
that	O
of	O
IL2R	B
alpha	O
and	O
IL2R	B
gamma	O
was	O
further	O
up-regulated,	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B
and	O
Stat	O
proteins	O
was	O
partly	O
normalized.	O

Yet,	O
IL-2	B
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B
/Stat	B
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	O
stimulation	O
.	O

In	O
conclusion,	O
our	O
data	O
suggest	O
that	O
SE	O
can	O
modulate	O
IL-2R	B
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak/Stat	B
pathway	O
in	O
CD4+	B
T-cell	O
lines	O
.	O

Constitutive	O
NF-kappa	B
B	O
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	O
kappa	O
B	O
alpha	O
-deficient	O
mice	O
.	O

Transcription	B
factors	O
belonging	O
to	O
the	O
NF-kappa	B
B	O
family	O
are	O
controlled	O
by	O
inhibitory	B
I	B
kappa	O
B	O
proteins	O
,	O
mainly	O
I	B
kappa	O
B	O
alpha	O
and	O
I	B
kappa	O
B	O
beta	O
.	O

Apparently	O
normal	O
at	O
birth,	O
I	B
kappa	O
B	O
alpha	O
-/-	O
mice	O
exhibit	O
severe	O
runting,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally,	O
typically	O
dying	O
by	O
8	O
days.	O

Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	B
NF-kappa	B
B	O
and	O
mRNAs	B
of	O
some,	O
but	O
not	O
all,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF-kappa	B
B	O
.	O

NF-kappa	B
B	O
elevation	O
results	O
in	O
these	O
phenotypic	O
abnormalities	O
because	O
mice	O
lacking	O
both	O
I	B
kappa	O
B	O
alpha	O
and	O
the	O
p50	B
subunit	O
of	O
NF-kappa	B
B	O
show	O
a	O
dramatically	O
delayed	O
onset	O
of	O
abnormalities	O
.	O

In	O
contrast	O
to	O
hematopoietic	B
cells	O
,	O
I	B
kappa	O
B	O
alpha	O
-/-	O
embryonic	O
fibroblasts	B
show	O
minimal	O
constitutive	O
NF-kappa	B
B	O
,	O
as	O
well	O
as	O
normal	O
signal-dependent	O
NF-kappa	B
B	O
activation	O
that	O
is	O
concomitant	O
with	O
I	B
kappa	O
B	O
beta	O
degradation	O
.	O

Our	O
results	O
indicate	O
that	O
I	B
kappa	O
b	O
beta,	O
but	O
not	O
I	B
kappa	O
B	O
alpha	O
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	B
B	O
in	O
fibroblasts	B
.	O

However,	O
I	B
kappa	O
B	O
alpha	O
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF-kappa	B
B	O
in	O
fibroblasts	B
.	O

These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	B
kappa	O
B	O
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF-kappa	B
B	O
.	O

Interleukin-7	B
can	O
induce	O
the	O
activation	O
of	O
Jak	B
1	O
,	O
Jak	B
3	O
and	O
STAT	O
5	O
proteins	O
in	O
murine	B
T	O
cells	O
.	O

The	O
activation	O
of	O
Janus	B
protein	O
tyrosine	B
kinases	O
(	O
Jak	B
)	O
and	O
STAT	B
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
proteins	O
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	B
.	O

IL-7	B
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose-dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B
1	O
and	O
Jak	B
3	O
and	O
concomitantly,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	B
proteins	O
.	O

The	O
STAT	B
proteins	O
utilized	O
by	O
IL-7	B
were	O
identical	O
to	O
those	O
induced	O
by	O
IL-2	B
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	B
5	O
isoforms	O
.	O

Moreover,	O
the	O
induction	O
of	O
both	O
Jak	B
1	O
and	O
3	O
,	O
and	O
STAT	B
5	O
activity	O
strongly	O
correlated	O
with	O
the	O
growth-promoting	O
effects	O
of	O
IL-7	B
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL-7	B
-induced	O
proliferation	O
.	O

Cytokine	B
-modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O

Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase/5-lipoxygenase	B
anti-inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation.	O

It	O
has	O
been	O
shown	O
to	O
possess	O
anti-inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL-2	B
induced	O
signal	O
transduction	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	B
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects.	O

In	O
human	B
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	B
)	O
stimulated	O
with	O
OKT3/PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	O
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM.	O

Additionally,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	O
(IC50	O
=	O
0.5	O
microM)	O
and	O
the	O
cytokines	B
IL-2	B
,	O
IL-6	B
and	O
TNF	B
alpha	O
(IC50	O
=	O
10-12	O
microM).	O

Cytotoxicity	O
was	O
not	O
demonstrated	O
at	O
these	O
concentrations.	O

Add-back	O
experiments	O
with	O
either	O
cytokines	B
(	O
IL-2	B
or	O
IL-6	B
),	O
LTB4	O
or	O
conditioned	O
media	O
failed	O
to	O
restore	O
the	O
proliferative	O
response	O
in	O
the	O
presence	O
of	O
tepoxalin	O
.	O

However,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O

Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	B
kappa	O
B	O
,	O
a	O
transcription	B
factor	O
which	O
acts	O
on	O
several	O
cytokine	B
genes	O
.	O

Tepoxalin	O
's	O
effect	O
on	O
NF	B
kappa	O
B	O
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	B
may	O
be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	B
kappa	O
B	O
and	O
subsequent	O
inhibition	O
of	O
cytokine	B
production	O
.	O

N-	B
and	O
C-terminal	O
sequences	O
control	O
degradation	O
of	O
MAD3/	B
I	B
kappa	O
B	O
alpha	O
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B
B	O
activity	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
inhibitory	B
protein	O
MAD3/	B
I	B
kappa	O
B	O
alpha	O
in	O
response	O
to	O
extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	B
factor	O
NF-kappa	B
B	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
human	B
I	B
kappa	O
B	O
alpha	O
protein	O
in	O
stable	O
transfectants	O
of	O
mouse	B
70Z/3	O
cells	O
shows	O
that,	O
as	O
for	O
the	O
endogenous	B
murine	O
protein,	O
exogenous	O
I	B
kappa	O
B	O
alpha	O
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF-kappa	B
B	O
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O

In	O
addition,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	O
inhibitor	O
N-Ac-Leu-Leu-norleucinal	O
inhibits	O
this	O
ligand-induced	O
degradation	O
and,	O
in	O
agreement	O
with	O
previous	O
studies,	O
stabilizes	O
a	O
hyperphosphorylated	O
form	O
of	O
the	O
human	B
I	B
kappa	O
B	O
alpha	O
protein	O
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	B
protein	O
in	O
this	O
cell	O
line	O
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand-induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	B
kappa	O
B	O
alpha	O
.	O

Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	B
terminus	O
of	O
the	O
I	B
kappa	O
B	O
alpha	O
molecule	O
up	O
to	O
amino	B
acid	O
279	O
abolishes	O
constitutive	O
but	O
not	O
ligand-inducible	O
phosphorylation	O
and	O
inhibits	O
ligand-inducible	O
degradation	O
.	O

Further	O
analysis	O
reveals	O
that	O
the	O
inducible	O
phosphorylation	O
of	O
I	B
kappa	O
B	O
alpha	O
maps	O
to	O
two	O
serines	O
in	O
the	O
N	B
terminus	O
of	O
the	O
protein	O
(residues	O
32	O
and	O
36)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	O
ligand-induced	O
degradation,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O
to	O
abolish	O
inducible	O
phosphorylation	O
of	O
the	O
protein.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

Microtubules	B
mediate	O
cellular	O
25-hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1,25-dihydroxyvitamin	O
D3	O
in	O
normal	B
human	O
monocytes	O
.	O

The	O
genomic	O
actions	O
of	O
1,25-dihydroxyvitamin	O
D3	O
(1,25(OH)2D3)	O
are	O
mediated	O
by	O
the	O
intracellular	B
vitamin	O
D	O
receptor	O
(	O
VDR	B
).	O

Although	O
immunocytochemistry	O
has	O
shown	O
that	O
disruption	O
of	O
microtubular	O
assembly	O
prevents	O
nuclear	O
access	O
of	O
the	O
sterol-	B
VDR	B
complex	O
,	O
the	O
role	O
of	O
microtubules	B
in	O
the	O
response	O
to	O
1,25(OH)2D3	O
has	O
not	O
been	O
studied	O
in	O
viable	B
cells	O
.	O

Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	B
human	O
monocytes	O
.	O

Monocytes	O
convert	O
25(OH)D3	O
to	O
1,25(OH)2D3	O
and	O
to	O
24-hydroxylated	O
metabolites	O
more	O
polar	O
than	O
1,25(OH)2D3	O
.	O

Microtubule	O
disruption	O
totally	O
abolished	O
the	O
ability	O
of	O
exogenous	O
1,25(OH)2D3	O
to	O
suppress	O
its	O
own	O
synthesis	O
and	O
to	O
induce	O
24-hydroxylase	B
mRNA	O
and	O
activity,	O
without	O
affecting	O
either	O
total	O
1,25(OH)2D3	O
uptake	O
or	O
maximal	O
1,25(OH)2D3	O
-VDR	B
binding	O
.	O

Thus,	O
intact	O
microtubules	B
are	O
essential	O
for	O
1,25(OH)2D3	O
-dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O

Interestingly,	O
microtubule	B
disruption	O
also	O
decreased	O
monocyte	O
1,25(OH)2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	B
mitochondrial	O
1	O
alpha-hydroxylase	O
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25(OH)2D3	O
.	O

We	O
examined	O
25(OH)D3	O
transport	O
.	O

Microtubule	B
disruption	O
did	O
not	O
affect	O
total	O
cellular	O
25(OH)D3	O
uptake	O
but	O
reduced	O
its	O
intracellular	O
trafficking	O
to	O
the	O
mitochondria	O
.	O

Thus,	O
microtubules	B
participate	O
in	O
intracellular	O
25(OH)D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1,25(OH)2D3	O
synthesis	O
.	O

Relationship	O
between	O
Rap1	B
protein	O
phosphorylation	O
and	O
regulation	O
of	O
Ca2+	O
transport	O
in	O
platelets	B
:	O
a	O
new	O
approach.	O

Although	O
the	O
interrelationship	O
between	O
the	O
two	O
messengers	O
Ca2+	O
and	O
cyclic	O
AMP	O
in	O
platelet	B
function	O
is	O
well	O
documented,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established.	O

We	O
investigated	O
here	O
the	O
question	O
of	O
the	O
regulation	O
of	O
platelet	B
Ca(2+)-ATPases	O
by	O
cyclic	O
AMP	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	O
using	O
a	O
pathological	O
model	O
.	O

We	O
first	O
found	O
experimental	O
conditions	O
where	O
Ca(2+)-transport	O
by	O
platelet	B
membrane	O
vesicles	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	O
.	O

Then,	O
we	O
studied	O
platelets	B
of	O
patients	O
with	O
congestive	O
heart	O
failure	O
for	O
their	O
expression	O
of	O
the	O
potential	O
97	O
kDa	O
Ca(2+)-ATPase	B
target	O
of	O
regulation	O
through	O
the	O
Rap1	B
protein	O
as	O
well	O
as	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	O
using	O
the	O
catalytic	B
subunit	O
of	O
the	O
cyclic	B
AMP	O
-dependent	O
protein	O
kinase	O
(	O
C.	B
Sub.	O
).	O

In	O
the	O
first	O
patients	O
studied,	O
we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	B
kDa	O
Ca(2+)-ATPase	O
by	O
Western	O
blotting	O
using	O
the	O
PL/IM	B
430	O
monoclonal	O
antibody	O
which	O
specifically	O
recognized	O
this	O
isoform.	O

In	O
contrast,	O
the	O
Rap1	B
protein	O
was	O
differentially	O
phosphorylated	O
when	O
using	O
15	O
micrograms/ml	O
of	O
the	O
C.	O
Sub.	O

These	O
results	O
allowed	O
us	O
to	O
use	O
these	O
pathological	B
platelets	O
to	O
study	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
Rap1	B
protein	O
and	O
the	O
regulation	O
of	O
Ca2+	O
transport	O
by	O
selecting	O
a	O
patient	O
with	O
severe	O
heart	O
failure	O
.	O

We	O
could	O
show	O
a	O
decrease	O
in	O
the	O
expression	O
as	O
well	O
as	O
in	O
the	O
phosphorylation	O
of	O
Rap1	B
protein	O
and	O
demonstrate	O
a	O
lower	O
effect	O
of	O
C.	B
Sub.	O
on	O
Ca2+	O
transport	O
.	O

Finally,	O
by	O
studying	O
a	O
further	O
series	O
of	O
patients	O
,	O
we	O
could	O
confirm	O
that	O
the	O
decrease	O
in	O
Rap1	B
protein	O
expression	O
in	O
heart	O
failure,	O
whatever	O
its	O
extent,	O
was	O
variable,	O
and	O
could	O
strictly	O
correlate	O
the	O
expression	O
of	O
Rap1	B
protein	O
with	O
the	O
stimulatory	O
effect	O
of	O
C.	B
Sub.	O
on	O
Ca2+	O
transport	O
.	O

Besides	O
the	O
evidence	O
for	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
Rap1	B
protein	O
in	O
platelets	B
from	O
patients	O
with	O
heart	O
failure	O
,	O
these	O
findings	O
constitute	O
a	O
new	O
approach	O
in	O
favour	O
of	O
the	O
regulation	O
of	O
platelet	O
Ca2+	O
transport	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	B
protein	O
.	O

An	O
IRF-1	B
-dependent	O
pathway	O
of	O
DNA	O
damage-induced	O
apoptosis	O
in	O
mitogen-activated	B
T	O
lymphocytes	O
.	O

Lymphocytes	B
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage-induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'	O
altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O

The	O
tumour	B
suppressor	O
p53	O
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	B
,	O
but	O
an	O
as	O
yet	O
unknown,	O
p53	B
-independent	O
pathway	O
(s)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen-activated	B
mature	B
T	O
lymphocytes	O
.	O

Here	O
we	O
show	O
DNA	O
damage-induced	O
apoptosis	O
in	O
these	O
T	B
lymphocytes	O
is	O
dependent	O
on	O
the	O
antioncogenic	B
transcription	O
factor	O
interferon	O
regulatory	O
factor	O
(IRF)-1	O
.	O

Thus	O
two	O
different	O
anti-onco-genic	B
transcription	B
factors	O
,	O
p53	B
and	O
IRF-1	B
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	B
lymphocytes	O
.	O

We	O
also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin-1	B
beta	O
converting	O
enzyme	O
(	O
ICE	B
)	O
gene	O
,	O
a	O
mammalian	B
homologue	O
of	O
the	O
Caenorhabditis	B
elegans	O
cell	O
death	O
gene	O
ced-3	O
,	O
is	O
IRF-1	B
-dependent	O
.	O

Ectopic	O
overexpression	O
of	O
IRF-1	B
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	B
gene	O
for	O
ICE	B
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation-induced	O
apoptosis	O
.	O

Circadian	O
rhythm	O
of	O
glucocorticoid	B
receptors	O
in	O
human	B
peripheral	O
leukocytes	O
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O

1)	O
There	O
exists	O
a	O
CR	B
of	O
GR	B
in	O
human	B
leukocytes	O
,	O
PMN	B
,	O
and	O
monocytes	B
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr.	O

The	O
difference	O
between	O
them	O
was	O
significant	O
statistically.	O

2)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	B
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	B
.	O

This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	B
may	O
be	O
of	O
functional	O
significance.	O

3)	O
In	O
Cushing's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	B
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed.	O

This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	B
from	O
that	O
of	O
cortisol	O
.	O

4)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	B
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
main	O
"	O
circadian	O
pacemaker	O
"	O
of	O
GR	B
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	B
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O

B-lymphoblastoid	B
cell	O
lines	O
from	O
multiple	O
sclerosis	O
patients	O
and	O
a	O
healthy	O
control	O
producing	O
a	O
putative	O
new	O
human	O
retrovirus	O
and	O
Epstein-Barr	O
virus	O
.	O

On	O
several	O
occasions	O
we	O
have	O
observed	O
retrovirus-like	B
particles	O
(	O
RVLPs	B
)	O
by	O
transmission	O
electron	O
microscopy	O
(	O
EM	O
)	O
of	O
cultured	B
T	O
cells	O
from	O
a	O
patient	O
with	O
MS	O
.	O

Later	O
we	O
established	O
spontaneously	O
formed	O
B-lymphoblastoid	B
cell	O
lines	O
(	O
LCLs	B
)	O
from	O
a	O
patient	O
with	O
an	O
MS	O
-like	O
disease	O
and	O
from	O
another	O
patient	O
with	O
MS	O
who	O
had	O
a	O
reactivated	O
Epstein-Barr	O
virus	O
(EBV)	O
infection	O
.	O

Both	O
LCLs	B
were	O
found	O
by	O
EM	O
to	O
produce	O
RVLP	B
and	O
EBV	B
particles	O
.	O

Reverse	B
transcriptase	O
(RT)	O
assays	O
were	O
positive	O
in	O
purified	O
viral	O
material	O
from	O
both	O
LCLs	B
.	O

To	O
substantiate	O
these	O
findings	O
we	O
initiated	O
an	O
intensified	O
culturing	O
procedure	O
and	O
were	O
able	O
to	O
establish	O
LCLs	B
from	O
5	O
out	O
of	O
21	O
consecutive	O
MS	O
patients	O
and	O
1	O
out	O
of	O
13	O
consecutive	O
healthy	O
controls	O
.	O

All	O
LCLs	B
were	O
found	O
to	O
produce	O
both	O
RVLP	B
and	O
EBV	B
particles	O
by	O
EM	O
.	O

Whether	O
the	O
putative	O
new	O
retrovirus	O
(es)	O
and	O
EBV	O
have	O
any	O
causal	O
relationship	O
to	O
MS	O
is	O
still	O
not	O
known,	O
but	O
the	O
findings	O
support	O
this	O
possibility.	O

Identification	O
of	O
an	O
ionomycin	B
/cyclosporin	O
A	O
-responsive	O
element	O
within	O
the	O
human	B
T	O
cell	O
receptor	O
gamma	O
enhancer	O
.	O

Activation	O
through	O
the	O
Ca2+	O
/	B
calcineurin	B
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	B
genes	O
.	O

The	O
conserved	O
cis-acting	B
sequence	O
,	O
GGAAAA	O
,	O
and	O
transcription	B
factors	O
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2+	O
concentrations	O
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non-cytokine	B
gene	O
,	O
the	O
human	B
T	O
cell	O
receptor	O
gamma	O
(	O
TCRG	B
)	O
enhancer	O
.	O

Results	O
from	O
site-directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin	O
-induced	O
activation	O
of	O
the	O
TCRG	B
enhancer	O
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	B
mRNA	O
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	B
cell	O
receptor	O
alpha	O
and	O
-beta	O
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

Coexpression	O
of	O
NF-kappa	B
B	O
/Rel	O
and	O
Sp1	B
transcription	B
factors	O
in	O
human	B
immunodeficiency	O
virus	O
1	O
-induced,	O
dendritic	O
cell-T-cell	O
syncytia	O
.	O

Productive	O
infection	O
of	O
T	B
cells	O
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
typically	O
requires	O
that	O
the	O
T	B
cells	O
be	O
stimulated	O
with	O
antigens	B
or	O
mitogens	O
.	O

This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B
factor	O
NF-kappa	B
B	O
,	O
which	O
synergizes	O
with	O
the	O
constitutive	O
transcription	B
factor	O
Sp1	B
to	O
drive	O
the	O
HIV-1	B
promoter	O
.	O

Recently,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV-1	O
takes	O
place	O
in	O
nonactivated	B
memory	O
T	O
cells	O
after	O
syncytium	O
formation	O
with	O
dendritic	B
cells	O
(	O
DCs	B
).	O

These	O
syncytia	O
lack	O
activated	B
cells	O
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki-67	B
cell	O
cycle	O
antigen.	O

The	O
expression	O
and	O
activity	O
of	O
NF-kappa	B
B	O
and	O
Sp1	B
were,	O
therefore,	O
analyzed	O
in	O
isolated	B
T	B
cells	O
and	O
DCs	B
from	O
humans	O
and	O
mice	O
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

T	B
cells	O
lack	O
active	O
NF-kappa	B
B	O
but	O
express	O
Sp1	B
as	O
expected.	O

DCs	B
express	O
high	O
levels	O
of	O
all	O
known	O
NF-kappa	B
B	O
and	O
Rel	B
proteins	O
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	B
,	O
p50	B
,	O
and	O
p65	B
.	O

However,	O
DCs	B
lack	O
Sp1	B
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV-1	O
to	O
replicate	O
in	O
purified	B
DCs	O
.	O

Coexpression	O
of	O
NF-kappa	B
B	O
and	O
Sp1	B
occurs	O
in	O
the	O
heterologous	O
DC-T-cell	B
syncytia	O
that	O
are	O
induced	O
by	O
HIV-1	O
.	O

Therefore,	O
HIV-1	O
-induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Since	O
DCs	B
and	O
memory	B
T	O
cells	O
frequently	O
traffic	O
together	O
in	O
situ,	O
these	O
unusual	O
heterologous	O
syncytia	O
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV-1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O

Cupric	O
ion	O
blocks	O
NF	B
kappa	O
B	O
activation	O
through	O
inhibiting	O
the	O
signal-induced	O
phosphorylation	O
of	O
I	B
kappa	O
B	O
alpha	O
.	O

A	O
transcription	B
factor	O
NF	B
kappa	O
B	O
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	B
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	B
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	O
protein	O
I	B
kappa	O
B	O
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B
kappa	O
B	O
alpha	O
to	O
release	O
NF	B
kappa	O
B	O
.	O

Cu2+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	B
kappa	O
B	O
induced	O
by	O
TNF-alpha	B
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF-alpha	B
in	O
the	O
presence	O
of	O
Cu2+	O
resulted	O
in	O
the	O
release	O
of	O
NF	B
kappa	O
B	O
from	O
I	B
kappa	O
B	O
alpha	O
,	O
indicating	O
that	O
Cu2+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	B
kappa	O
B	O
-I	B
kappa	O
B	O
complex	O
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B
kappa	O
B	O
alpha	O
was	O
observed	O
upon	O
TNF-alpha	B
stimulation	O
in	O
the	O
presence	O
of	O
Cu2+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2+	O
inhibits	O
the	O
release	O
of	O
NF	B
kappa	O
B	O
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B
kappa	O
B	O
alpha	O
.	O

Cloning	O
a	O
cDNA	B
from	O
human	B
NK/	O
T	O
cells	O
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O

A	O
cDNA	B
clone	O
,	O
B4-2	B
,	O
was	O
isolated	O
from	O
a	O
natural	B
killer	O
(NK)	O
minus	O
T	O
cell	O
subtractive	O
library	O
.	O

The	O
B4-2	B
clone	O
coded	O
for	O
an	O
mRNA	B
of	O
2061	O
bp	O
in	O
length.	O

It	O
encodes	O
a	O
deduced	O
327	B
aa	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
35.2	O
kDa.	O

Searching	O
of	O
B4-2	B
DNA	O
and	O
protein	B
sequences	O
against	O
various	O
databases	O
revealed	O
no	O
high	O
homology	O
to	O
other	O
sequences.	O

However,	O
B4-2	B
has	O
an	O
unusually	O
high	O
proline	O
content	O
(13%),	O
contains	O
a	O
putative	O
nuclear	B
targeting	O
sequence	O
,	O
and	O
has	O
several	O
SPXX	B
motifs	O
which	O
are	O
frequently	O
found	O
in	O
gene	B
regulatory	O
proteins	O
.	O

One	O
of	O
the	O
stretches	O
of	O
prolines	O
in	O
B4-2	B
closely	O
resembles	O
the	O
ligand	O
for	O
proteins	O
with	O
SH3	B
domains	O
.	O

Northern	O
hybridization	O
data	O
showed	O
that	O
B4-2	B
is	O
not	O
a	O
lymphoid	B
specific	O
gene	O
and	O
is	O
expressed	O
in	O
a	O
hepatoma	B
cell	O
line	O
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O
in	O
a	O
variety	O
of	O
other	O
cells.	O

A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B
B4-2	B
recognizes	O
a	O
32-34	B
kDa	O
protein	O
in	O
lymphocytes	B
.	O

Activation	O
of	O
JAK3	B
,	O
but	O
not	O
JAK1	B
,	O
is	O
critical	O
for	O
IL-2	B
-induced	O
proliferation	O
and	O
STAT5	B
recruitment	O
by	O
a	O
COOH-terminal	B
region	O
of	O
the	O
IL-2	B
receptor	O
beta-chain	O
.	O

A	O
number	O
of	O
cytokines	B
and	O
growth	B
factors	O
use	O
the	O
JAK	B
-STAT	B
pathway	O
to	O
signal	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
.	O

While	O
homodimerizing	B
cytokine	O
receptors	O
may	O
transmit	O
signal	O
via	O
a	O
single	O
form	O
of	O
JAK	B
(i.e.	O
growth	B
hormone	O
receptors	O
),	O
several	O
multicomponent	O
cytokine	B
receptors	O
have	O
been	O
shown	O
to	O
require	O
simultaneous	O
activation	O
of	O
pairs	O
of	O
different	O
JAK	B
kinases	O
(i.e.	O
interferon	B
receptors	O
).	O

Recent	O
evidence	O
for	O
a	O
preferential	O
coupling	O
of	O
JAK3	B
to	O
interleukin-2	B
receptor-gamma	O
(	O
IL-2R	B
gamma	O
)	O
and	O
JAK1	B
to	O
IL-2R	B
beta	O
supports	O
the	O
concept	O
of	O
heterotrans-activation	O
of	O
JAK1	B
and	O
JAK3	B
caused	O
by	O
IL-2	B
-induced	O
heterodimerization	O
of	O
their	O
receptor	O
partners	O
.	O

The	O
present	O
study	O
verified	O
the	O
ability	O
of	O
IL-2	B
to	O
cause	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
JAK1	B
and	O
JAK3	B
,	O
but	O
demonstrated	O
that	O
IL-2	B
stimulated	O
JAK3	B
to	O
a	O
significantly	O
larger	O
extent	O
than	O
JAK1	B
in	O
human	B
T	O
lymphocytes	O
and	O
the	O
YT	B
cell	O
line	O
.	O

This	O
conclusion	O
was	O
based	O
upon	O
several	O
independent	O
criteria,	O
including	O
more	O
vigorous	O
tyrosine	O
phosphorylation	O
of	O
JAK3	B
,	O
more	O
marked	O
enzymatic	O
activation	O
of	O
JAK3	B
as	O
well	O
as	O
higher	O
abundance	O
of	O
JAK3	B
in	O
activated	O
IL-2	B
receptor	O
complexes	O
.	O

Furthermore,	O
when	O
human	B
IL-2R	O
beta	O
was	O
stably	O
expressed	O
in	O
murine	B
BA/F3	O
cells	O
,	O
robust	O
IL-2	B
-induced	O
proliferation	O
and	O
JAK3	B
activation	O
occurred	O
without	O
detectable	O
involvement	O
of	O
either	O
JAK1	B
,	O
JAK2	B
or	O
TYK2	B
.	O

We	O
therefore	O
propose	O
that	O
IL-2	B
receptor	O
signal	O
transduction	O
does	O
not	O
depend	O
on	O
equimolar	O
heterodimerization	O
of	O
JAK1	B
and	O
JAK3	B
following	O
IL-2	B
-induced	O
heterodimerization	O
of	O
IL-2R	B
beta	O
and	O
IL-2R	B
gamma	O
.	O

Nonetheless,	O
a	O
membrane-proximal	B
region	O
of	O
human	B
IL-2R	O
beta	O
(	O
Asn240-Leu335	B
)	O
was	O
critical	O
for	O
JAK3	B
activation,	O
and	O
the	O
amount	O
of	O
JAK3	B
present	O
in	O
activated	O
IL-2	B
receptor	O
complexes	O
increased	O
with	O
time,	O
suggesting	O
that	O
stabilization	O
of	O
JAK3	B
binding	O
to	O
the	O
receptor	O
complex	O
relies	O
on	O
both	O
IL-2R	B
beta	O
and	O
IL-2R	B
gamma	O
.	O

Moreover,	O
STAT5	B
was	O
found	O
to	O
be	O
the	O
predominant	O
STAT	B
transcription	O
factor	O
used	O
by	O
IL-2	B
in	O
human	B
T	O
cells	O
,	O
and	O
specifically	O
required	O
a	O
COOH-terminal	B
region	O
of	O
IL-2R	B
beta	O
(	O
Ser386-Val525	B
),	O
while	O
STAT5	B
recruitment	O
was	O
not	O
correlated	O
to	O
activation	O
of	O
IL-2R	B
gamma	O
or	O
JAK3	B
.	O

Up-regulation	O
of	O
high-affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	B
human	O
T	O
lymphocytes	O
.	O

Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
unknown.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole-cell	O
binding	O
assay	O
in	O
a	O
human	B
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	B
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high-affinity	B
binding	O
sites	O
for	O
DHEA	O
(dissociation	O
constant	O
=	O
7.4	O
+/-	O
0.53	O
nmol/L,	O
mean	O
+/-	O
SE,	O
n	O
=	O
4)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2+	O
ionophore	O
A23187.	O

Bound	O
[3H]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	O
receptor	O
,	O
but	O
also	O
suggest	O
that	O
T	B
cells	O
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal-induced	O
activation	O
.	O

Ubiquitin-mediated	O
processing	O
of	O
NF-kappa	B
B	O
transcriptional	O
activator	O
precursor	O
p105	B
.	O

Reconstitution	O
of	O
a	O
cell-free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin-carrier	B
protein	O
,	O
E2	B
,	O
and	O
a	O
novel	O
ubiquitin-protein	B
ligase	O
,	O
E3	B
,	O
involved	O
in	O
conjugation.	O

In	O
most	O
cases,	O
the	O
transcriptional	B
factor	O
NF-kappa	B
B	O
is	O
a	O
heterodimer	B
consisting	O
of	O
two	O
subunits,	O
p50	B
and	O
p65	B
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	B
family	O
.	O

p50	B
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	B
kDa	O
.	O

The	O
C-terminal	B
domain	O
of	O
the	O
precursor	O
is	O
rapidly	O
degraded,	O
forming	O
the	O
mature	B
p50	B
subunit	O
consisted	O
of	O
the	O
N-terminal	B
region	O
of	O
the	O
molecule.	O

The	O
mechanism	O
of	O
generation	O
of	O
p50	B
is	O
not	O
known.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B
-proteasome	O
system	O
is	O
involved	O
in	O
the	O
process;	O
however,	O
the	O
specific	O
enzymes	O
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared,	O
have	O
been	O
obscure.	O

Palombella	O
and	O
colleagues	O
(Palombella,	O
V.J.,	O
Rando,	O
O.J.,	O
Goldberg,	O
A.L.,	O
and	O
Maniatis,	O
T.(1994)	O
Cell	O
78,	O
773-785)	O
have	O
shown	O
that	O
ubiquitin	B
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell-free	O
system	O
of	O
a	O
truncated,	B
artificially	O
constructed,	O
60-kDa	O
precursor	O
.	O

They	O
have	O
also	O
shown	O
that	O
proteasome	O
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo.	O

In	O
this	O
study,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell-free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that:	O
(a)	O
the	O
ubiquitin	B
-proteasome	O
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	B
precursor,	O
(b)	O
conjugation	O
of	O
ubiquitin	B
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing,	O
(c)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin	B
-carrier	O
protein	O
,	O
E2-F1	B
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	B
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	B
precursor	O
,	O
and	O
(d)	O
a	O
novel,	O
approximately	O
320-kDa	O
species	O
of	O
ubiquitin	B
-protein	O
ligase	O
,	O
is	O
involved	O
in	O
the	O
process.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6-AP	B
,	O
the	O
p53	B
-conjugating	O
ligase	O
,	O
and	O
from	O
E3	B
alpha	O
,	O
the	O
"N-end	B
rule"	O
ligase	O
.	O

Flutamide	O
in	O
the	O
treatment	O
of	O
hirsutism	O
:	O
long-term	O
clinical	O
effects	O
,	O
endocrine	O
changes	O
,	O
and	O
androgen	B
receptor	O
behavior	O
.	O

OBJECTIVE:	O
To	O
investigate	O
the	O
long-term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B
receptor	O
status,	O
in	O
hirsute	O
women	O
.	O

DESIGN:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months.	O

Barrier	O
or	O
intrauterine	O
contraception	O
was	O
used	O
during	O
the	O
study	O
in	O
sexually	O
active	O
women	O
.	O

Safety	O
parameters	O
were	O
assessed	O
throughout	O
the	O
study.	O

Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman-Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment.	O

Gonadotropin-releasing	O
hormone	O
and	O
ACTH	O
stimulation	O
tests	O
were	O
performed	O
before	O
and	O
after	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O

In	O
addition,	O
the	O
concentration	O
of	O
androgen	B
receptors	O
in	O
mononuclear	B
leukocytes	O
was	O
measured,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment.	O

RESULTS:	O
Flutamide	O
was	O
well	O
tolerated	O
in	O
all	O
women	O
,	O
with	O
the	O
noticeable	O
exception	O
of	O
one	O
patient	O
who	O
presented	O
increased	O
serum	B
transaminase	O
after	O
8	O
months	O
of	O
therapy	O
.	O

Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman-Gallwey	O
score	O
after	O
1	O
year:	O
4.1	O
+/-	O
0.5	O
versus	O
14.1	O
+/-	O
0.9).	O

A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH-stimulated	B
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha-hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O

Cycles	O
remained	O
ovulatory.	O

Before	O
treatment,	O
the	O
number	O
of	O
androgen	B
receptors	O
was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O

This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O

CONCLUSIONS:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O

Androgen	B
receptor	O
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O

Flutamide	O
affects	O
androgen	B
receptor	O
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O

The	O
meaning	O
of	O
this	O
finding	O
remains	O
to	O
be	O
elucidated	O
.	O

Constitutive	O
expression	O
of	O
HIV-1	B
tat	O
protein	O
in	O
human	B
Jurkat	O
T	O
cells	O
using	O
a	O
BK	O
virus	O
vector	O
.	O

The	O
production	O
and	O
characterization	O
of	O
Jurkat	B
cell	O
lines	O
that	O
constitutively	O
express	O
functional	O
human	B
immune	O
deficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
tat	O
protein	O
,	O
using	O
a	O
BK	B
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV-1	B
tat	O
cDNA	O
,	O
is	O
described.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat-tat	B
cell	O
lines	O
as	O
compared	O
with	O
control	B
cell	O
lines	O
was	O
observed.	O

A	O
PEBP2	B
alpha/AML-1-related	O
factor	O
increases	O
osteocalcin	B
promoter	O
activity	O
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B
cis-acting	O
element	O
.	O

To	O
identify	O
osteoblast-specific	B
cis-acting	O
elements	O
and	O
trans-acting	B
factors	O
,	O
we	O
initiated	O
an	O
analysis	O
of	O
the	O
promoter	B
of	O
a	O
mouse	B
osteocalcin	O
gene	O
,	O
an	O
osteoblast-specific	B
gene	O
.	O

In	O
this	O
promoter,	B
we	O
identified	O
two	O
osteoblast-specific	B
cis-acting	O
elements	O
(Ducy,	O
P.and	O
Karsenty,	O
G.(1995)	O
Mol.Cell.Biol.15,	O
1858-1869).	O

The	O
sequence	O
of	O
one	O
of	O
these	O
elements	O
,	O
OSE2	B
,	O
is	O
identical	O
to	O
the	O
DNA-binding	B
site	O
of	O
the	O
PEBP2	B
alpha/AML-1	O
transcription	B
factors	O
,	O
the	O
mammalian	O
homologues	O
of	O
the	O
Drosophila	B
Runt	O
protein	O
.	O

Here	O
we	O
show,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B
protein	O
,	O
and	O
a	O
specific	O
antiserum	O
against	O
AML-1	B
proteins	O
in	O
DNA-binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family,	O
AML-1B	B
,	O
binds	O
specifically	O
to	O
OSE2	B
and	O
is	O
immunologically	O
related	O
to	O
OSF2	B
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O
that	O
binds	O
to	O
OSE2	B
.	O

By	O
DNA	O
cotransfection	O
experiments	O
,	O
we	O
also	O
demonstrate	O
that	O
AML-1B	B
can	O
increase	O
the	O
activity	O
of	O
a	O
short	O
osteocalcin	B
promoter	O
through	O
its	O
binding	O
to	O
OSE2	B
.	O

Lastly,	O
the	O
different	O
mobilities	O
of	O
osteoblast	B
nuclear	O
extract-DNA	O
complexes	O
compared	O
with	O
T-cell	B
nuclear	O
extract-DNA	O
complexes	O
,	O
along	O
with	O
the	O
inability	O
of	O
OSF2	B
to	O
be	O
upregulated	O
by	O
retinoic	O
acid	O
,	O
unlike	O
the	O
other	O
PEBP2	B
alpha	O
factors	O
,	O
suggest	O
that	O
OSF2	B
is	O
a	O
new	O
member	O
of	O
this	O
family	O
of	O
transcription	B
factors	O
.	O

Thus,	O
this	O
study	O
demonstrates	O
that	O
AML-1B	B
can	O
increase	O
gene	O
expression	O
of	O
an	O
osteoblast-specific	B
gene	O
through	O
its	O
binding	O
to	O
an	O
osteoblast-specific	B
cis-acting	O
element	O
and	O
presents	O
evidence	O
that	O
OSF2	B
is	O
a	O
member	O
of	O
the	O
PEBP2	B
alpha/AML-1	O
family	O
of	O
transcription	B
factors	O
.	O

Initiation	B
binding	O
repressor	O
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	B
initiation	O
site	O
of	O
the	O
histone	B
h5	O
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	B
growth	O
regulators	O
[corrected]	O
[published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb;16(2):735]	O

Initiation	B
binding	O
repressor	O
[corrected]	O
(	O
IBR	B
)	O
is	O
a	O
chicken	B
erythrocyte	O
factor	O
(apparent	O
molecular	O
mass,	O
70	O
to	O
73	O
kDa)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	B
initiation	O
site	O
of	O
the	O
histone	B
h5	O
gene	O
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells,	O
including	O
transformed	B
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	B
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	B
(68	O
to	O
70	O
kDa)	O
that	O
recognizes	O
the	O
same	O
IBR	B
sites.	O

We	O
have	O
cloned	O
the	O
IBR	B
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	B
and	O
IBF	B
.	O

IBR	B
is	O
a	O
503-amino-acid-long	B
acidic	O
protein	O
which	O
is	O
99.0%	O
identical	O
to	O
the	O
recently	O
reported	O
human	B
NRF-1/alpha-Pal	O
factor	O
and	O
highly	O
related	O
to	O
the	O
invertebrate	B
transcription	B
factors	O
P3A2	B
and	O
erected	O
wing	B
gene	O
product	O
(	O
EWG	B
).	O

We	O
present	O
evidence	O
that	O
IBR	B
and	O
IBF	B
are	O
most	O
likely	O
identical	O
proteins,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	B
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	B
homodimers	O
and	O
that	O
the	O
dimer	B
is	O
the	O
relevant	O
DNA-binding	B
species	O
.	O

The	O
evolutionarily	B
conserved	O
N-terminal	B
half	O
of	O
IBR/F	B
harbors	O
the	O
DNA-binding/dimerization	B
domain	O
(outer	O
limits,	O
127	B
to	O
283),	O
one	O
or	O
several	O
casein	B
kinase	O
II	O
sites	O
(37	O
to	O
67),	O
and	O
a	O
bipartite	B
nuclear	O
localization	O
signal	O
(89	O
to	O
106)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	B
consensus	O
constitutes	O
high-affinity	B
IBR/F	B
binding	B
sites	O
and	O
that	O
the	O
direct-repeat	B
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth-related	O
metabolism	O
.	O

Triggering	O
of	O
the	O
human	B
interleukin-6	O
gene	O
by	O
interferon-gamma	B
and	O
tumor	B
necrosis	O
factor-alpha	O
in	O
monocytic	B
cells	O
involves	O
cooperation	O
between	O
interferon	B
regulatory	O
factor-1	O
,	O
NF	B
kappa	O
B	O
,	O
and	O
Sp1	B
transcription	B
factors	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon-gamma	B
(	O
IFN-gamma	B
)/	O
tumor	B
necrosis	O
factor-alpha	O
(	O
TNF-alpha	B
)	O
of	O
human	B
interleukin-6	O
(IL-6)	O
gene	O
in	O
THP-1	B
monocytic	O
cells	O
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
).	O

Functional	O
studies	O
with	O
IL-6	B
promoter	O
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN-gamma	B
and/or	O
TNF-alpha	B
action,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O

The	O
three	O
regions	O
concerned	O
are:	O
1)	O
a	O
region	O
between	O
-73	B
and	O
-36,	O
which	O
is	O
the	O
minimal	O
element	O
inducible	O
by	O
LPS	O
or	O
TNF-alpha	B
;	O
2)	O
an	O
element	O
located	O
between	O
-181	B
and	O
-73,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN-gamma	B
and	O
TNF-alpha	B
negatively;	O
and	O
3)	O
a	O
distal	B
element	O
upstream	O
of	O
-224,	B
which	O
was	O
inducible	O
by	O
IFN-gamma	B
alone.	O

LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	B
kappa	O
B	O
activation	O
by	O
the	O
p50/p65	B
heterodimers	O
.	O

Synergistic	O
induction	O
of	O
the	O
IL-6	B
gene	O
by	O
IFN-gamma	B
and	O
TNF-alpha	B
,	O
in	O
monocytic	B
cells	O
,	O
involved	O
cooperation	O
between	O
the	O
IRF-1	B
and	O
NF	B
kappa	O
B	O
p65	B
homodimers	O
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	B
control	O
element	O
present	O
in	O
the	O
IL-6	B
promoter	O
.	O

This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	B
Sp1	O
factor	O
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN-gamma	B
.	O

Mutation	O
of	O
Jak3	B
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	B
in	O
lymphoid	O
development	O
.	O

Males	O
with	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	B
cytokine	O
receptor	O
gamma	O
chain	O
(	O
gamma	B
c	O
)	O
gene	O
that	O
encodes	O
a	O
shared,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin-2	B
(	O
IL-2	B
),	O
IL-4	B
,	O
IL-7	B
,	O
IL-9	B
,	O
and	O
IL-15	B
.	O

The	O
Janus	B
family	O
tyrosine	O
kinase	O
Jak3	B
is	O
the	O
only	O
signaling	B
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B
c	O
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	B
might	O
cause	O
an	O
XSCID	O
-like	O
phenotype	O
.	O

A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O
analysis.	O

An	O
Epstein-Barr	B
virus	O
(	O
EBV	O
)-transformed	O
cell	O
line	O
derived	O
from	O
her	O
lymphocytes	B
had	O
normal	O
gamma	B
c	O
expression	O
but	O
lacked	O
Jak3	B
protein	O
and	O
had	O
greatly	O
diminished	O
Jak3	B
messenger	O
RNA	O
.	O

Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B
JH4	O
domain	O
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	B
JH2	O
domain	O
.	O

The	O
lack	O
of	O
Jak3	B
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL-4	B
to	O
activate	O
Stat6	B
in	O
the	O
EBV	B
-transformed	O
cell	O
line	O
from	O
the	O
patient.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B
c	O
are	O
dependent	O
on	O
Jak3	B
and	O
that	O
Jak3	B
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling.	O

Constitutive	O
overexpression	O
of	O
the	O
L-selectin	B
gene	O
in	O
fresh	O
leukemic	B
cells	O
of	O
adult	O
T-cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	B
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax	O
.	O

L-selectin	B
is	O
an	O
adhesion	B
molecule	O
of	O
the	O
selectin	B
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O

Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L-selectin	B
gene	O
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
leukemic	O
cell	O
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L-selectin	B
mRNA	O
in	O
fresh	O
leukemic	B
cells	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L-selectin	B
promoter	O
to	O
human	B
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	O
,	O
which	O
is	O
a	O
viral	B
transcriptional	O
transactivator	O
.	O

Flow	O
cytometry	O
showed	O
that	O
L-selectin	B
was	O
expressed	O
on	O
fresh	O
ATL	B
cells	O
along	O
with	O
other	O
activation	B
antigens	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	B
cells	O
overexpressed	O
that	O
L-selectin	B
mRNA	O
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O

Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L-selectin	B
mRNA	O
in	O
the	O
infiltrating	B
leukemic	O
cells	O
in	O
the	O
liver	O
of	O
two	O
ATL	O
patients	O
.	O

Intravenous	O
injection	O
of	O
a	O
rat	B
T-cell	O
line	O
that	O
overexpresses	O
L-selectin	B
showed	O
increased	O
organ	O
infiltration	O
.	O

The	O
induction	O
of	O
Tax	B
expression	O
in	O
JPX9	B
cells	O
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	O
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O

Chloramphenicol	B
acetyltransferase	O
(	O
CAT	B
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L-selectin	B
promoter	O
by	O
Tax	B
.	O

The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L-selectin	B
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(mean	O
+/-	O
SD,	O
4,215.4	O
+/-	O
4,111	O
ng/mL)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(mean	O
+/-	O
SD,	O
1,148.0	O
+/-	O
269.0	O
ng/mL	O
and	O
991.9	O
+/-	O
224	O
ng/mL,	O
respectively).	O

These	O
results	O
indicated	O
that	O
ATL	B
cells	O
constitutively	O
overexpress	O
the	O
L-selectin	B
gene	O
that	O
can	O
be	O
transactivated	O
by	O
HTLV-1	B
Tax	O
.	O

The	O
overexpression	O
of	O
L-selectin	B
,	O
as	O
well	O
as	O
of	O
inflammatory	B
cytokines	O
,	O
by	O
ATL	B
cells	O
may	O
provide	O
a	O
basis	O
for	O
ATL	B
cells	O
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O

Human	O
herpesvirus	O
6	O
variant	O
A	O
,	O
but	O
not	O
variant	O
B	O
,	O
infects	O
EBV	B
-positive	O
B	O
lymphoid	O
cells	O
,	O
activating	O
the	O
latent	B
EBV	O
genome	O
through	O
a	O
BZLF-1	B
-dependent	O
mechanism	O
.	O

Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV	B
-positive	O
B	O
cell	O
lines	O
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O

Here	O
we	O
have	O
confirmed	O
and	O
extended	O
such	O
observations,	O
showing	O
that	O
(1)	O
this	O
phenomenon	O
is	O
restricted	O
to	O
the	O
variant	O
A	O
of	O
HHV-6	O
:	O
in	O
fact	O
two	O
isolates	O
belonging	O
to	O
the	O
HHV-6	O
variant	O
B	O
(	O
BA92	O
and	O
Z29	O
)	O
were	O
neither	O
able	O
to	O
infect	O
any	O
B	B
cell	O
line	O
,	O
independently	O
of	O
the	O
EBV	O
status	O
,	O
nor	O
to	O
induce	O
the	O
EBV	B
genome	O
expression	O
.	O

The	O
only	O
exception	O
is	O
represented	O
by	O
the	O
P3HR1	B
cells	O
,	O
in	O
which,	O
however,	O
the	O
infection	O
by	O
the	O
variant	O
B	O
does	O
not	O
determine	O
induction	O
of	O
EBV	B
antigens	O
;	O
(2)	O
the	O
presence	O
of	O
the	O
EBV	B
genome	O
contributes	O
to	O
the	O
susceptibility	O
of	O
the	O
B	B
cell	O
lines	O
to	O
HHV-6	O
infection	O
,	O
increasing	O
the	O
binding	B
sites	O
and	O
the	O
percentage	O
of	O
infectable	O
cells	O
,	O
as	O
detected	O
by	O
immunoelectron	O
microscopy	O
;	O
and	O
(3)	O
HHV-6	B
infected	O
T	B
cells	O
,	O
transfected	O
with	O
plasmids	O
bearing	O
the	O
promoter	B
regions	O
of	O
the	O
EBV	B
early	O
genes	O
BZLF1	B
and	O
BMRF1	B
,	O
show	O
a	O
strong	O
transactivation	O
of	O
these	B
promoters	B
.	O

Evidence	O
for	O
normal	O
vitamin	B
D	O
receptor	O
messenger	O
ribonucleic	O
acid	O
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O

Absorptive	O
hypercalciuria	O
(a	O
stone-forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O

Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	B
D	O
receptor	O
(	O
VDR	B
)	O
gene	O
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O

We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	B
fragment	O
length	O
polymorphism	O
(	O
Bsm	B
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	B
gene	O
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race-	O
and	O
age-matched	O
control	O
subjects	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	B
alleles	O
in	O
the	O
patient	O
population	O
when	O
compared	O
with	O
the	O
normal	O
population	O
.	O

The	O
coding	B
region	O
of	O
VDR	B
messenger	O
RNA	O
was	O
also	O
normal,	O
as	O
determined	O
by	O
both	O
DNA	B
sequence	O
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	B
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O
.	O

On	O
the	O
basis	O
of	O
these	O
results,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	B
and	O
are	O
not	O
linked	O
to	O
a	O
common	O
VDR	B
genotype	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
human	B
C-type	O
lectin	O
leukocyte	O
receptor	O
AIM/CD69	B
and	O
functional	O
characterization	O
of	O
its	O
tumor	B
necrosis	O
factor-alpha	O
-responsive	O
elements	O
.	O

The	O
human	B
activation	O
antigen	O
CD69	B
is	O
a	O
member	O
of	O
the	O
C-type	B
animal	O
lectin	O
superfamily	O
that	O
functions	O
as	O
a	O
signal-transmitting	B
receptor	O
.	O

Although	O
the	O
expression	O
of	O
CD69	B
can	O
be	O
induced	O
in	O
vitro	O
on	O
cells	O
of	O
most	O
hematopoietic	B
lineages	O
with	O
a	O
wide	O
variety	O
of	O
stimuli,	O
in	O
vivo	O
it	O
is	O
mainly	O
expressed	O
by	O
T-	B
lymphocytes	O
located	O
in	O
the	O
inflammatory	O
infiltrates	O
of	O
several	O
human	O
diseases	O
.	O

To	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
CD69	B
by	O
leukocytes	B
,	O
we	O
isolated	O
the	O
promoter	B
region	O
of	O
the	O
CD69	B
gene	O
and	O
carried	O
out	O
its	O
functional	O
characterization	O
.	O

Sequence	O
analysis	O
of	O
the	O
5'-flanking	B
region	O
of	O
the	O
CD69	B
gene	O
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	B
element	O
30	O
base	O
pairs	O
upstream	O
of	O
the	O
major	B
transcription	O
initiation	O
site	O
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	B
factors	O
(	O
NF-kappa	B
B	O
,	O
Egr-1	B
,	O
AP-1	B
),	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene.	O

Transient	O
expression	O
of	O
CD69	B
promoter-based	O
reporter	O
gene	O
constructs	O
in	O
K562	B
cells	O
indicated	O
that	O
the	O
proximal	B
promoter	O
region	O
spanning	O
positions	B
-78	B
to	O
+16	O
contained	O
the	O
cis-acting	B
sequences	O
necessary	O
for	O
basal	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
-inducible	O
transcription	O
of	O
the	O
CD69	B
gene	O
.	O

Removal	O
of	O
the	O
upstream	O
sequences	O
located	O
between	O
positions	O
-78	B
and	O
-38	O
resulted	O
in	O
decreased	O
promoter	O
strength	O
and	O
abolished	O
the	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate.	O

We	O
also	O
found	O
that	O
tumor	B
necrosis	O
factor-alpha	O
(	O
TNF-alpha	B
)	O
is	O
capable	O
of	O
inducing	O
the	O
surface	O
expression	O
of	O
the	O
CD69	B
molecule	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
of	O
fusion	B
plasmids	O
that	O
contain	O
5'-flanking	B
sequences	O
of	O
the	O
CD69	B
gene,	O
suggesting	O
that	O
this	O
cytokine	B
may	O
regulate	O
in	O
vivo	O
the	O
expression	O
of	O
CD69	B
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS)	O

Characterization	O
of	O
5'	B
end	O
of	O
human	B
thromboxane	O
receptor	O
gene	O
.	O

Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	B
kinase	O
C--responsive	O
elements	O
regulating	O
expression	O
in	O
platelets	B
.	O

Platelet	B
thromboxane	O
receptors	O
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O

To	O
determine	O
if	O
platelet	B
thromboxane	O
receptors	O
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	B
genomic	O
DNA	O
clones	O
containing	O
the	O
5'	B
flanking	O
region	O
of	O
the	O
thromboxane	B
receptor	O
gene	O
.	O

The	O
exon-intron	B
structure	O
of	O
the	O
5'	B
portion	O
of	O
the	O
thromboxane	B
receptor	O
gene	O
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	O
sequence	O
of	O
the	O
5'	B
flanking	O
genomic	O
clone	O
with	O
that	O
of	O
a	O
novel	O
human	B
uterine	O
thromboxane	O
receptor	O
cDNA	O
that	O
extended	O
the	O
mRNA	B
141	O
bp	O
further	O
upstream	O
than	O
the	O
previously	O
identified	O
human	B
placental	O
cDNA	O
.	O

A	O
major	B
transcription	B
initiation	O
site	O
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	B
bp	O
upstream	O
from	O
the	O
translation	B
initiation	O
codon	O
and	O
380	B
bp	O
upstream	O
from	O
any	O
previously	O
identified	O
transcription	B
initiation	O
site	O
.	O

The	O
thromboxane	B
receptor	O
gene	O
has	O
neither	O
a	O
TATA	B
nor	O
a	O
CAAT	B
consensus	O
site	O
.	O

Promoter	O
function	O
of	O
the	O
5'	B
flanking	O
region	O
of	O
the	O
thromboxane	B
receptor	O
gene	O
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	B
receptor	O
gene	O
promoter/	O
chloramphenicol	B
acetyltransferase	O
(	O
CAT	B
)	O
chimera	O
plasmids	O
into	O
platelet-like	B
K562	O
cells	O
.	O

Thromboxane	B
receptor	O
promoter	O
activity	O
,	O
as	O
assessed	O
by	O
CAT	B
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Functional	O
analysis	O
of	O
5'	B
deletion	O
constructs	O
in	O
transfected	B
K562	O
cells	O
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	B
ester	O
-responsive	O
motifs	O
in	O
the	O
thromboxane	B
receptor	O
gene	O
promoter	O
to	O
a	O
cluster	O
of	O
activator	B
protein-2	O
(	O
AP-2	B
)	O
binding	O
consensus	O
sites	O
located	O
approximately	O
1.8	B
kb	O
5'	O
from	O
the	O
transcription	B
initiation	O
site	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5'	B
end	O
of	O
the	O
thromboxane	B
receptor	O
gene	O
and	O
demonstrate	O
that	O
thromboxane	B
receptor	O
gene	O
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	B
kinase	O
C	O
via	O
induction	O
of	O
an	O
AP-2	B
-like	O
nuclear	O
factor	O
binding	O
to	O
upstream	B
promoter	O
elements	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	B
thromboxane	B
receptors	O
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	B
receptor	O
gene	O
transcription	O
in	O
platelet-progenitor	B
cells	O
.	O

Estrogen	B
receptor	O
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
early-stage	O
breast	O
cancer	O
patients	O
.	O

Confirmation	O
of	O
a	O
model.	O

Previous	O
work	O
of	O
ours	O
has	O
demonstrated	O
that	O
a	O
significant	O
amount	O
of	O
natural	O
killer	O
(NK)	O
activity	O
variance	O
after	O
surgery	O
in	O
stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
both	O
the	O
estrogen	B
receptor	O
(	O
ER	B
)	O
status	O
of	O
the	O
tumor	O
and	O
by	O
social	O
factors	O
,	O
namely,	O
perceived	O
social	O
support	O
and	O
seeking	O
social	O
support	O
as	O
a	O
general	O
coping	O
strategy	O
.	O

As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value,	O
we	O
sought	O
to	O
test	O
the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow-up	O
NK	O
activity	O
in	O
this	O
serially	O
assessed	O
group	O
of	O
patients	O
.	O

It	O
was	O
found	O
that	O
the	O
most	O
significant	O
variable	O
predicting	O
NK	O
activity	O
at	O
follow-up	O
was	O
tumor	O
ER	B
concentration	O
,	O
with	O
higher	O
NK	O
activity	O
associated	O
with	O
ER	B
-status	O
.	O

In	O
addition,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(multivariate	O
F	O
=	O
5.25,	O
p	O
less	O
than	O
0.001).	O

If,	O
as	O
the	O
literature	O
suggests,	O
NK	O
activity	O
is	O
relevant	O
to	O
breast	O
cancer	O
control	O
,	O
and	O
since	O
ER	O
-tumors	O
have	O
a	O
worse	O
prognosis,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	O
are	O
resistant	O
to	O
control	O
by	O
NK	B
cells	O
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	B
cells	O
to	O
the	O
tumor	O
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	O
prevent	O
local	O
tumor	O
control	O
at	O
the	O
site	O
of	O
action.	O

The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O

This	O
finding,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	O
cancer	O
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	B
support	O
variable	O
.	O

Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O

Solution	O
structure	O
of	O
the	O
sequence-specific	B
HMG	O
box	O
of	O
the	O
lymphocyte	B
transcriptional	O
activator	O
Sox-4	B
.	O

Two	O
groups	O
of	O
HMG	B
box	O
proteins	O
are	O
distinguished.	O

Proteins	O
in	O
the	O
first	O
group	O
contain	O
multiple	O
HMG	B
boxes	O
,	O
are	O
non-sequence-specific	O
,	O
and	O
recognize	O
structural	O
features	O
as	O
found	O
in	O
cruciform	B
DNA	O
and	O
cross-over	B
DNA	O
.	O

The	O
abundant	O
chromosomal	B
protein	O
HMG-1	B
belongs	O
to	O
this	O
subgroup.	O

Proteins	O
in	O
the	O
second	O
group	O
carry	O
a	O
single	O
HMG	B
box	O
with	O
affinity	O
for	O
the	O
minor	B
groove	O
of	O
the	O
heptamer	B
motif	O
AACAAAG	O
or	O
variations	O
thereof.	O

A	O
solution	O
structure	O
for	O
the	O
non-sequence-specific	B
C-terminal	O
HMG	O
box	O
of	O
HMG-1	B
has	O
recently	O
been	O
proposed.	O

Now,	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
sequence-specific	B
HMG-box	O
of	O
the	O
SRY-related	B
protein	O
Sox-4	B
.	O

NMR	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
three	O
alpha-helices	B
(	O
Val10-Gln22	B
,	O
Glu30-Leu41	B
and	O
Phe50-Tyr65	B
)	O
connected	O
by	O
loop	B
regions	O
(	O
Ser23-Ala49	B
and	O
Leu42-Pro49	B
).	O

Helices	B
I	O
and	O
II	O
are	O
positioned	O
in	O
an	O
antiparallel	O
mode	O
and	O
form	O
one	O
arm	O
of	O
the	O
HMG	B
box	O
.	O

Helix	B
III	O
is	O
less	O
rigid,	O
makes	O
an	O
average	O
angle	O
of	O
about	O
90	O
degrees	O
with	O
helices	B
I	O
and	O
II	O
,	O
and	O
constitutes	O
the	O
other	O
arm	O
of	O
the	O
molecule.	O

As	O
in	O
HMG1B	B
,	O
the	O
overall	O
structure	O
of	O
the	O
Sox-4	B
HMG	O
box	O
is	O
L-shaped	O
and	O
is	O
maintained	O
by	O
a	O
cluster	O
of	O
conserved,	O
mainly	O
aromatic	O
residues	O
.	O

Nuclear	B
factor-IL6	O
activates	O
the	O
human	B
IL-4	O
promoter	O
in	O
T	B
cells	O
.	O

Positive	B
regulatory	O
element	O
I	O
(	O
PRE-I	B
)	O
is	O
a	O
strong	B
enhancer	O
element	O
essential	O
for	O
expression	O
of	O
the	O
human	B
IL-4	O
gene	O
.	O

To	O
identify	O
transcription	B
factors	O
binding	O
to	O
PRE-I	B
,	O
we	O
screened	O
a	O
cDNA	B
expression	O
library	O
from	O
Jurkat	B
T	O
cells	O
and	O
isolated	O
a	O
cDNA	B
encoding	O
nuclear	O
factor	O
(NF)-IL6	O
(also	O
known	O
as	O
C/EBP	B
beta	O
).	O

NF-IL6	B
mRNA	O
was	O
found	O
in	O
human	B
Jurkat	O
T	O
cells	O
and	O
in	O
the	O
mouse	B
Th2	O
clone	O
D10	O
,	O
but	O
not	O
in	O
Th1	B
clone	O
29	O
.	O

rNF-IL6	B
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE-I	B
.	O

PRE-I	B
forms	O
multiple	O
DNA-protein	B
complexes	O
with	O
nuclear	O
extracts	O
from	O
Jurkat	B
cells	O
.	O

Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	B
by	O
using	O
anti-	B
C/EBP	B
beta	O
Abs	O
.	O

Overexpression	O
of	O
NF-IL6	B
enhanced	O
expression	O
of	O
the	O
chloramphenicol	B
acetyl	O
transferase	O
reporter	O
gene	O
linked	O
to	O
the	O
PRE-I	B
-thymidine	O
kinase	O
or	O
the	O
human	B
IL-4	B
promoter	O
more	O
than	O
10-fold	O
in	O
Jurkat	B
cells	O
.	O

Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	B
binding	B
sites	O
located	O
at	O
positions	O
-44	B
to	O
-36	O
(	O
C/EBP	B
proximal	O
)	O
and	O
-87	B
to	O
-79	O
(	O
C/EBP	B
medial	O
),	O
respectively.	O

Our	O
results	O
demonstrate	O
that	O
NF-IL6	B
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	B
IL-4	B
promoter	O
in	O
T	B
cells	O
.	O

Identification	O
of	O
an	O
I	B
kappa	O
B	O
alpha-associated	O
protein	O
kinase	O
in	O
a	O
human	B
monocytic	O
cell	O
line	O
and	O
determination	O
of	O
its	O
phosphorylation	B
sites	O
on	O
I	B
kappa	O
B	O
alpha	O
.	O

Nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	B
kappa	O
B	O
.	O

Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B
kappa	O
B	O
alpha	O
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)-dependent	O
cell-free	O
activation	O
system	O
of	O
NF-kappa	B
B	O
in	O
association	O
with	O
the	O
induction	O
of	O
I	B
kappa	O
B	O
alpha	O
phosphorylation	O
.	O

In	O
this	O
study,	O
we	O
have	O
identified	O
a	O
kinase	O
in	O
cell	O
extracts	O
from	O
the	O
LPS	B
-stimulated	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	B
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B
kappa	O
B	O
alpha	O
.	O

LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	B
kappa	O
B	O
alpha	O
-bound	O
kinase	O
activity	O
in	O
THP-1	B
cells	O
.	O

Mutational	O
analyses	O
of	O
I	B
kappa	O
B	O
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	B
sites	O
by	O
the	O
bound	O
kinase	O
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C-terminal	B
acidic	O
domain	O
of	O
I	B
kappa	O
B	O
alpha	O
.	O

Moreover,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C-terminal	B
acidic	O
domain	O
of	O
I	B
kappa	O
B	O
alpha	O
,	O
blocked	O
the	O
LPS	O
-induced	O
NF-kappa	B
B	O
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	B
I	B
kappa	O
B	O
alpha	O
in	O
a	O
cell-free	O
system	O
using	O
THP-1	B
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	O
kinase	O
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C-terminal	B
region	O
of	O
I	B
kappa	O
B	O
alpha	O
and	O
subsequent	O
dissociation	O
of	O
the	O
NF-kappa	B
B	O
.	B
I	B
kappa	O
B	O
alpha	O
complex	O
.	O

Bik	B
,	O
a	O
novel	O
death-inducing	B
protein	O
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl-2	B
family	O
proteins	O
and	O
interacts	O
with	O
viral	B
and	O
cellular	O
survival-promoting	O
proteins	O
.	O

The	O
survival-promoting	O
activity	O
of	O
the	O
Bcl-2	B
family	O
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	B
proteins	O
.	O

We	O
have	O
identified	O
a	O
novel	B
cellular	O
protein	O
,	O
Bik	B
,	O
that	O
interacts	O
with	O
the	O
cellular	B
survival-promoting	O
proteins	O
,	O
Bcl-2	B
and	O
Bcl-xL	B
,	O
as	O
well	O
as	O
the	O
viral	B
survival-promoting	O
proteins	O
,	O
Epstein	B
Barr	O
virus	O
-BHRF1	O
and	O
adenovirus	B
E1B-19	O
kDa	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
Bik	B
promotes	O
cell	O
death	O
in	O
a	O
manner	O
similar	O
to	O
the	O
death-promoting	B
members	O
of	O
the	O
Bcl-2	B
family	O
,	O
Bax	B
and	O
Bak	B
.	O

This	O
death-promoting	O
activity	O
of	O
Bik	B
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl-2	B
,	O
Bcl-XL	B
,	O
EBV-BHRF1	B
and	O
E1B-19	B
kDa	O
proteins	O
suggesting	O
that	O
Bik	B
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	B
and	O
viral	O
anti-apoptotic	O
proteins	O
.	O

While	O
Bik	B
does	O
not	O
show	O
overt	O
homology	O
to	O
the	O
BH1	B
and	O
BH2	B
conserved	O
domains	O
characteristic	O
of	O
the	O
Bcl-2	B
family	O
,	O
it	O
does	O
share	O
a	O
9	B
amino	O
acid	O
domain	O
(	O
BH3	B
)	O
with	O
Bax	B
and	O
Bak	B
which	O
may	O
be	O
a	O
critical	O
determinant	O
for	O
the	O
death-promoting	O
activity	O
of	O
these	O
proteins.	O

The	O
human	B
TCF-1	O
gene	O
encodes	O
a	O
nuclear	B
DNA-binding	O
protein	O
uniquely	O
expressed	O
in	O
normal	B
and	O
neoplastic	O
T-lineage	B
lymphocytes	O
.	O

The	O
TCF-1	B
gene	O
encodes	O
a	O
putative	O
transcription	B
factor	O
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T-cell	B
enhancers	O
.	O

TCF-1	B
mRNA	O
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell-specific	O
fashion	O
within	O
a	O
set	O
of	O
human	B
and	O
mouse	O
cell	O
lines	O
.	O

In	O
contrast,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O

We	O
have	O
now	O
raised	O
a	O
monoclonal	B
antibody	O
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	B
TCF-1	B
protein	O
.	O

As	O
expected,	O
the	O
TCF-1	B
protein	O
was	O
detectable	O
only	O
in	O
cell	B
lines	O
of	O
T	B
lineage	O
.	O

Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O

Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF-1	B
protein	O
was	O
found	O
exclusively	O
in	O
thymocytes	B
and	O
in	O
CD3+	B
T	O
cells	O
in	O
peripheral	O
lymphoid	O
tissues	O
.	O

Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	B
kD	O
to	O
55	B
kD,	O
resulting	O
from	O
extensive	O
alternative	O
splicing	O
.	O

The	O
TCF-1	B
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T-cell	B
malignancies	O
of	O
various	O
stages	O
of	O
maturation,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	O
neoplasms	O
.	O

These	O
observations	O
imply	O
a	O
T	O
cell-specific	O
function	O
for	O
TCF-1	B
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf-1	B
knock-out	O
mice	O
.	O

In	O
addition,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF-1	B
expression	O
can	O
serve	O
as	O
a	O
pan-T-lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O

Cross-linking	O
of	O
Fc	B
gamma	O
receptors	O
activates	O
HIV-1	B
long	O
terminal	O
repeat	O
-driven	O
transcription	O
in	O
human	B
monocytes	O
.	O

Elevation	O
of	O
the	O
levels	O
of	O
circulating	B
immune	O
complexes	O
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O

Here	O
we	O
report	O
that	O
cross-linking	O
of	O
Fc	B
gamma	O
RI	O
or	O
Fc	B
gamma	O
RII	O
by	O
adherent	B
human	O
IgG	O
or	O
by	O
specific	O
anti-Fc	B
gamma	O
R	O
mAb	O
activates	O
HIV-1	O
gene	O
expression	O
in	O
the	O
human	B
monocytic	O
cell	O
line	O
BF24	O
and	O
increased	O
HIV	B
RNA	O
expression	O
in	O
monocytes	B
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription-PCR	O
.	O

In	O
THP-1	B
cells	O
,	O
Fc	B
gamma	O
R	O
cross-linking	O
induced	O
NF-kappa	B
B	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	B
region	O
of	O
the	O
long	B
terminal	O
repeat	O
(	O
LTR	B
)	O
of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O
Anti-TNF-alpha	B
antibody	O
but	O
not	O
anti-IL-1	B
beta	O
antibody	O
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1	B
-	O
LTR	B
-driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF-kappa	B
B	O
by	O
Fc	B
gamma	O
R	O
cross-linking	O
.	O

These	O
results	O
indicate	O
that	O
Fc	B
gamma	O
R	O
can	O
mediate	O
a	O
TNF-alpha	B
-dependent	O
induction	O
of	O
HIV-1	B
gene	O
transcription	O
and	O
suggest	O
that	O
immune	B
complexes	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	B
.	O

Signalling	O
via	O
CD28	B
of	O
human	B
naive	O
neonatal	O
T	O
lymphocytes	O
.	O

Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge.	O

We	O
have	O
examined	O
the	O
role	O
of	O
CD28	B
in	O
modulating	O
the	O
'	O
naive'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti-CD2	B
-mediated	O
activation	O
.	O

To	O
compare	O
the	O
role	O
of	O
CD28	B
,	O
neonatal	B
and	O
adult	O
T	O
cells	O
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	O
anti-CD2	B
antibodies	O
in	O
the	O
presence	O
or	O
absence	O
of	O
anti-	B
CD28	B
MoAb	O
.	O

With	O
anti-CD2	B
alone,	O
neonatal	B
T	O
cells	O
proliferated	O
slightly	O
but	O
produced	O
no	O
detectable	O
IL-2	B
,	O
whereas	O
adult	B
T	O
cells	O
proliferated	O
vigorously,	O
with	O
significant	O
IL-2	B
production	O
.	O

Costimulation	O
with	O
anti-	B
CD28	B
MoAb	O
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	B
T	O
cells	O
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	B
T	O
cells	O
,	O
whereas	O
adult	B
T	O
cells	O
showed	O
only	O
slight	O
increases.	O

Although	O
IL-2	B
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O
anti-	B
CD28	B
MoAb	O
,	O
neonatal	O
T	O
cell	O
IL-2	B
production	O
remained	O
lower	O
than	O
in	O
adults	O
.	O

In	O
contrast,	O
enhancement	O
of	O
IL-2	B
mRNA	O
expression	O
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O
.	O

Anti-	B
CD28	B
MoAb	O
costimulation	O
increased	O
NF	B
kappa	O
B	O
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O

The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	B
T	O
lymphocytes	O
to	O
anti-CD2	B
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	B
kappa	O
B	O
induction	O
,	O
reduced	O
IL-2	B
mRNA	O
expression	O
and	O
deficient	O
IL-2	B
production	O
.	O

Although	O
anti-	B
CD28	B
MoAb	O
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals,	O
NF	B
kappa	O
B	O
and	O
IL-2	B
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O

TCL1	B
oncogene	O
activation	O
in	O
preleukemic	B
T	O
cells	O
from	O
a	O
case	O
of	O
ataxia-telangiectasia	O
.	O

The	O
TCL1	B
oncogene	O
on	O
human	B
chromosome	O
14q32.1	O
is	O
involved	O
in	O
chromosome	B
translocations	O
[	O
t(14;14)(q11;q32.1)	B
and	O
t(7;14)(q35;q32.1)	B
]	O
and	O
inversions	O
[	O
inv14(q11;q32.1)	B
]	O
with	O
TCR	B
alpha/beta	O
loci	O
in	O
T-cell	B
leukemias	O
,	O
such	O
as	O
T-prolymphocytic	O
(	O
T-PLL	O
).	O

It	O
is	O
also	O
involved	O
in	O
T-	O
acute	O
and-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia-telangiectasia	O
(	O
AT	O
),	O
an	O
immunodeficiency	O
syndrome	O
.	O

Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	B
expanded	O
T	B
cells	O
in	O
AT	O
patients	O
before	O
the	O
appearance	O
of	O
the	O
overt	O
leukemia	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	B
mRNA	O
and	O
protein	O
in	O
peripheral	B
blood	O
lymphocytes	O
(	O
PBLs	B
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O

We	O
found	O
that	O
the	O
TCL1	B
gene	O
was	O
overexpressed	O
in	O
the	O
PBLs	B
of	O
an	O
AT	O
patient	O
with	O
a	O
large	O
clonal	O
T-cell	B
population	O
exhibiting	O
the	O
t(14;14)	B
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	B
of	O
the	O
other	O
cases.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	B
genomic	O
locus	O
to	O
lymphocyte	B
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t(14;14)	B
translocation	O
lies	O
within	O
the	O
TCL1	B
locus	O
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	O
part	O
of	O
chromosome	B
14	O
.	O

These	O
data	O
indicate	O
that	O
TCL1	B
is	O
activated	O
in	O
preleukemic	B
clonal	O
cells	O
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	B
locus	O
at	O
14q11	B
.	O

Deregulation	O
of	O
TCL1	B
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O

C/EBP	B
proteins	O
activate	O
transcription	O
from	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
macrophages/	B
monocytes	B
.	O

Three	O
binding	O
sites	O
for	O
C/EBP	B
proteins	O
are	O
found	O
in	O
the	O
human	B
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	B
)	O
(V.M.	O
Tesmer,	O
A.Rajadhyaksha,	O
J.Babin,	O
and	O
M.Bina,	O
Proc.Natl.Acad.Sci.	O
USA	O
90:7298-7302,	O
1993).	O

We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C/EBP	B
proteins	O
and	O
C/EBP	B
sites	O
in	O
regulating	O
transcription	O
from	O
the	O
HIV-	B
1	O
LTR	O
in	O
monocytes	B
/macrophages	O
.	O

Inhibition	O
of	O
endogenous	O
C/EBP	B
proteins	O
,	O
using	O
either	O
an	O
excess	O
of	O
C/EBP	B
binding	O
sites	O
or	O
a	O
trans-	O
dominant	O
negative	O
inhibitor	O
,	O
demonstrated	O
that	O
C/EBP	B
proteins	O
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV-1	B
LTR	O
transcription	O
in	O
the	O
promonocytic	B
cell	O
line	O
U937	O
.	O

Northern	O
(RNA)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF-IL6	B
is	O
the	O
only	O
known	O
C/EBP	B
family	O
member	O
which	O
is	O
increased	O
when	O
U937	B
cells	O
are	O
activated.	O

Mutational	O
analyses	O
of	O
the	O
HIV-1	B
LTR	O
showed	O
that	O
one	O
C/EBP	B
site	O
is	O
required	O
for	O
normal	O
LTR	B
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3'	B
C/EBP	B
sites	O
are	O
functionally	O
equivalent.	O

However,	O
transcription	O
from	O
crippled	O
HIV-1	B
LTRs	O
lacking	O
C/EBP	B
sites	O
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	B
cells	O
.	O

Several	O
models	O
are	O
suggested	O
for	O
how	O
elevated	O
NF-IL6	B
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	B
expression	O
,	O
and	O
HIV	O
replication	O
.	O

Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	B
and	O
their	O
activation	O
by	O
T-cell	B
activators	O
.	O

The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	O
elements	O
in	O
their	O
long	B
terminal	O
repeats	O
(	O
LTRs	B
),	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	B
elements	O
in	O
the	O
HIV-2	B
LTR	O
.	O

The	O
HIV-2	B
LTR	O
was	O
found	O
to	O
contain	O
two	O
enhancers	B
.	O

One	O
of	O
these	O
enhancers	O
is,	O
in	O
part,	O
identical	O
to	O
the	O
HIV-1	B
enhancer	O
.	O

This	O
enhancer	O
in	O
HIV-1	O
is	O
the	O
T-cell	B
activation	O
response	O
element	O
;	O
in	O
HIV-2	O
,	O
however,	O
it	O
is	O
the	O
second	O
enhancer	O
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T-cell	B
activators	O
.	O

The	O
second	O
enhancer	O
interacts	O
with	O
two	O
nuclear	B
binding	O
proteins	O
(85	O
kD	O
and	O
27	O
kD	O
mobility)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation.	O

Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O

NF-M	B
(	O
chicken	B
C/EBP	O
beta	O
)	O
induces	O
eosinophilic	O
differentiation	O
and	O
apoptosis	O
in	O
a	O
hematopoietic	B
progenitor	O
cell	O
line	O
.	O

CAAT/enhancer	B
binding	O
proteins	O
(	O
C/EBPs	B
)	O
are	O
transcriptional	B
activators	O
implicated	O
in	O
the	O
differentiation	O
processes	O
of	O
various	B
cell	B
lineages.	O

We	O
have	O
shown	O
earlier	O
that	O
NF-M	B
,	O
the	O
chicken	O
homolog	O
of	O
C/EBP	B
beta	O
,	O
is	O
specifically	O
expressed	O
in	O
myelomonocytic	B
and	O
eosinophilic	O
cells	O
of	O
the	O
hematopoietic	O
system.	O

To	O
investigate	O
the	O
role	O
of	O
NF-M	B
in	O
hematopoietic	O
cell	O
lineage	O
commitment,	O
we	O
constructed	O
a	O
conditional	O
form	O
of	O
the	O
protein	O
by	O
fusing	O
it	O
to	O
the	O
hormone	B
binding	O
domain	O
of	O
the	O
human	B
estrogen	O
receptor	O
.	O

This	O
construct	O
was	O
stably	O
expressed	O
in	O
a	O
multipotent	B
progenitor	O
cell	O
line	O
transformed	O
by	O
the	O
Myb-Ets	B
oncoprotein	O
.	O

We	O
report	O
here	O
that	O
both	O
NF-M	B
-dependent	O
promoter	O
constructs	O
and	O
resident	B
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta-estradiol	O
to	O
the	O
NF-M	B
-estrogen	O
receptor	O
expressing	O
progenitors	O
.	O

At	O
the	O
same	O
time,	O
we	O
observed	O
a	O
down-regulation	O
of	O
progenitor-specific	B
surface	O
markers	O
and	O
the	O
up-regulation	O
of	O
differentiation	B
markers	O
restricted	O
to	O
the	O
eosinophil	B
and	O
myeloid	B
lineages	O
.	O

In	O
addition	O
to	O
the	O
onset	O
of	O
differentiation	O
,	O
cell	O
death	O
was	O
induced	O
with	O
typical	O
apoptotic	O
features.	O

Our	O
results	O
suggest	O
that	O
NF-M	B
plays	O
an	O
important	O
role	O
in	O
commitment	O
along	O
the	O
eosinophil	B
lineage	O
and	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O

Prolactin	B
and	O
interleukin-2	O
receptors	O
in	O
T	B
lymphocytes	O
signal	O
through	O
a	O
MGF-STAT5-like	B
transcription	O
factor	O
.	O

The	O
cell	B
surface	O
receptors	O
for	O
PRL	B
and	O
interleukin-2	B
(	O
IL-2	B
)	O
are	O
structurally	O
distinct,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	B
lymphocytes	O
.	O

They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over-lapping	O
sets	O
of	O
genes	B
of	O
T	B
cells	O
.	O

PRL	B
and	O
IL-2	B
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak/Stat	B
(	O
signal	B
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
pathway	O
.	O

We	O
investigated	O
the	O
ability	O
of	O
PRL	B
and	O
IL-2	B
to	O
activate	O
Stat	B
proteins	O
in	O
different	O
T	B
cell	O
lines	O
.	O

The	O
DNA	O
binding	O
specificities,	O
the	O
reactivities	O
toward	O
Stat-specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL-2	B
-and	O
PRL	O
-induced	O
DNA-binding	O
proteins	O
in	O
Nb2	B
and	O
C196	O
T	O
cell	O
lines	O
were	O
investigated.	O

A	O
comparison	O
with	O
the	O
Stat	B
proteins	O
induced	O
by	O
interferon-gamma	B
,	O
PRL	B
,	O
and	O
IL-6	B
in	O
T47D	B
mammary	O
tumor	O
cells	O
was	O
made.	O

We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL-	B
and	O
IL-2-	O
induced	O
factors	O
.	O

A	O
transcription	B
factor	O
closely	O
related	O
to	O
mammary	B
gland	O
factor-Stat5	O
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL-2	B
and	O
PRL	B
with	O
their	O
respective	O
receptors.	O

Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	B
was	O
also	O
observed.	O

Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	B
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	B
factors	O
mammary	B
gland	O
factor-Stat5	O
and	O
Stat1	B
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O

ETS1	B
transactivates	O
the	O
human	B
GM-CSF	O
promoter	O
in	O
Jurkat	B
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	B
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte-macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
is	O
one	O
such	O
cytokine	B
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis-acting	B
elements	O
with	O
NF	B
kappa	O
B	O
,	O
AP-1	O
and	O
ETS-like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	B
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation.	O

A	O
number	O
of	O
the	O
ETS	B
family	O
of	O
transcription	B
factors	O
are	O
expressed	O
in	O
T	B
cells	O
,	O
including	O
ETS1	B
and	O
ELF1	B
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	B
),	O
located	O
within	O
the	O
CLE0	B
element	O
,	O
-47	B
to	O
-40	O
upstream	O
of	O
the	O
GM-CSF	B
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	B
,	O
but	O
not	O
ELF1	B
,	O
can	O
transactivate	O
GM-CSF	B
,	O
through	O
the	O
GM5	B
site,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS-like	B
factors	O
present	O
in	O
Jurkat	B
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	B
.	O

Mutation	O
of	O
the	O
core	B
ETS	O
binding	O
site	O
from	O
-GGAA-	O
to	O
-GGAT-	O
prevents	O
the	O
binding	O
of	O
ETS-like	B
factors	O
with	O
the	O
exception	O
of	O
ETS1	B
.	O

The	O
GM-CSF	B
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction,	O
in	O
addition	O
to	O
ETS1	B
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	B
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM-CSF	B
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Quantitation	O
of	O
beta	B
1	O
triiodothyronine	O
receptor	O
mRNA	O
in	O
human	O
tissues	O
by	O
competitive	O
reverse	B
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Thyroid	O
hormones	O
act	O
by	O
binding	O
to	O
nuclear	B
receptor	O
proteins	O
,	O
the	O
thyroid	B
hormone	O
receptors	O
(	B
TR	O
)	O
alpha	O
and	O
beta	O
.	O

Data	O
from	O
cell	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
TR	B
expression	O
may	O
be	O
regulated	O
to	O
modulate	O
target	O
organ	O
responsiveness	O
to	O
thyroid	O
hormone	O
.	O

To	O
investigate	O
whether	O
such	O
adaptive	O
changes	O
in	O
TR	B
expression	O
occur	O
in	O
humans,	O
we	O
determined	O
the	O
mRNA	O
levels	O
of	O
the	O
hTR	B
beta	O
1	O
in	O
various	O
thyroid	O
states	O
.	O

Patients	O
with	O
overt	O
hypo	O
-or	O
hyper	O
thyroidism	O
were	O
enrolled	O
in	O
the	O
study.	O

Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	B
blood	O
mononuclear	O
cells	O
and	O
hTR	B
beta	O
1	O
mRNA	O
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O

For	O
comparison,	O
hTR	B
beta	O
1	O
mRNA	O
levels	O
were	O
determined	O
in	O
lymphocytes	B
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O

Human	B
TR	O
beta	O
1	O
mRNA	O
levels	O
in	O
lymphocytes	B
were	O
1.8	O
+/-	O
0.4,	O
1.9	O
+/-	O
0.5,	O
1.1	O
+/-	O
0.4	O
10(-18)	O
mol/microgram	O
RNA	O
in	O
hypo	O
-,	O
eu	O
-and	O
hyper	O
thyroid	O
patients	O
,	O
respectively,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell.	O

Although	O
the	O
mean	O
hTR	B
beta	O
1	O
mRNA	O
levels	O
were	O
40%	O
lower	O
in	O
hyperthyroid	O
than	O
in	O
euthyroid	O
subjects,	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Similar	O
levels	O
of	O
hTR	B
beta	O
1	O
mRNA	O
levels	O
were	O
detected	O
in	O
thyroid	O
gland	O
from	O
euthyroid	O
patients	O
.	O

In	O
summary,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O
determination	O
of	O
hTR	B
beta	O
1	O
mRNA	O
levels	O
in	O
small	O
human	O
tissue	O
samples	O
,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	B
RNA.	O

Absolute	O
hTR	B
beta	O
1	O
mRNA	O
levels	O
are	O
very	O
low	O
with	O
an	O
estimated	O
one	O
molecule	O
of	O
mRNA	B
being	O
present	O
in	O
a	O
mononuclear	B
blood	O
cell	O
or	O
thyrocyte	B
.	O

No	O
up-regulation	O
of	O
hTR	B
beta	O
1	O
was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O

However,	O
there	O
is	O
a	O
non-significant	O
trend	O
towards	O
a	O
down-regulation	O
of	O
hTR	B
beta	O
1	O
mRNA	O
levels	O
in	O
hyperthyroid	O
patients	O
.	O

Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	B
inhibitory	O
protein	O
repressor	O
element	O
in	O
the	O
human	B
interleukin-3	O
promoter	O
.	O

T	O
cell	O
expression	O
of	O
interleukin	B
3	O
(	O
IL-3	B
)	O
is	O
directed	O
by	O
positive	O
and	O
negative	B
cis-acting	O
DNA	O
elements	O
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	B
start	O
site	O
.	O

A	O
strong	B
repressor	O
element	O
,	O
termed	O
nuclear	B
inhibitory	O
protein	O
(	O
NIP	B
),	O
was	O
previously	O
mapped	O
to	O
a	O
segment	O
of	O
the	O
IL-3	B
promoter	O
between	O
nucleotides	B
-271	O
and	O
-250	O
.	O

Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	B
promoter	O
.	O

DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O

Using	O
varying	O
conditions,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	B
region	O
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O

Complex	B
1	O
results	O
from	O
binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3'	B
portion	O
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O
.	O

Complex	B
2	O
corresponds	O
to	O
binding	O
of	O
transcription	B
factor	O
(	O
upstream	B
stimulatory	O
factor	O
)	O
to	O
an	O
E-box	B
motif	O
in	O
the	O
5'	B
portion	O
of	O
the	O
NIP	B
region	O
.	O

DNA	O
binding	O
specificity	O
of	O
complex	B
3	O
overlaps	O
with	O
that	O
of	O
upstream	B
stimulatory	O
factor	O
but	O
is	O
clearly	O
distinct.	O

To	O
determine	O
which	O
of	O
the	O
latter	O
two	O
complexes	O
represents	O
NIP	B
activity	O
,	O
we	O
incorporated	O
small	O
alterations	O
into	O
the	O
NIP	B
site	O
of	O
an	O
IL-3	B
promoter	O
-linked	O
reporter	O
construct	O
and	O
examined	O
their	O
effects	O
on	O
NIP	B
-mediated	O
repression	O
.	O

Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	B
3	O
;	O
both	O
repressor	O
activity	O
and	O
complex	B
3	O
binding	O
require	O
the	O
consensus	B
sequence	O
CTCACNTNC	O
.	O

The	O
hematopoietic	B
transcription	O
factor	O
PU.1	B
is	O
downregulated	O
in	O
human	B
multiple	O
myeloma	O
cell	O
lines	O
.	O

PU.1	B
is	O
a	O
hematopoietic	B
transcription	O
factor	O
belonging	O
to	O
the	O
Ets-family	B
.	O

It	O
is	O
identical	O
to	O
the	O
Spi-1	B
oncogene	O
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus-forming	O
virus-induced	O
murine	O
erythroleukemias	O
.	O

PU.1	B
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	O
hematopoietic	B
lineages	O
,	O
but	O
its	O
expression	O
in	O
mature	B
cells	O
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell-and	B
monocyte/macrophage-	O
differentiation	O
lineage	O
.	O

It	O
binds	O
the	O
so-called	O
Pu	B
box	O
,	O
an	O
important	O
tissue-specific	B
regulatory	O
DNA	O
element	O
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	O
lineages	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	B
during	O
human	O
B-cell	O
development	O
using	O
a	O
panel	O
of	O
B-cell	B
lines	O
representing	O
different	O
stages	O
of	O
maturation,	O
from	O
early	B
precursors	O
to	O
differentiated	B
plasma	O
cells	O
.	O

PU.1	B
mRNA	O
expression	O
and	O
PU.1	B
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively,	O
were	O
evident	O
in	O
cell	B
lines	O
representing	O
pro-B	B
,	O
pre-B	O
,	O
and	O
mature	O
B	O
cells	O
.	O

We	O
could	O
also	O
show	O
Pu	B
box	O
-dependent	O
transactivation	O
of	O
a	O
reporter	B
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	B
lines	O
.	O

In	O
contrast,	O
in	O
a	O
number	O
of	O
multiple	B
myeloma	O
cell	O
lines	O
,	O
representing	O
differentiated,	O
plasma	B
cell-like	O
B	B
cells	O
,	O
PU.1	B
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	B
box	O
-dependent	O
transactivation	O
were	O
absent	O
or	O
detectable	O
at	O
a	O
very	O
low	O
level.	O

In	O
lymphoblastoid	B
cell	O
lines	O
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed.	O

The	O
findings	O
in	O
the	O
human	B
multiple	O
myeloma	O
cell	O
lines	O
represent	O
the	O
first	O
examples	O
of	O
B	B
cells	O
with	O
downregulated	O
PU.1	B
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	B
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	B
cell	O
lines	O
.	O

At	O
present,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	B
expression	O
and	O
activity	O
in	O
human	B
multiple	O
myeloma	O
cell	O
lines	O
represents	O
a	O
malignancy-associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	B
differentiated	O
B	B
cells	O
.	O

Regulation	O
of	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
and	O
E-selectin	B
expression	O
in	O
endothelial	B
cells	O
by	O
cyclosporin	O
A	O
and	O
the	O
T-cell	B
transcription	O
factor	O
NFAT	B
.	O

Nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
)	O
was	O
originally	O
described	O
as	O
a	O
T-cell-specific	B
transcription	O
factor	O
athat	O
supported	O
the	O
activation	O
of	O
cytokine	B
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	B
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
).	O

As	O
we	O
observed	O
that	O
activated	O
endothelial	B
cells	O
also	O
expressed	O
NFAT	B
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	B
cells	O
.	O

Significantly,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	B
in	O
endothelial	B
cells	O
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
gene	O
regulatory	O
elements	O
that	O
use	O
NFAT	B
by	O
60%.	O

CsA	O
similarly	O
mediated	O
a	O
reduction	O
of	O
up	O
to	O
65%	O
in	O
GM-CSF	B
mRNA	O
and	O
protein	O
expression	O
in	O
activated	O
endothelial	B
cells	O
.	O

CsA	O
also	O
suppressed	O
E-selectin	B
,	O
but	O
not	O
vascular	B
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	B
)	O
expression	O
in	O
endothelial	B
cells,	O
even	O
though	O
the	O
E-selectin	B
promoter	O
is	O
activated	O
by	O
NF-kappa	B
B	O
rather	O
than	O
NFAT	B
.	O

Hence,	O
induction	O
of	O
cell	O
surface	O
expression	O
of	O
this	O
leukocyte	B
adhesion	O
molecule	O
by	O
tumor	B
necrosis	O
factor	O
(TNF)-alpha	O
was	O
reduced	O
by	O
40%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29%	O
decrease	O
in	O
neutrophil	B
adhesion	O
.	O

The	O
effects	O
of	O
CsA	O
on	O
endothelial	B
cells	O
were	O
also	O
detected	O
at	O
the	O
chromatin	B
structure	O
level	O
,	O
as	O
DNasel	B
hypersensitive	O
sites	O
within	O
both	O
the	O
GM-CSF	B
enhancer	O
and	O
the	O
E-selectin	B
promoter	O
were	O
suppressed	O
by	O
CsA	O
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	B
in	O
endothelial	B
cells	O
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O

Costimulation	O
requirement	O
for	O
AP-1	B
and	O
NF-kappa	B
B	O
transcription	B
factor	O
activation	O
in	O
T	B
cells	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IL-2	B
promoter	O
requires	O
T-cell	O
costimulation	O
delivered	O
by	O
the	O
TCR	B
and	O
the	O
auxiliary	B
receptor	O
CD28	O
.	O

Several	O
transcription	B
factors	O
participate	O
in	O
IL-2	B
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP-1	B
-like	O
factors	O
and	O
NF-kappa	B
B	O
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors:	O
(1)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP-1	B
protein	O
c-Jun	B
;	O
and	O
(2)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	B
inhibitor	O
,	O
I	B
kappa	O
B	O
,	O
from	O
NF-kappa	B
B	O
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T-cell	O
costimulation	O
.	O

Furthermore,	O
in	O
activated	B
T	O
cells	O
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar.	O

According	O
to	O
our	O
results,	O
however,	O
the	O
kinases	B
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities.	O

Whereas	O
TPCK	O
inhibits	O
phosphorylation	O
of	O
I	B
kappa	O
B	O
and,	O
consequently,	O
activation	O
of	O
NF-kappa	B
B	O
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	B
,	O
the	O
MAP	B
kinase-related	O
kinase	O
that	O
phosphorylates	O
the	O
transactivation	B
domain	O
of	O
c-Jun	B
.	O

We,	O
therefore,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T-cell	O
costimulation	O
.	O

Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	B
factors	O
,	O
AP-1	B
and	O
NF-kappa	B
B	O
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	B
and	O
CD28	B
engagement	O
occurs	O
along	O
this	O
pathway,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B
kappa	O
B	O
phosphorylation	O
and	O
NF-kappa	B
B	O
activation	O
on	O
the	O
one	O
hand,	O
and	O
JNK	B
activation	O
and	O
c-Jun	B
phosphorylation	O
on	O
the	O
other.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1	B
/	B
NF-kappa	B
B	O
pathway	O
.	O

Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	B
gene	O
expression	O
in	O
myeloid	B
cells	O
by	O
NF-kappa	B
B	O
/Rel	O
transcription	B
factors	O
.	O

CD4+	B
macrophages	O
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	B
cells	O
in	O
bone	O
marrow	O
,	O
and	O
peripheral	B
blood	O
monocytes	O
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O

HIV-1	B
-infected	O
myeloid	O
cells	O
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O
participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O

HIV-1	O
infection	O
of	O
myeloid	B
cells	O
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	B
receptors	O
associated	O
with	O
cellular	O
activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	B
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens.	O

Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA-binding	O
activity	O
of	O
cellular	B
transcription	B
factors	O
such	O
as	O
NF-kappa	B
B	O
.	O

NF-kappa	B
B	O
binds	O
to	O
the	O
HIV-1	B
enhancer	O
region	O
of	O
the	O
long	B
terminal	O
repeat	O
and	O
contributes	O
to	O
the	O
inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents.	O

Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	B
inhibitor	O
I	B
kappa	O
B	O
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF-kappa	B
B	O
DNA-binding	O
activity	O
.	O

Both	O
N-	B
and	O
C-	O
terminal	O
residues	O
of	O
I	B
kappa	O
B	O
alpha	O
are	O
required	O
for	O
inducer-mediated	O
degradation	O
.	O

Chronic	O
HIV-1	O
infection	O
of	O
myeloid	B
cells	O
leads	O
to	O
constitutive	O
NF-kappa	B
B	O
DNA-binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O

Increased	O
intracellular	O
stores	O
of	O
latent	O
NF-kappa	B
B	O
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF-kappa	B
B	O
-dependent	O
cytokine	B
gene	O
expression	O
.	O

In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge,	O
cytokine	O
gene	O
expression	O
is	O
rapidly	O
induced,	O
enhanced,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O
HIV-1	B
-infected	O
myeloid	O
cells	O
compared	O
with	O
uninfected	B
cells	O
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	B
cytokines	B
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV-1	O
-infected	O
individuals	O
.	O

Secretion	O
of	O
myeloid	B
cell-derived	O
cytokines	B
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O

Steroid	O
mediated	O
lysis	O
of	O
lymphoblasts	B
requires	O
the	O
DNA	B
binding	O
region	O
of	O
the	O
steroid	B
hormone	O
receptor.	O

Glucocorticoids	O
kill	O
certain	O
types	O
of	O
lymphoblasts	B
,	O
but	O
the	O
mechanisms	O
are	O
unknown.	O

It	O
is	O
clear	O
that	O
sufficient	O
numbers	O
of	O
functional	O
glucocorticoid	B
receptors	O
are	O
required	O
to	O
mediate	O
lysis,	O
but	O
whether	O
they	O
do	O
so	O
through	O
the	O
classical	O
model	O
of	O
steroid	O
hormone	O
activation	O
and	O
modulation	O
of	O
gene	O
expression	O
has	O
not	O
been	O
established.	O

In	O
this	O
report	O
we	O
have	O
asked	O
which	O
region(s)	O
of	O
the	O
steroid	B
receptor	O
are	O
important	O
for	O
mediating	O
lysis	O
in	O
leukemic	B
T	O
lymphoblasts	O
.	O

CEM-ICR	B
27	O
leukemic	O
lymphoblasts	O
,	O
a	O
clone	O
of	O
CEM	B
cells	O
which	O
lack	O
functional	O
glucocorticoid	B
receptors	O
and	O
therefore	O
are	O
neither	O
lysed	O
by	O
dexamethasone	O
nor	O
capable	O
of	O
showing	O
glutamine	B
synthetase	O
induction	O
,	O
were	O
provided	O
with	O
steroid	B
receptors	O
by	O
DNA	O
transfections	O
of	O
various	O
receptor	B
gene	O
constructs.	O

We	O
measured	O
steroid	O
mediated	O
lysis	O
,	O
receptor	O
number	O
and	O
induction	O
of	O
glutamine	B
synthetase	O
in	O
the	O
transfected	B
cells	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
lysis	O
mechanism	O
in	O
the	O
ICR27	B
lymphoblasts	O
is	O
restored	O
when	O
functional	O
receptor	O
number	O
is	O
restored.	O

The	O
DNA	B
binding	O
region	O
specifying	O
high	O
affinity	O
for	O
GRE	B
sites	O
is	O
required.	O

Lysis	O
is	O
mediated	O
by	O
any	O
steroid	O
that	O
allows	O
for	O
activation	O
of	O
the	O
receptor	O
containing	O
such	O
a	O
region.	O

Our	O
data	O
support	O
the	O
view	O
that	O
steroid	O
-mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid	B
-receptor	O
complexes	O
with	O
the	O
genome.	O

Functional	O
characterization	O
of	O
the	O
murine	B
homolog	O
of	O
the	O
B	B
cell-specific	O
coactivator	O
BOB.1/OBF.1	B
.	O

B	B
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	B
motif	O
requires	O
the	O
Oct1	B
or	O
Oct2	B
protein	O
and	O
additional	O
B	B
cell-restricted	O
cofactors	O
.	O

One	O
such	O
cofactor	B
,	O
BOB.1/OBF.1	B
,	O
was	O
recently	O
isolated	O
from	O
human	B
B	O
cells	O
.	O

Here,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	B
homolog	O
.	O

Full-length	B
cDNAs	O
and	O
genomic	B
clones	O
were	O
isolated,	O
and	O
the	O
gene	O
structure	O
was	O
determined.	O
Comparison	O
of	O
the	O
deduced	O
amino	B
acids	O
shows	O
88%	O
sequence	O
identity	O
between	O
mouse	B
and	O
human	B
BOB.1/OBF.1	B
.	O

The	O
NH2-terminal	B
126	O
amino	O
acids	O
of	O
BOB.1/OBF.1	B
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	B
domains	O
of	O
either	O
Oct1	B
or	O
Oct2	B
.	O

This	O
protein-protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B
proteins	O
to	O
DNA,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	B
-DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB.1/OBF.1	B
to	O
Oct1	B
or	O
Oct2	B
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA.	O

BOB.1/OBF.1	B
can	O
efficiently	O
activate	O
octamer-dependent	B
promoters	O
in	O
fibroblasts	B
;	O
however,	O
it	O
fails	O
to	O
stimulate	O
octamer-dependent	B
enhancer	O
activity	O
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	B
with	O
the	O
GAL4	B
DNA	O
binding	O
domain	O
reveals	O
that	O
both	O
NH2-	B
and	O
COOH-	O
terminal	O
domains	O
of	O
BOB.1/OBF.1	B
contribute	O
to	O
full	O
transactivation	O
function,	O
the	O
COOH-terminal	B
domain	O
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

Consistent	O
with	O
the	O
failure	O
of	O
full-length	B
BOB.1/OBF.1	B
to	O
stimulate	O
octamer-dependent	B
enhancer	O
elements	O
in	O
non	B
B	O
cells	O
,	O
the	O
GAL4	B
fusions	O
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	B
position	O
.	O

Anti-immunoglobulin	B
M	O
activates	O
nuclear	B
calcium/calmodulin-dependent	O
protein	O
kinase	O
II	O
in	O
human	B
B	O
lymphocytes	O
.	O

We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	B
protein	O
,	O
Ets-1	B
,	O
is	O
phosphorylated	O
in	O
a	O
calcium-dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	B
(Ig)	O
M	O
on	O
B	B
lymphocytes	O
.	O

As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	B
kinase	O
C	O
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium/calmodulin-dependent	B
protein	O
kinase	O
(	O
CaM	B
kinase	O
)	O
might	O
phosphorylate	O
the	O
Ets-1	B
protein	O
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O

The	O
dephosphorylated	O
form	O
of	O
Ets-1	B
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	B
,	O
suggesting	O
that	O
the	O
operative	O
kinase	O
should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O

We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	B
B	O
cell	O
lines	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	B
protein.	O

Activity	O
of	O
the	O
CaM	B
kinases	O
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	B
kinase	O
family	O
,	O
KN-62	B
.	O

Stimulation	O
of	O
cells	O
with	O
anti-IgM	B
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	B
kinase	O
that	O
could	O
phosphorylate	O
the	O
peptide,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN-62	B
.	O

Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	O
specific	O
for	O
CaM	B
kinase	O
II	O
.	O

Two-dimensional	O
phosphopeptide	O
maps	O
of	O
the	O
Ets-1	B
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti-IgM	B
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	B
cells.	O

Incubation	O
of	O
isolated	O
Ets-1	B
protein	O
with	O
purified	B
CaM	O
kinase	O
II	O
produced	O
phosphorylation	O
of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti-IgM	B
or	O
ionomycin	O
.	O

These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O
by	O
the	O
antigen	B
receptor	O
on	O
B	B
lymphocytes	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	B
CaM	O
kinase	O
II	O
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O
regulation	O
of	O
DNA-binding	B
proteins	O
.	O

Transcriptional	O
activation	O
and	O
repression	O
,	O
two	O
properties	O
of	O
the	O
lymphoid-specific	B
transcription	O
factor	O
Oct-2a	B
.	O

The	O
lymphoid-specific	B
transcription	O
factor	O
Oct-2a	B
contains	O
two	O
transcriptional	B
activation	O
domains	O
which	O
are	O
located	O
within	O
the	O
N-terminal	B
and	O
C-terminal	O
regions	O
.	O

To	O
study	O
their	O
differential	O
activation	O
properties	O
,	O
we	O
linked	O
the	O
isolated	O
effector	O
domains	O
to	O
the	O
GAL4	B
DNA-binding	O
domain	O
.	O

We	O
have	O
shown	O
that	O
both	O
activating	O
regions	O
of	O
Oct-2a	B
,	O
isolated	O
from	O
their	O
natural	O
context,	O
can	O
activate	O
transcription	O
as	O
promoter	B
factors	O
.	O

In	O
contrast	O
to	O
the	O
C-terminus	B
,	O
activation	O
by	O
the	O
N-terminal	B
domain	O
is	O
dependent	O
on	O
a	O
yet	O
unidentified	O
factor(s)	O
binding	O
to	O
the	O
simian	B
virus	O
40	O
enhancer	O
.	O

The	O
results	O
obtained	O
by	O
duplication	O
of	O
activation	O
domains	O
or	O
their	O
mixed	O
combination	O
suggest	O
that	O
the	O
domains	O
are	O
functionally	O
independent.	O

However,	O
activation	O
from	O
a	O
remote	O
position	O
could	O
only	O
be	O
achieved	O
with	O
the	O
C-terminus	B
of	O
Oct-2a	B
in	O
B	B
cells	O
.	O

In	O
lymphoid	B
cells	O
,	O
higher	O
activation	O
levels	O
were	O
observed,	O
suggesting	O
that	O
distinct	O
B-cell-specific	B
cofactors	O
in	O
concert	O
with	O
the	O
effector	B
domains	O
of	O
Oct-2a	B
might	O
be	O
involved	O
in	O
mediating	O
transcription	O
from	O
proximal	O
and	O
remote	O
positions	O
.	O

Furthermore,	O
we	O
identified	O
a	O
repression	B
domain	O
at	O
the	O
N-terminus	B
of	O
Oct-2a	B
.	O

When	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcriptional	O
stimulation	O
was	O
inhibited	O
efficiently.	O

These	O
results	O
underscore	O
the	O
modular	O
structure	O
of	O
Oct-2a	B
with	O
separable	B
domains	O
for	O
activation	O
and	O
repression	O
and	O
suggest	O
that	O
Oct-2a	B
might	O
have	O
complex	O
regulatory	O
functions	O
in	O
vivo.	O

Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	B
and	O
polymorphonuclear	B
leukocytes	O
requires	O
the	O
presence	O
of	O
the	O
bacterial	B
flagellum	O
.	O

Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood.	O

To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P.	O
aeruginosa	O
PAK	O
lacking	O
pili	B
,	O
flagella	B
,	O
and	O
the	O
RpoN	B
sigma	O
factor	O
were	O
undertaken.	O

The	O
RpoN	B
mutant	O
,	O
lacking	O
pili	B
,	O
flagella	B
,	O
and	O
nonpilus	B
adhesins	O
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	B
and	O
neutrophils	B
.	O

Pili	B
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P.	O
aeruginosa	O
.	O

The	O
presence	O
of	O
a	O
flagellum	B
was	O
not	O
required	O
for	O
binding	O
of	O
P.	O
aeruginosa	O
to	O
macrophages	B
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O

Identification	O
of	O
essential	O
GATA	B
and	O
Ets	O
binding	O
motifs	O
within	O
the	O
promoter	B
of	O
the	O
platelet	B
glycoprotein	O
Ib	O
alpha	O
gene	O
.	O

Platelet	B
glycoprotein	O
(	O
GP	O
)	O
Ib-IX-V	O
is	O
a	O
multisubunit	B
adhesion	O
receptor	O
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O

The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
"giant"	B
platelets	O
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O

To	O
understand	O
better	O
the	O
expression	O
of	O
the	O
GP	B
Ib-IX-V	O
complex	O
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	O
elements	O
supporting	O
the	O
expression	O
of	O
the	O
alpha-subunit	B
of	O
the	O
complex	O
(	O
GP	B
Ib	O
alpha	O
).	O

GP	B
Ib	O
alpha	O
promoter	O
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	B
erythroleukemia	O
cells	O
with	O
reporter	B
plasmids	O
coding	O
for	O
the	O
enzyme	O
,	O
luciferase	B
.	O

Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2,738	B
nucleotides	O
5'	O
to	O
the	O
transcription	B
start	O
site	O
and	O
lead	O
to	O
the	O
identification	O
of	O
253	B
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	B
erythroleukemia	O
cells	O
.	O

In	O
cells	O
of	O
nonhematopoietic	B
lineage	O
,	O
human	B
endothelial	O
and	O
HeLa	B
cells	O
,	O
the	O
GP	B
Ib	O
alpha	O
promoter	O
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	B
constructs	O
.	O

Gel	O
shift	O
assays	O
and	O
site-directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	B
and	O
Ets	O
binding	O
motifs	O
93	B
and	O
150	O
nucleotides	O
upstream	O
of	O
the	O
transcription	B
start	O
site	O
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	B
gene	O
expression	O
.	O

The	O
results	O
define	O
essential	O
cis-acting	B
elements	O
responsible	O
for	O
the	O
expression	O
of	O
GP	B
Ib	O
alpha	O
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	B
platelets	O
into	O
the	O
bloodstream	O
.	O

CD30	B
ligation	O
induces	O
nuclear	B
factor-kappa	O
B	O
activation	O
in	O
human	B
T	O
cell	O
lines	O
.	O

CD30	B
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B
necrosis	O
factor	O
/nerve	O
growth	O
factor	O
receptor	O
superfamily	O
.	O

In	O
this	O
report,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	B
cells	O
(	O
Hodgkin's	B
disease	O
-derived,	O
T	O
cell-like,	O
CD30	B
+	O
cells	O
)	O
with	O
the	O
agonistic	O
anti-	B
CD30	B
monoclonal	B
antibodies	O
(	O
mAb	B
)	O
M44	B
and	O
M67	B
,	O
two	O
nuclear	B
factor	O
(NF)-kappa	O
B	O
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O

The	O
effect	O
of	O
the	O
mAb	B
towards	O
NF-kappa	B
B	O
activation	O
was	O
rapid,	O
as	O
it	O
occurred	O
within	O
20	O
min,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h.	O

By	O
comparison,	O
an	O
isotype-matched	B
antibody	O
had	O
no	O
effect	O
on	O
NF-kappa	B
B	O
activation	O
.	O

Moreover,	O
in	O
human	B
T	O
helper	O
(Th)	O
clones	O
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0,	O
type	B
1	O
and	O
type	B
2	O
(28%,	O
&lt;	O
1%	O
und	O
93%	O
CD30+,	B
respectively),	O
the	O
extent	O
of	O
CD30	B
-mediated	O
NF-kappa	B
B	O
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30+	B
cells	O
.	O

In	O
all	O
cell	B
lines	O
investigated,	O
the	O
NF-kappa	B
B	O
complexes	O
induced	O
following	O
CD30	B
engagement	O
were	O
shown	O
to	O
contain	O
p50	B
NF-kappa	B
B1	O
,	O
p65	B
RelA	O
,	O
and	O
possibly	O
other	O
transcription	B
factors	O
.	O

Collectively,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF-kappa	B
B	O
rank	O
among	O
the	O
short-term	O
cellular	O
responses	O
elicited	O
following	O
CD30	B
ligation	O
.	O

Pathogenesis	O
of	O
atherosclerosis	O
.	O

The	O
earliest	O
lesion	O
in	O
the	O
development	O
of	O
an	O
atherosclerotic	O
plaque	O
is	O
the	O
fatty	O
streak	O
.	O

This	O
chronic	O
inflammatory	O
reaction	O
results	O
from	O
a	O
sequence	O
of	O
events	O
that	O
begins	O
with	O
the	O
trapping	O
of	O
low	B
density	O
lipoprotein	O
(	O
LDL	B
)	O
in	O
the	O
subendothelial	O
space	O
of	O
the	O
artery	O
wall	O
.	O

The	O
trapped	O
LDL	B
is	O
seeded	O
with	O
oxidative	O
species	O
released	O
by	O
the	O
overlying	O
endothelium	O
,	O
and	O
lipid	O
oxidation	O
is	O
initiated	O
within	O
the	O
LDL	B
particle.	O
Some	O
of	O
the	O
lipids	O
that	O
result	O
lead	O
to	O
the	O
activation	O
of	O
NFkB-like	B
transcription	B
factors	O
that	O
cause	O
the	O
expression	O
of	O
genes	O
whose	O
protein	B
products	O
mediate	O
monocyte	O
binding	O
,	O
monocyte	O
chemotaxis	O
into	O
the	O
subendothelial	O
space	O
,	O
and	O
conversion	O
into	O
macrophages	B
.	O

At	O
least	O
1	O
major	O
gene	O
modulates	O
the	O
oxidation	O
of	O
LDL	B
lipids	O
and/or	O
the	O
biologic	O
response	O
to	O
these	O
lipids.	O

The	O
inverse	O
relation	O
between	O
high	B
density	O
lipoprotein	O
(	O
HDL	B
)	O
and	O
atherosclerotic	O
events	O
may	O
in	O
part	O
be	O
due	O
to	O
enzymes	O
associated	O
with	O
HDL	B
that	O
destroy	O
the	O
biologically	O
active	O
lipids	O
generated	O
in	O
LDL	B
.	O

Estrogen	B
and	O
progesterone	O
receptors	O
in	O
vernal	O
keratoconjunctivitis	O
.	O

PURPOSE:	O
Sex-related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
),	O
an	O
allergic	O
eosinophilic	O
disease.	O

METHODS:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	B
and	O
progesterone	O
receptors	O
by	O
using	O
monoclonal	B
antibodies	O
with	O
a	O
peroxidase-antiperoxidase	O
technique	O
.	O

RESULTS:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	B
and	O
progesterone	O
receptors	O
.	O

Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	B
and	O
progesterone	O
receptors	O
with	O
eosinophil	B
cationic	O
protein	O
showed	O
that	O
approximately	O
70%	O
of	O
positive	O
cells	O
were	O
eosinophils	B
.	O

CONCLUSIONS:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	O
,	O
may	O
influence	O
the	O
activity	O
of	O
eosinophils	B
in	O
patients	O
with	O
VKC	O
.	O

CIITA	B
activates	O
the	O
expression	O
of	O
MHC	B
class	O
II	O
genes	O
in	O
mouse	B
T	O
cells.	O

It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	B
class	O
II	O
molecules	O
are	O
expressed	O
in	O
human	B
T	O
cells	O
after	O
activation	O
but	O
not	O
in	O
mouse	B
T	O
cells	O
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O

Recently	O
the	O
MHC	B
class	O
II	O
transactivator	O
(	O
CIITA	B
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
regulatory	O
factor	O
for	O
both	O
the	O
constitutive	O
and	O
IFN	B
inducible	O
expression	O
of	O
MHC	B
class	O
II	O
genes	O
.	O

Here	O
we	O
show	O
that	O
human	B
T	O
cells	O
expressing	O
MHC	B
class	O
II	O
have	O
CIITA	B
transcripts	O
while	O
MHC	B
class	O
II-negative	O
human	O
T	O
cells	O
and	O
mouse	B
T	O
cells	O
do	O
not.	O

The	O
expression	O
of	O
MHC	B
class	O
II	O
genes	O
in	O
mouse	B
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	B
CIITA	B
cDNA	O
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	B
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	B
class	O
II	O
in	O
human	B
and	O
mouse	O
T	O
cells	O
respectively.	O

Anti-Ro(SSA)	B
autoantibodies	O
are	O
associated	O
with	O
T	B
cell	O
receptor	O
beta	O
genes	O
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O

Several	O
of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	O
lupus	O
erythematosus	O
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	B
.	O

Associations	O
between	O
HLA	B
class	O
II	O
antigens	O
and	O
autoantibodies	B
to	O
the	O
ribonucleoproteins	B
Ro(SSA)	B
and	O
La(SSB)	B
have	O
been	O
reported	O
in	O
these	O
patients.	O

Because	O
HLA	B
class	O
II	O
molecules	O
present	O
antigen	O
to	O
T	B
cell	O
receptors	O
(	O
TCRs	B
),	O
we	O
have	O
searched	O
for	O
a	O
TCR	B
gene	O
associated	O
with	O
the	O
production	O
of	O
anti-	B
Ro(SSA)	B
antibodies	O
.	O

A	O
pair	O
of	O
restriction	B
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	B
),	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	B
constant	O
region	O
C	O
beta	O
1	O
and	O
the	O
other	O
to	O
the	O
C	B
beta	O
2	O
gene	O
,	O
has	O
been	O
identified,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	B
beta	O
locus	O
.	O

This	O
RFLP	B
pair	O
occurs	O
in	O
76%	O
of	O
patients	O
with	O
Ro(SSA)	B
precipitins,	O
84%	O
of	O
anti-	O
Ro(SSA)	O
-positive	O
patients	O
lacking	O
La(SSB)	B
precipitins	O
,	O
but	O
only	O
41%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B
(P	O
=	O
0.0004).	O

This	O
disproportionate	O
occurrence	O
in	O
a	O
subset	O
of	O
lupus	O
patients	O
indicates	O
that	O
these	O
RFLPs	B
are	O
not	O
disease	O
susceptibility	O
markers,	O
but	O
rather	O
are	O
important	O
markers	O
for	O
TCR	B
genes	O
whose	O
products	O
are	O
involved	O
in	O
the	O
production	O
of	O
anti-	B
Ro(SSA)	B
antibodies	O
.	O

The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	B
and	O
HLA	B
class	O
II	O
antigens	O
previously	O
associated	O
with	O
the	O
anti-	B
Ro(SSA)	B
response	O
make	O
this	O
antibody,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	O
occur	O
in	O
response	O
to	O
Ro(SSA)	B
.	O

Inhibition	O
of	O
NF-AT	B
-dependent	O
transcription	O
by	O
NF-kappa	B
B	O
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	B
helper	O
cell	O
subsets	O
.	O

Activation	O
of	O
individual	O
CD4+	B
T	O
cells	O
results	O
in	O
differential	O
lymphokine	B
expression	O
:	O
interleukin	B
2	O
(	O
IL-2	B
)	O
is	O
preferentially	O
produced	O
by	O
T	B
helper	O
type	O
1	O
(TH1)	O
cells	O
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses,	O
whereas	O
IL-4	B
is	O
synthesized	O
by	O
TH2	B
cells	O
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

The	O
Ca(2+)	B
-dependent	O
factor	O
NF-ATp	B
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	B
genes	O
.	O

However,	O
while	O
IL2	B
expression	O
requires	O
the	O
contribution	O
of	O
Ca(2+)-	O
and	O
protein	O
kinase	O
C	O
-dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	O
IL4	B
transcription	O
through	O
the	O
Ca(2+)-dependent	O
pathway	O
is	O
diminished	O
by	O
protein	B
kinase	O
C	O
stimulation	O
in	O
Jurkat	B
T	O
cells	O
.	O

This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF-ATp	B
and	O
NF-kappa	B
B	O
to	O
the	O
P	B
sequence	O
,	O
an	O
element	O
located	O
69	B
bp	O
upstream	O
of	O
the	O
IL4	B
transcription	O
initiation	O
site	O
.	O

Human	B
IL4	O
promoter	O
-mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	B
cells	O
stimulated	O
with	O
the	O
NF-kappa	B
B	O
-activating	O
cytokine	O
tumor	B
necrosis	O
factor	O
alpha	O
and	O
suppressed	O
in	O
RelA	B
-overexpressing	O
cells	O
.	O

In	O
contrast,	O
protein	B
kinase	O
C	O
stimulation	O
or	O
RelA	B
overexpression	O
does	O
not	O
affect	O
the	O
activity	O
of	O
a	O
human	B
IL4	B
promoter	O
containing	O
a	O
mouse	B
P	O
sequence	O
,	O
which	O
is	O
a	O
higher-affinity	O
site	O
for	O
NF-ATp	B
and	O
a	O
lower-affinity	O
site	O
for	O
RelA	B
.	O

Thus,	O
competition	O
between	O
two	O
general	O
transcriptional	O
activators	O
,	O
RelA	B
and	O
NF-ATp	B
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	B
kinase	O
C	O
stimulation	O
on	O
IL4	B
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	B
cells	O
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	B
production	O
and	O
the	O
signal	B
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	B
and	O
inflammatory	O
synovial	O
fluids.	O

The	O
balance	O
between	O
type	B
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	B
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity,	O
and	O
skewed	O
patterns	O
of	O
cytokine	B
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	B
activate	O
signal	B
transducer	O
and	O
activation	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factors	O
,	O
which,	O
in	O
turn,	O
activate	O
transcription	O
of	O
inflammatory	B
effector	O
genes.	O

We	O
used	O
mononuclear	B
cell	O
priming	O
cultures	O
and	O
inflammatory	O
synovial	O
fluids	O
(	O
SFs	O
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	B
production	O
and	O
STAT	B
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	O
during	O
priming	O
resulted	O
in	O
an	O
81%	O
inhibition	O
of	O
interferon	B
(IFN)-gamma	O
,	O
but	O
not	O
interleukin	B
(IL)	O
4	O
,	O
production	O
by	O
effector	B
cells	O
generated	O
in	O
priming	B
cultures.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	B
and	O
IL-10	B
and	O
inhibition	O
of	O
IL-12	B
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12.	B

SFs	B
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	B
factor	O
Stat1	B
,	O
but	O
not	O
Stat3	B
,	O
during	O
the	O
priming	O
period,	O
and	O
Stat1	B
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	B
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN-gamma	B
production	O
.	O

Active	O
Stat3	B
,	O
but	O
not	O
Stat1	B
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	B
and	O
Stat3	B
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

Triggering	O
of	O
complement	B
receptors	O
CR1	B
(	O
CD35	B
)	O
and	O
CR3	B
(	O
CD11b/CD18	B
)	O
induces	O
nuclear	O
translocation	O
of	O
NF-kappa	B
B	O
(	O
p50/p65	B
)	O
in	O
human	B
monocytes	O
and	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B
monocytic	O
cells	O
.	O

Monocyte/macrophages	B
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time.	O

Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	B
such	O
as	O
TNF-alpha	B
in	O
vitro.	O

The	O
effect	O
of	O
LPS	O
and	O
TNF-alpha	B
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA-binding	B
heterodimer	O
NF-kappa	B
B	O
(	O
p50/p65	B
),	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV-long	B
terminal	O
repeat	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	B
receptors	O
CR1	B
(	O
CD35	B
)	O
and	O
CR3	B
(	O
CD11b/CD18	B
)	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	B
human	O
monocytic	O
cells	O
.	O

Monocytic	B
cell	O
lines	O
and	O
normal	B
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F(ab')2	B
fragments	O
of	O
monoclonal	B
anti-	O
CR1	B
or	O
anti-	B
CR3	B
Abs	O
or	O
with	O
C3	B
fragments	O
.	O

Stimulation	O
of	O
CR1	B
or	O
CR3	B
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell-associated	O
and	O
released	O
p24	B
Ag	O
in	O
cell	O
cultures	O
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	O
cultures	O
triggered	O
with	O
LPS	O
.	O

We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	B
or	O
CR3	B
induces	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	B
B	O
p50/p65	O
in	O
infected	B
cells	O
.	O

Translocation	O
of	O
NF-kappa	B
B	O
p50/p65	O
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	B
or	O
CR3	B
of	O
uninfected	B
peripheral	O
blood	O
monocytes	O
from	O
HIV-seronegative	O
donors	O
.	O

The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF-alpha	B
.	O

TNF-alpha	B
did	O
not	O
mediate	O
the	O
translocation	O
of	O
NF-kappa	B
B	O
p50/p65	O
induced	O
by	O
triggering	O
of	O
complement	B
receptors	O
.	O

Taken	O
together,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	B
monocytes	B
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement-opsonized	O
particles	O
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	B
receptor	O
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF-kappa	B
B	O
complex	O
.	O

Attenuation	O
of	O
gamma	B
interferon	O
-induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	B
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	B
kinases	O
and	O
Stat1	B
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	B
interferon	O
is	O
impaired	O
in	O
mononuclear	B
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	B
interferon	O
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	B
protein	O
tyrosine	O
kinases	O
,	O
including	O
the	O
Janus	B
kinases	O
Jak1	B
and	O
Jak2	B
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B
factor	O
Stat1	B
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	B
interferon	O
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	B
and	O
Jak2	B
and	O
phosphorylation	O
of	O
Stat1	B
was	O
developed	O
in	O
phorbol	B
12-myristate	O
13-acetate	O
-differentiated	O
U-937	O
cells	O
.	O

Analysis	O
of	O
whole-cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	B
interferon	O
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	B
cells	O
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h.	O

Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon-treated	B
cells	O
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation.	O

Tyrosine	O
phosphorylation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
increased	O
markedly,	O
in	O
a	O
dose-dependent	O
manner,	O
in	O
U-937	B
cells	O
incubated	O
with	O
gamma	B
interferon	O
.	O

In	O
contrast,	O
in	O
cells	O
infected	O
with	O
L.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1	B
was	O
markedly	O
impaired.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	B
cells	O
were	O
also	O
obtained	O
with	O
human	B
peripheral	O
blood	O
monocytes	O
.	O

These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	B
mononuclear	O
phagocytes	O
with	O
L.	O
donovani	O
leads	O
to	O
impaired	O
gamma	B
interferon	O
-mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak-	B
Stat1	B
pathway	O
.	O

Unresponsiveness	O
to	O
gamma	B
interferon	O
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania-infected	B
cells	O
.	O

Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	B
attachment	O
region	O
binding	O
protein	O
and	O
the	O
NF-muNR	B
enhancer	O
repressor	O
.	O

Implications	O
for	O
regulation	O
of	O
immunoglobulin	B
heavy	O
chain	O
expression	O
.	O

The	O
immunoglobulin	B
heavy	O
chain	O
(	O
IgH	B
)	O
intronic	O
enhancer	O
stimulates	O
transcription	O
from	O
functional	B
promoters	O
in	O
B	B
lymphocytes	O
but	O
not	O
other	O
cell	O
types.	O

The	O
observation	O
that	O
binding	O
sites	O
for	O
the	O
nuclear	B
factor-mu	O
negative	O
regulator	O
(	O
NF-muNR	B
)	O
enhancer	O
repressor	O
overlap	O
nuclear	B
matrix	O
attachment	O
regions	O
(	O
MARs	B
)	O
in	O
this	O
enhancer	O
has	O
lead	O
to	O
the	O
hypothesis	O
that	O
the	O
cell	O
type	O
specificity	O
of	O
the	O
enhancer	O
might	O
be	O
controlled	O
by	O
regulating	O
nuclear	O
matrix	O
attachment	O
(Scheuermann,	O
R.	O
H.,	O
and	O
Chen,	O
U.	O
(1989)	O
Genes	O
&amp;	O
Dev.	O
3,	O
1255-1266).	O

To	O
understand	O
the	O
role	O
of	O
MARs	B
in	O
IgH	B
enhancer	O
regulation	O
,	O
we	O
have	O
identified	O
a	O
novel	O
MAR-binding	B
protein	O
,	O
MAR-BP1	B
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	B
associated	O
with	O
the	O
IgH	B
enhancer	O
.	O

Purified	O
MAR-BP1	B
migrates	O
as	O
a	O
33-kDa	B
protein	O
,	O
and	O
it	O
can	O
be	O
found	O
in	O
nuclear	O
matrix	O
preparations	O
from	O
a	O
number	O
of	O
different	O
types	O
of	O
lymphoid	B
cell	O
lines	O
.	O

Although	O
specific	O
binding	O
sites	O
have	O
been	O
difficult	O
to	O
localize	O
by	O
chemical	O
or	O
enzymatic	O
footprinting	O
procedures	O
,	O
NF-muNR	B
binding	O
sites	O
are	O
critical	O
for	O
efficient	O
MAR-BP1	B
binding	O
.	O

Indeed,	O
binding	O
of	O
the	O
IgH	B
enhancer	O
to	O
either	O
intact	O
nuclear	O
matrix	O
preparations	O
or	O
to	O
MAR-BP1	B
is	O
mutually	O
exclusive	O
to	O
NF-muNR	B
binding	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
for	O
cell-type	O
specific	O
regulation	O
in	O
which	O
binding	O
of	O
the	O
NF-muNR	B
repressor	O
to	O
the	O
IgH	B
enhancer	O
prevents	O
nuclear	O
matrix	O
attachment	O
in	O
inappropriate	O
cells	O
by	O
interfering	O
with	O
MAR-BP1	B
/enhancer	O
interaction	O
.	O

PU.1	B
(	O
Spi-1	B
)	O
and	O
C/EBP	B
alpha	O
regulate	O
expression	O
of	O
the	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
receptor	O
alpha	O
gene	O
.	O

Growth	B
factor	O
receptors	O
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	B
factors	O
activating	O
the	O
expression	O
of	O
the	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
(	O
GM-CSF	B
)	O
receptor	O
alpha	O
gene	O
.	O

Here,	O
we	O
demonstrate	O
that	O
the	O
human	B
GM-CSF	B
receptor	O
alpha	O
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue-specific	O
fashion	O
in	O
myelomonocytic	B
cells	O
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O

The	O
GM-CSF	B
receptor	O
alpha	O
promoter	O
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	B
-53	O
and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	B
constructs	O
.	O

We	O
show	O
that	O
the	O
myeloid	B
and	O
B	O
cell	O
transcription	B
factor	O
PU.1	B
binds	O
specifically	O
to	O
this	O
site.	O

Furthermore,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	B
site	O
located	O
upstream	O
of	O
the	O
PU.1	B
site	O
between	O
positions	O
-70	B
and	O
-54	O
is	O
involved	O
in	O
positive-negative	O
regulation	O
of	O
the	O
GM-CSF	B
receptor	O
alpha	O
promoter	O
activity	O
.	O

C/EBP	B
alpha	O
is	O
the	O
major	O
CCAAT/enhancer	B
-binding	O
protein	O
(	O
C/EBP	B
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	B
cells	O
.	O

Point	O
mutations	O
of	O
either	O
the	O
PU.1	B
site	O
or	O
the	O
C/EBP	B
site	O
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM-CSF	B
receptor	O
alpha	O
promoter	O
activity	O
in	O
myelomonocytic	B
cells	O
only.	O

Furthermore,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU.1	B
forms	O
a	O
novel,	O
specific,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU-SF	B
)	O
when	O
binding	O
the	O
GM-CSF	B
receptor	O
alpha	O
promoter	B
PU.1	B
site	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B
on	O
a	O
myeloid	B
PU.1	B
binding	O
site	O
.	O

The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	B
cell	O
enhancer	O
sites	O
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU.1	B
to	O
extracts	O
from	O
certain	O
nonmyeloid	O
cell	O
types	O
which	O
do	O
not	O
express	O
PU.1	B
,	O
including	O
T	B
cells	O
and	O
epithelial	B
cells	O
,	O
but	O
not	O
from	O
erythroid	B
cells	O
.	O

Furthermore,	O
we	O
demonstrate	O
that	O
the	O
PU-SF	B
complex	O
binds	O
to	O
PU.1	B
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	B
promoters	O
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU.1	B
site	O
adjacent	O
to	O
a	O
single-stranded	B
region.	O

Expression	O
of	O
PU.1	B
in	O
nonmyeloid	B
cells	O
can	O
activate	O
the	O
GM-CSF	B
receptor	O
alpha	O
promoter	O
.	O

Deletion	O
of	O
the	O
amino-terminal	B
region	O
of	O
PU.1	B
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU-SF	B
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU-SF	B
complex	O
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM-CSF	B
receptor	O
alpha	O
promoter	O
.	O

Finally,	O
we	O
demonstrate	O
that	O
C/EBP	B
alpha	O
can	O
also	O
active	O
the	O
GM-CSF	B
receptor	O
alpha	O
promoter	O
in	O
nonmyeloid	B
cells	O
.	O

(ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS)	O

HMG-I	B
binds	O
to	O
GATA	B
motifs	O
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	B
protein	O
HMG-I	B
to	O
the	O
human	B
gamma-globin	O
promoter	O
.	O

We	O
find	O
that	O
HMG-I	B
binds	O
preferentially	O
to	O
the	O
more	O
3'	O
of	O
a	O
pair	O
of	O
GATA	B
motifs	O
in	O
the	O
gamma-globin	B
promoter	O
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	B
factor	O
GATA-1	B
.	O

A	O
naturally	O
occurring	O
mutation	O
(-175	O
T-C)	O
in	O
the	O
area	O
bound	O
by	O
HMG-I	B
results	O
in	O
overexpression	O
of	O
gamma-globin	B
in	O
adult	B
red	O
blood	O
cells	O
(	O
HPFH	B
)	O
and	O
up-regulation	O
of	O
the	O
gamma-globin	B
promoter	O
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG-I	B
does	O
not	O
bind	O
to	O
this	O
mutant	O
sequence	O
.	O

A	O
survey	O
of	O
GATA	B
motifs	O
from	O
other	O
globin	B
cis-elements	O
demonstrates	O
HMG-I	B
binding	O
to	O
most	O
of	O
them.	O

These	O
findings	O
implicate	O
HMG-I	B
in	O
the	O
HPFH	B
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	B
complexes	O
that	O
regulate	O
globin	B
gene	O
expression	O
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	B
tyrosine	B
kinases	O
in	O
human	B
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
tax	O
protein	O
or	O
virus-transformed	B
cells	O
.	O

HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

The	O
viral	B
encoded	O
protein	O
tax	O
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	O
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	B
transforms	O
mouse	B
fibroblasts	O
but	O
not	O
thymocytes	B
,	O
despite	O
comparable	O
levels	O
of	O
tax	B
expression	O
in	O
both	O
tissues.	O

Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	B
protein	O
(s)	O
was	O
observed	O
in	O
the	O
tax	B
transformed	O
fibroblast	O
B	O
line	O
and	O
in	O
HTLV-1	B
transformed	O
human	O
lymphoid	O
lines	O
,	O
but	O
not	O
in	O
thymocytes	B
from	O
Thy-tax	B
transgenic	O
mice	O
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	B
kinase	O
specific	O
antibodies	O
,	O
identified	O
p130	B
as	O
Jak2	B
in	O
the	O
tax	B
transformed	O
mouse	O
fibroblastic	O
cell	O
line	O
and	O
Jak3	B
in	O
HTLV-1	B
transformed	O
human	O
T	O
cell	O
lines	O
.	O

Phosphorylation	O
of	O
Jak2	B
in	O
tax	B
transformed	O
cells	O
resulted	O
from	O
high	O
expression	O
of	O
IL-6	B
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb/c3T3	B
cells	O
using	O
a	O
supernatant	O
from	O
the	O
B	B
line	O
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	B
neutralizing	O
antibodies	O
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	B
kinases	O
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	B
infected	O
human	O
T	O
cells	O
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Regulation	O
of	O
c-jun	B
mRNA	O
expression	O
by	O
hydroxyurea	O
in	O
human	B
K562	O
cells	O
during	O
erythroid	O
differentiation	O
[published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27;1264(3):409]	O

Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O

In	O
addition,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B
hemoglobin	O
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c-jun	B
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	B
cells	O
.	O

HU	O
induced	O
a	O
dose-dependent	O
stimulation	O
of	O
c-jun	B
synthesis.	O

The	O
levels	O
of	O
c-jun	B
mRNA	O
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O
2	O
h.	O

This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h.	O

Both	O
nuclear	O
run-on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	O
c-jun	B
mRNA	O
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O
as	O
well	O
as	O
stabilizing	O
the	O
c-jun	B
mRNA	O
.	O

In	O
addition,	O
the	O
level	O
of	O
jun	B
protein	O
was	O
elevated	O
by	O
2	O
to	O
5-fold	O
within	O
4	O
h	O
in	O
HU	O
treated	O
cells	O
.	O

Furthermore,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1	B
/CAT	B
activity	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post-transcription	O
regulation	O
of	O
c-jun	B
during	O
erythroid	O
differentiation	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	B
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	B
receptors	O
.	O

Interrelations	O
between	O
the	O
hypothalamic-pituitary-adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well-documented	O
biological	O
phenomenon	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(Con	O
A)-	O
and	O
phytohemagglutinin	O
(PHA)-	O
induced	O
T-cell	O
proliferation	O
,	O
pokeweed	B
mitogen	O
(	O
PWM	B
)-driven	O
B-cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	B
receptor	O
function	O
,	O
dose-response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	B
-induced	O
T-cell	O
mitogenesis	O
,	O
PWM	B
-generated	O
B-cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
).	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	B
-induced	O
B-cell	B
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O
vivo.	O

These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	B
receptor	O
function	O
.	O

The	O
decrease	O
in	O
PWM	B
-generated	O
B-cell	B
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	B
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid	O
-mediated	O
induction	O
of	O
interleukin-1	B
receptor	O
synthesis	O
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types.	O

Application	O
of	O
a	O
"formamide	O
free"	O
and	O
thus	O
"material	O
preserving"	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	O
of	O
the	O
myf3	B
gene	O
revealed	O
the	O
following	O
results:	O
Human	B
rhabdomyosarcoma	O
cells	O
,	O
characterized	O
by	O
a	O
high	O
expression	O
of	O
myf3	B
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O

RNase	B
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals.	O

In	O
comparison,	O
isolated	O
nuclei	O
of	O
human	B
lymphocytes	O
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O
this	O
gene	O
exists,	O
show	O
barely	O
hybridization	O
signals	O
.	O

Correspondingly,	O
RNase	B
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all.	O

In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	B
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O

Oncogenicity	O
of	O
human	B
papillomavirus-	O
or	O
adenovirus-	O
transformed	O
cells	O
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O
natural	B
killer	O
cells	O
.	O

The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B
and	O
E7	O
proteins	O
to	O
target	O
cells	O
for	O
rejection	O
by	O
the	O
host	O
natural	B
killer	O
(NK)	O
cell	O
response	O
.	O

As	O
one	O
test	O
of	O
this	O
hypothesis,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B
-and	O
E7	O
-expressing	O
human	O
fibroblastic	O
or	O
keratinocyte-derived	O
human	O
cells	O
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	B
or	O
interferon	O
(IFN)-activated	O
NK	O
cells	O
.	O

Cells	O
expressing	O
the	O
E1A	B
oncoprotein	O
were	O
selectively	O
killed	O
by	O
unstimulated	B
NK	O
cells	O
,	O
while	O
the	O
same	O
parental	O
cells	O
but	O
expressing	O
the	O
HPV	B
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	O
oncoprotein	O
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O

The	O
ability	O
of	O
IFN-activated	B
NK	O
cells	O
to	O
selectively	O
kill	O
virally	B
transformed	O
cells	O
depends	O
on	O
IFN	B
's	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	B
(i.e.,	O
non-viral	B
oncogene-expressing	O
)	O
but	O
not	O
virally	B
transformed	O
cells	O
.	O

E1A	B
blocked	O
IFN	B
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus-transformed	B
cells	O
by	O
IFN	B
-activated	O
NK	O
cells	O
.	O

The	O
extent	O
of	O
IFN	B
-induced	O
NK	O
cell	O
killing	O
of	O
E1A	B
-expressing	O
cells	O
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	B
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	B
to	O
block	O
IFN	B
-stimulated	O
gene	O
expression	O
in	O
target	B
cells	O
.	O

In	O
contrast,	O
E7	B
blocked	O
neither	O
IFN	B
-stimulated	O
gene	O
expression	O
nor	O
IFN	B
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV	B
-transformed	O
cells	O
by	O
IFN	B
-activated	O
NK	B
cells	O
.	O

In	O
conclusion,	O
E1A	B
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	O
cell	O
response	O
,	O
whereas	O
the	O
E7	B
oncoprotein	O
lacks	O
this	O
activity.	O

Regulation	O
of	O
IkB	B
alpha	O
phosphorylation	O
by	O
PKC-	B
and	O
Ca(2+)-	O
dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca(2+)	B
-dependent	O
phosphatase	O
calcineurin	B
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	B
-induced	O
activation	O
of	O
nuclear	B
factor	O
(NF)-kappa	O
B	O
in	O
T	B
cell	O
lines	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism(s)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF-kappa	B
B	O
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types,	O
in	O
the	O
monocytic	B
cell	O
line	O
U937	O
calcineurin	B
is	O
also	O
sufficient	O
to	O
activate	O
NF-kappa	B
B	O
.	O

Having	O
previously	O
shown	O
that	O
Ca(2+)-	O
and	O
PKC-	B
dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	B
alpha	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	B
alpha	O
phosphorylation	O
.	O

While	O
PKC	B
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	B
alpha	O
in	O
T	B
cell	O
lines	O
,	O
co-activation	O
of	O
Ca(2+)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	B
alpha	O
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation.	O

Activation	O
of	O
Ca(2+)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	B
alpha	O
in	O
Jurkat	B
T	O
or	O
in	O
U937	B
cells	O
.	O

Treatment	O
of	O
T	B
cells	O
with	O
the	O
selective	O
PKC	B
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA	O
-induced	O
IkB	B
alpha	O
phosphorylation	O
/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca(2+)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	B
alpha	O
induced	O
by	O
TNF-alpha	B
,	O
a	O
PKC	B
-independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	B
,	O
Ca(2+)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	B
not	O
at	O
the	O
level	O
of	O
IkB	B
alpha	O
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation.	O

These	O
results	O
indicate	O
that	O
Ca(2+)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	B
calcineurin	B
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF-kappa	B
B	O
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	O
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	B
alpha	O
phosphorylation	O
and	O
degradation	O
.	O

Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4	O
-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	B
factor	O
kappa	O
B	O
binding	O
.	O

Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies.	O

Oxidative	O
stress	O
enhances	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
)	O
activity	O
,	O
and	O
NF-kappa	B
B	O
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	B
cytokines	O
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water-soluble	O
emulsion	O
of	O
alpha-tocopherol	O
.	O

Alpha-tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF-kappa	B
B	O
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	B
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	B
B	O
binding	O
and	O
an	O
increase	O
in	O
tumor	B
necrosis	O
factor-alpha	O
(	O
TNF-alpha	B
)	O
messenger	O
RNA	O
levels	O
.	O

Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF-kappa	B
B	O
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O

These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha-tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF-kappa	B
B	O
binding	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF-kappa	B
B	O
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	O
cytokine	B
synthesis	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	B
B	O
activity	O
through	O
induction	O
of	O
I	B
kappa	O
B	O
synthesis	O
[see	O
comments]	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	B
and	O
of	O
several	O
cell	B
surface	O
molecules	O
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear.	O
Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	B
factor	O
kappa	O
B	O
(	O
NF-kappa	B
B	O
)	O
activation	O
in	O
mice	O
and	O
cultured	B
cells	O
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	B
kappa	O
B	O
alpha	O
inhibitory	O
protein,	O
which	O
traps	O
activated	O
NF-kappa	B
B	O
in	O
inactive	O
cytoplasmic	B
complexes	O
.	O

Because	O
NF-kappa	B
B	O
activates	O
many	O
immunoregulatory	B
genes	O
in	O
response	O
to	O
pro-inflammatory	O
stimuli,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti-inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

Transcriptional	O
repression	O
of	O
the	O
interleukin-2	B
gene	O
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	B
complex	O
formation	O
by	O
a	O
nuclear	B
hormone	O
receptor	O
.	O

T-	B
lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25(OH)2D3	O
],	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	B
2	O
(IL-2)	O
,	O
gamma	B
interferon	O
,	O
and	O
granulocyte-macrophage	B
colony-stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1,25(OH)2D3	O
-mediated	O
repression	O
in	O
Jurkat	B
cells	O
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B
expression	O
by	O
the	O
vitamin	B
D3	O
receptor	O
(	O
VDR	B
).	O

We	O
therefore	O
examined	O
vitamin	O
D3	O
-mediated	O
repression	O
of	O
activated	O
IL-2	B
expression	O
by	O
cotransfecting	O
Jurkat	B
cells	O
with	O
IL-2	B
promoter/reporter	O
constructs	O
and	O
a	O
VDR	B
overexpression	O
vector	O
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1,25(OH)2D3	O
-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	B
region	O
encompassing	O
an	O
important	O
positive	B
regulatory	O
element	O
,	O
NF-AT-1	B
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	B
transcription	O
factor	O
,	O
NFATp	B
,	O
as	O
well	O
as	O
by	O
AP-1	B
.	O

VDR	B
DNA-binding	O
mutants	O
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo;	O
the	O
VDR	B
DNA-binding	O
domain	O
alone,	O
however,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	B
expression	O
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B
repression	O
.	O

By	O
combining	O
partially	B
purified	O
proteins	O
in	O
vitro,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp	B
/AP-1-DNA	O
complex	O
upon	O
inclusion	O
of	O
VDR	B
or	O
VDR	B
-retinoid	O
X	O
receptor	O
.	O

Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR	B
-retinoid	O
X	O
receptor	O
heterodimer	O
blocks	O
NFATp	B
/	O
AP-1	B
complex	O
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF-AT-1	B
element	O
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	B
hormone	O
receptor	O
of	O
transcriptional	B
activators	O
of	O
the	O
IL-2	B
gene	O
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

Tissue-specific	O
regulation	O
of	O
the	O
rabbit	B
15-lipoxygenase	O
gene	O
in	O
erythroid	B
cells	O
by	O
a	O
transcriptional	B
silencer	O
.	O

The	O
15-lipoxygenase	B
(lox)	O
gene	O
is	O
expressed	O
in	O
a	O
tissue-specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	B
cells	O
but	O
also	O
in	O
airway	B
epithelial	O
cells	O
and	O
eosinophils	B
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5'	B
flanking	O
DNA	O
of	O
the	O
15-lox	B
gene	O
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	B
cell	O
lines	O
but	O
not	O
in	O
two	O
erythroid	B
cell	O
lines	O
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	B
'silencer'	O
since	O
it	O
functions	O
in	O
both	O
orientations.	O

The	O
main	O
activity	O
of	O
the	O
silencer	B
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5'	B
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	B
sites	O
for	O
a	O
nuclear	B
factor	O
present	O
in	O
non-	B
erythroid	B
cells	O
but	O
not	O
in	O
erythroid	B
cells	O
.	O

These	O
binding	B
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	B
sites	O
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	B
lox	O
promoter	O
fragment	O
.	O

The	O
5'	B
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	B
sites	O
for	O
the	O
GATA	B
family	O
of	O
transcription	B
factors	O
.	O

Phosphorylation	O
of	O
the	O
transcription	B
factor	O
NFATp	B
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	B
A-treated	O
human	O
B	O
and	O
T	O
cells	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	B
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
),	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	B
genes.	O

This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	B
calcineurin	B
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B
component	O
to	O
the	O
nucleus.	O

Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	B
B	O
and	O
Jurkat	O
T	O
cell	O
lines	O
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B
that	O
is	O
inhibited	O
in	O
DNA-binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B
complex	O
with	O
Fos	B
and	O
Jun	B
.	O

Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[32P]orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B
migration	O
on	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution.	O

Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B
or	O
alkaline	B
phosphatase	O
restores	O
NFATp	B
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B
complex	O
with	O
Fos	B
and	O
Jun	B
proteins.	O

These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA	O
-sensitive	O
regulation	O
of	O
NFATp	B
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding.	O

Transcription	B
factors	O
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	B
lymphocytes	O
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	B
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time-frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which,	O
if	O
any,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL-2	B
gene	O
as	O
a	O
candidate,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	O
gene	O
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	B
factors	O
AP-1	B
,	O
NF-kappa	B
B	O
,	O
NF-AT	B
and	O
Oct1	B
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	B
mRNA.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	B
mRNA	O
and	O
secretion	O
of	O
IL-2	B
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	B
factor	O
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	B
and	O
NF-kappa	B
B	O
extracted	O
from	O
mitogen-stimulated	B
cells	O
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly,	O
Oct1	B
and	O
NF-AT	B
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner.	O

The	O
identification	O
of	O
regulatory	B
proteins	O
,	O
such	O
as	O
transcription	B
factors	O
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	B
lymphocytes	O
.	O

Sex	O
and	O
age	O
distribution	O
of	O
1,25(OH)2D3	B
receptors	O
in	O
peripheral	B
blood	O
mononuclear	O
cells	O
from	O
normal	O
human	O
subjects	O
.	O

Specific	O
receptors	O
for	O
1,25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	B
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	B
).	O

We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution.	O

Twenty	O
two	O
healthy	O
men	O
aged	O
21-66	O
yr	O
(mean	O
+/-	O
SD	O
41.0	O
+/-	O
13.6)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22-60	O
yr	O
(38.9	O
+/-	O
13.9)	O
have	O
been	O
studied.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(1.35	O
+/-	O
0.70	O
x	O
10(-10)	O
M	O
in	O
males,	O
1.13	O
+/-	O
0.66	O
x	O
10(-10)	O
M	O
in	O
females),	O
but	O
the	O
concentration	O
of	O
binding	B
sites	O
(Nmax)	O
was	O
significantly	O
lower	O
in	O
females	O
(2.32	O
+/-	O
0.92	O
fmol/10(7)	O
PBMC	B
vs	O
4.43	O
+/-	O
1.38	O
fmol/10(7)	O
PBMC	B
in	O
males	O
;	O
p	O
=	O
0.0001).	O

Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age.	O

No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
post	O
menopausal	O
women	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	B
receptors	O
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O

Expression	O
of	O
Id2	B
and	O
Id3	O
mRNA	O
in	O
human	B
lymphocytes	O
.	O

Helix-loop-helix	B
(	O
HLH	O
)	O
transcription	O
factors	O
are	O
involved	O
in	O
cellular	O
growth	O
and	O
differentiation	O
.	O

The	O
Id	B
(	O
inhibitor	O
of	O
DNA	O
binding	O
and	O
differentiation	O
)	O
HLH	O
proteins	O
,	O
in	O
a	O
dominantly	O
negative	O
fashion,	O
regulate	O
transcriptional	O
activities	O
of	O
basic	B
HLH	O
proteins	O
.	O

We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	B
and	O
Id3	O
mRNA	O
in	O
human	B
leukemia/lymphoma	O
lines	O
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	B
and	O
activated	O
normal	O
human	O
lymphocytes	O
from	O
peripheral	O
blood	O
(	O
PBL	B
).	O

The	O
Id2	B
mRNA	O
was	O
abundantly	O
expressed	O
in	O
5/12	B
T-cell	O
and	O
3/4	O
B-cell	O
lines	O
,	O
and	O
Id3	B
mRNA	O
was	O
detected	O
in	O
4/12	O
T-cell	O
and	O
3/4	O
B-cell	O
lines	O
.	O

Interestingly,	O
Id2	B
,	O
but	O
not	O
Id3	B
,	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
4/5	B
T-cell	O
lines	O
infected	O
with	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
(	O
ATL-1k	O
,	O
MT-2	O
,	O
S-LB1	O
)	O
and	O
type	O
II	O
(	O
Mo	O
)	O
.	O

Another	O
unexpected	O
finding	O
was	O
that	O
T-cell	B
leukemias	O
and	O
T-cell	B
lines	O
often	O
expressed	O
either	O
Id2	B
or	O
Id3	O
mRNA	O
.	O

In	O
addition,	O
resting	B
PBL	O
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	B
mRNA	O
,	O
but	O
not	O
Id3	B
mRNA	O
.	O

Upon	O
PHA	B
-stimulation	O
,	O
Id2	B
expression	O
decreased	O
and	O
Id3	B
levels	O
increased	O
with	O
biphasic	O
kinetics.	O

Taken	O
together,	O
our	O
studies	O
revealed	O
three	O
unexpected	O
findings	O
which	O
require	O
further	O
analysis:	O
(1)	O
expression	O
of	O
Id2	B
mRNA	O
is	O
often	O
associated	O
with	O
lymphocytic	O
transformation	O
by	O
HTLV-I	O
or	O
-II;	O
(2)	O
T-cells	B
usually	O
express	O
either	O
Id2	B
or	O
Id3	B
mRNA	O
,	O
but	O
B-cells	B
often	O
express	O
both	O
simultaneously;	O
(3)	O
non-dividing,	B
normal	O
PBL	B
express	O
high	O
levels	O
of	O
Id2	B
and	O
no	O
Id3	B
mRNA	O
;	O
and	O
with	O
the	O
onset	O
of	O
cellular	O
proliferation,	O
levels	O
of	O
Id2	B
mRNA	O
decrease	O
while	O
levels	O
of	O
Id3	B
mRNA	O
increase,	O
suggesting	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
closely	O
related	O
genes	O
is	O
disparate.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	B
factor	O
gene	O
in	O
human	B
monocytic	O
cells	O
.	O

Binding	O
of	O
plasma	B
Factor	O
VII/VIIa	O
to	O
the	O
tissue	B
factor	O
(TF)	O
receptor	O
initiates	O
the	O
coagulation	B
protease	O
cascades	O
.	O

TF	B
expression	O
by	O
circulating	B
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases.	O

Transcriptional	O
activation	O
of	O
the	O
human	B
TF	B
gene	O
in	O
monocytic	B
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B
heterodimers	O
to	O
a	O
kappa	B
B	O
site	O
in	O
the	O
TF	B
promoter	O
.	O

Here,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates,	O
inhibited	O
LPS	O
induction	O
of	O
TF	B
activity	O
and	O
TF	B
gene	O
transcription	O
in	O
human	B
monocytes	O
and	O
monocytic	B
THP-1	O
cells	O
at	O
clinically	O
relevant	O
doses.	O

Furthermore,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-induced	O
proteolytic	O
degradation	O
of	O
I	B
kappa	O
B	O
alpha	O
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B
heterodimers	O
.	O

In	O
contrast,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B
gene	O
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B
gene	O
transcription	O
in	O
monocytic	B
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B
heterodimers	O
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	O
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Critical	O
role	O
for	O
IL-6	B
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	B
Ags	O
with	O
TCR	B
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes.	O

The	O
activation	O
of	O
signal	B
transducer	O
and	O
activator	O
of	O
transcription	O
(STAT)	O
proteins	O
in	O
a	O
primary	O
TCR	B
-mediated	O
activation	O
of	O
T	B
cells	O
have	O
been	O
explored.	O

In	O
purified	B
human	O
peripheral	O
blood	O
T	O
cells	O
,	O
nuclear	B
STAT	B
proteins	O
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	B
anti-CD3	O
Abs	O
.	O

These	O
STAT	B
proteins	O
were	O
detected	O
by	O
using	O
the	O
IFN-gamma-activated	B
sequence	O
(	O
GAS	B
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	B
Abs	O
indicated	O
that	O
they	O
contained	O
STAT-3	B
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	B
family	O
.	O

The	O
induction	O
of	O
STAT	B
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B
factor	O
produced	O
by	O
the	O
activated	B
T	O
cells	O
.	O

As	O
neutralizing	O
anti-	B
IL-6	B
Abs	O
effectively	O
down-regulated	O
the	O
early	O
induction	O
of	O
STAT	B
proteins	O
and	O
as	O
exogenously	O
added	O
IL-6	B
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	B
-mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL-6	B
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	B
proteins	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	B
B	O
lymphocytes	O
by	O
Epstein-Barr	O
virus	O
.	O

B	B
lymphocytes	O
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O

Antigen	O
recognition	O
stimulates	O
limited	O
proliferation,	O
whereas	O
infection	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	B
cell	O
lines	O
.	O

Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	B
B	O
lymphocytes	O
are	O
arrested,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	B
cycle-associated	O
genes	O
in	O
quiescent	O
and	O
stimulated	B
cells	O
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	B
genes	O
,	O
cdc-2	B
,	O
cyclin	B
E	O
,	O
CD23	B
,	O
and	O
cyclin	B
D2	O
,	O
are	O
up-regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV	O
-mediated	O
immortalization	O
.	O

Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Transient	O
stimulation	O
of	O
quiescent	B
B	O
lymphocytes	O
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	B
,	O
anti-IgM	B
,	O
and	O
IL4	B
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes,	O
suggesting	O
that,	O
after	O
infection,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	O
cell	O
cycle	O
activation	O
.	O

Expression	O
of	O
the	O
chemokine	B
receptor	O
BLR2/EBI1	B
is	O
specifically	O
transactivated	O
by	O
Epstein-Barr	B
virus	O
nuclear	O
antigen	O
2	O
.	O

In	O
our	O
attempt	O
to	O
identify	O
chemokine	B
receptors	O
that	O
are	O
related	O
to	O
Burkitt's	B
lymphoma	O
receptor	O
1	O
(	O
BLR1	B
)	O
and	O
are	O
expressed	O
in	O
activated	B
lymphocytes	O
we	O
used	O
RT-PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	B
encoding	O
a	O
seven	B
transmembrane	O
receptor	O
termed	O
BLR2	B
.	O

The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G-protein	B
coupled	O
chemokine	O
receptors	O
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B
EBI1	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	B
mRNA	O
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	B
and	O
anti-CD3-	O
treated	O
peripheral	O
blood	O
lymphocytes	O
.	O

BLR2	B
-specific	O
mRNA	O
could	O
be	O
detected	O
in	O
all	O
Epstein-Barr	B
virus	O
positive	O
B	O
cell	O
lines	O
.	O

We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	B
gene	O
could	O
be	O
specifically	O
induced	O
in	O
Epstein-Barr	B
virus	O
negative	O
BL	O
41	O
cells	O
via	O
estrogen-mediated	O
activation	O
of	O
Epstein-Barr	B
virus	O
nuclear	O
antigen	O
2	O
,	O
a	O
key	O
regulator	O
of	O
viral	B
and	O
cellular	O
genes	O
in	O
immortalized	B
B	O
cells	O
.	O

Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	B
lymphocytes	O
and	O
in	O
viral	O
pathogenesis	O
.	O

A	O
central	O
role	O
for	O
a	O
single	O
c-Myb	B
binding	O
site	O
in	O
a	O
thymic	B
locus	O
control	O
region	O
.	O

Locus	B
control	O
regions	O
(	O
LCRs	B
)	O
are	O
powerful	O
assemblies	O
of	O
cis	B
elements	O
that	O
organize	O
the	O
actions	O
of	O
cell-type-specific	B
trans-acting	O
factors	O
.	O

A	O
2.3-kb	B
LCR	B
in	O
the	O
human	B
adenosine	O
deaminase	O
(ADA)	O
gene	O
first	O
intron	O
,	O
which	O
controls	O
expression	O
in	O
thymocytes	B
,	O
is	O
composed	O
of	O
a	O
200-bp	B
enhancer	O
domain	O
and	O
extended	B
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	B
.	O

Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	O
contains	O
a	O
28-bp	B
core	O
region	O
and	O
local	B
adjacent	O
augmentative	O
cis	O
elements	O
.	O

We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c-Myb	B
binding	O
site	O
.	O

In	O
both	O
transiently	B
cotransfected	O
human	O
cells	O
and	O
stable	B
chromatin-integrated	O
yeast	O
cells	O
,	O
c-Myb	B
strongly	O
transactivated	B
reporter	O
constructs	O
that	O
contained	O
polymerized	B
core	O
sequences	O
.	O

c-Myb	B
protein	O
was	O
strongly	O
evident	O
in	O
T	B
lymphoblasts	O
in	O
which	O
the	O
enhancer	O
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O

Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c-myb	B
expression	O
with	O
that	O
of	O
mouse	O
ADA	O
and	O
human	O
ADA	O
LCR	B
-directed	O
transgene	O
expression	O
.	O

Point	O
mutation	O
of	O
the	O
c-Myb	B
site	O
within	O
the	O
intact	O
2.3-kb	B
LCR	B
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	B
activity	O
in	O
transgenic	B
thymocytes	O
.	O

Within	O
the	O
context	O
of	O
a	O
complex	B
enhancer	O
and	O
LCR	B
,	O
c-Myb	B
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte-specific	O
gene	O
expression	O
via	O
a	O
single	B
binding	O
site.	O

A	O
regulatory	B
element	O
in	O
the	O
human	B
interleukin	O
2	O
gene	O
promoter	O
is	O
a	O
binding	B
site	O
for	O
the	O
zinc	B
finger	O
proteins	O
Sp1	B
and	O
EGR-1	B
.	O

Activation	O
of	O
the	O
interleukin	B
2	O
(	O
IL-2	B
)	O
gene	O
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	B
factors	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	B
promoter	O
in	O
stimulated	B
T	O
lymphocytes	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	B
element	O
within	O
the	O
IL-2	B
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	B
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
domain	O
.	O

This	O
region	O
(termed	O
the	O
zinc	B
finger	O
protein	O
binding	O
region	O
(	O
ZIP	B
))	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	B
finger	O
proteins	O
:	O
the	O
constitutively	O
expressed	O
transcription	B
factor	O
Sp1	B
and	O
the	O
inducible	B
early	O
growth	O
response	O
protein	O
EGR-1	B
.	O

In	O
unstimulated	O
cells	O
which	O
do	O
not	O
secrete	O
IL-2	B
,	O
only	O
Sp1	B
binds	O
to	O
this	O
region,	O
while	O
in	O
stimulated	O
IL-2	B
secreting	O
cells	O
the	O
inducible	O
EGR-1	B
protein	O
recognizes	O
this	O
element.	O

In	O
Jurkat	B
T	O
cells	O
,	O
the	O
ZIP	B
site	O
serves	O
as	O
an	O
activator	O
for	O
IL-2	B
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	B
and	O
NFAT	O
binding	O
sites	O
is	O
required	O
for	O
maximal	O
IL-2	B
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	B
site	O
for	O
IL-2	B
promoter	O
activity	O
.	O

Activation	O
of	O
the	O
HIV-1	B
enhancer	O
by	O
the	O
LEF-1	B
HMG	O
protein	O
on	O
nucleosome-assembled	B
DNA	O
in	O
vitro.	O

Lymphoid	B
enhancer-binding	O
factor	O
1	O
(	O
LEF-1	B
)	O
is	O
a	O
regulatory	B
high	O
mobility	O
group	O
(HMG)	O
protein	O
that	O
activates	O
the	O
T	B
cell	O
receptor	O
alpha	O
(	O
TCR	O
alpha	O
)	O
enhancer	O
in	O
a	O
context-restricted	O
manner	O
in	O
T	B
cells	O
.	O

In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	B
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
enhancer	O
,	O
which	O
contains	O
DNA-binding	B
sites	O
for	O
LEF-1	B
and	O
Ets-1,	B
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF-1	B
.	O

First,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1	B
-binding	O
site	O
inhibit	O
the	O
activity	O
of	O
multimerized	B
copies	O
of	O
the	O
HIV-1	B
enhancer	O
in	O
Jurkat	B
T	O
cells	O
,	O
and	O
that	O
LEF-1	B
/GAL4	O
can	O
activate	O
a	O
GAL4-substituted	B
HIV-1	B
enhancer	O
80-	O
to	O
100-fold	O
in	O
vivo.	O

Second,	O
recombinant	B
LEF-1	B
is	O
shown	O
to	O
activate	O
HIV-1	O
transcription	O
on	O
chromatin-assembled	B
DNA	O
in	O
vitro.	O

By	O
using	O
a	O
nucleosome	O
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	B
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	B
(or	O
LEF-1	B
and	O
Ets-1	B
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter-binding	B
protein	O
,	O
Sp1	B
.	O

Addition	O
of	O
TFE-3	B
,	O
which	O
binds	O
to	O
an	O
E-box	B
motif	O
upstream	O
of	O
the	O
LEF-1	B
and	O
Ets-1	O
sites	O
,	O
further	O
augments	O
transcription	O
in	O
this	O
system.	O

Individually	O
or	O
collectively,	O
none	O
of	O
the	O
three	O
enhancer-binding	B
proteins	O
(	O
LEF-1	B
,	O
Ets-1	B
,	O
and	O
TFE-3	B
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O
of	O
Sp1	B
.	O

A	O
truncation	B
mutant	O
of	O
LEF-1	B
(	O
HMG-88	B
),	O
which	O
contains	O
the	O
HMG	B
box	O
but	O
lacks	O
the	O
trans-activation	B
domain	O
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	B
DNA	O
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B
domain	O
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro.	O

We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF-1	B
in	O
vitro	O
is	O
a	O
chromatin	B
-dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans-activation	B
domain	O
in	O
addition	O
to	O
the	O
HMG	B
domain	O
.	O

HIV-1	B
envelope	O
glycoproteins	O
induce	O
activation	O
of	O
activated	B
protein-1	O
in	O
CD4+	B
T	O
cells	O
[published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1;270(48):29038]	O

Activation	O
of	O
CD4	B
positive	O
T	O
cells	O
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B
positive	O
T	O
cell	O
lines	O
and	O
purified	B
T	O
cells	O
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	B
envelope	O
glycoproteins	O
of	O
HIV	O
,	O
gp	B
160	O
,	O
can	O
induce	O
activation	O
of	O
transcription	B
factor,	O
activated	B
protein-1	O
(	O
AP-1	B
).	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	B
molecule	O
,	O
since	O
treatment	O
of	O
gp160	O
with	O
soluble	O
CD4-IgG	B
abrogates	O
its	O
activity,	O
and	O
CD4	B
negative	O
T	O
cell	O
lines	O
fail	O
to	O
be	O
stimulated	O
with	O
gp160	O
.	O

Immunoprecipitation	O
of	O
the	O
gp	O
160	O
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B
antibodies	O
to	O
Fos	B
and	O
Jun	B
proteins	O
indicates	O
that	O
AP-1	B
complex	O
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins.	O

The	O
gp160	B
-induced	O
AP-1	B
complex	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis-independent	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B
kinase	O
C	O
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

This	O
gp160	O
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	B
cells	O
:	O
pre-treatment	O
of	O
CD4+	B
T	B
cells	O
with	O
gp160	O
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti-CD3	B
-induced	O
interleukin-2	B
secretion	O
.	O

Effects	O
similar	O
to	O
gp160	O
were	O
seen	O
with	O
anti-CD4	B
mAb	O
.	O

The	O
aberrant	O
activation	O
of	O
AP-1	B
by	O
gp160	O
in	O
CD4	B
positive	O
T	O
cells	O
could	O
result	O
in	O
up-regulation	O
of	O
cytokines	B
containing	O
AP-1	B
sites	O
,	O
e.g.	O
interleukin-3	B
and	O
granulocyte	B
macrophage	O
colony-stimulating	O
factor	O
,	O
and	O
concurrently	O
lead	O
to	O
T	O
cell	O
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	B
secretion	O
.	O
